

CITATION REPORT

List of articles citing

Clinical end points in coronary stent trials: a case for standardized definitions

DOI: 10.1161/circulationaha.106.685313
Circulation, 2007, 115, 2344-51.

Source: <https://exaly.com/paper-pdf/42199686/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2309	.		
2308	.		
2307	.		
2306	Confocal microscopy and biochemical analysis reveal spatial and functional separation between anandamide uptake and hydrolysis in human keratinocytes. 2005 , 62, 386-95		53
2305	Late coronary stent thrombosis. <i>Circulation</i> , 2007 , 116, 1952-65	16.7	186
2304	Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. <i>Circulation</i> , 2007 , 116, 745-54	16.7	392
2303	Drug-eluting stents "deliver heartburn": how do we spell relief going forward?. <i>Circulation</i> , 2007 , 115, 2990-4	16.7	12
2302	Coronary stents and noncardiac surgery. <i>Circulation</i> , 2007 , 116, e378-82	16.7	49
2301	Current World Literature. 2007 , 22, 586-601		
2300	The conundrum of late and very late stent thrombosis following drug-eluting stent implantation. 2007 , 22, 565-71		21
2299	Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. 2007 , 370, 567-74		31
2298	Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. 2007 , 370, 937-48		1141
2297	Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. 2007 , 50, 138-45		69
2296	Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives. 2007 , 50, 119-27		104
2295	Revascularization before noncardiac surgery: is there an impact of drug-eluting stent thrombosis?. 2007 , 50, 1398; author reply 1399		
2294	Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. 2007 , 50, 1299-304		180
2293	High-risk patients undergoing major vascular surgery: to operate or not to operate?. 2007 , 50, 1398-9; author reply 1399		5

2292	The Emperor's new clothes: another cypher versus taxus post-hoc meta-analysis. 2007 , 50, 1381-5	6
2291	Impact of late drug-eluting stent malapposition on 3-year clinical events. 2007 , 50, 1515-6	36
2290	Advancing the knowledge base on the efficacy-safety ratio with drug-eluting stents contributions from the European Society of Cardiology Congress, Vienna, Austria, September 1-5, 2007. 2007 , 50, 2431-3	0
2289	Lesões no segmento proximal da artéria coronária descendente anterior: resultados entre o tratamento cirúrgico (mamãia) e o percutâneo (stent com fármaco). 2007 , 15, 370-377	1
2288	Outcomes after primary coronary intervention with drug-eluting stent implantation in diabetic patients with acute ST elevation myocardial infarction. 2007 , 120, 1862-1867	10
2287	Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications. 2007 , 100, 1619-24	36
2286	Drug-eluting stent safety. 2007 , 100, 10M-17M	23
2285	[Treatment after drug-eluting stent placement]. 2007 , 32, 301-6	0
2284	Positionspapier der DGK zur Wirksamkeit und Sicherheit von Medikamente freisetzenden Koronarstents (DES). 2007 , 1, 84-111	21
2283	Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation. 2008 , 1, 56-61	74
2282	Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design. 2008 , 22, 313-20	17
2281	Drug-eluting coronary stent very late thrombosis revisited. 2008 , 33, 334-42	22
2280	[Optimal platelet inhibition after coronary stent implantation. Current status]. 2008 , 33, 244-53	4
2279	Drug-eluting coronary stents: as safe as bare-metal stents, but optimized antiplatelet therapy may further improve clinical outcome. 2008 , 64, 227-32	1
2278	Late adverse events after drug-eluting stent implantation. 2008 , 10, 253-62	1
2277	Antiplatelet therapy in the era of late stent thrombosis. 2008 , 10, 12-7	3
2276	Unprotected left main disease managed with drug-eluting stents: long-term outcome of 100 patients with increased surgical risk. 2008 , 71, 533-8	16
2275	Late outcomes of drug-eluting versus bare metal stents in saphenous vein grafts: Propensity score analysis. 2008 , 72, 7-12	29

2274	Usage patterns and 2-year outcomes with the TAXUS express stent: results of the US ARRIVE 1 registry. 2008 , 72, 433-45	36
2273	Subintimal tracking and re-entry technique with contrast guidance: a safer approach. 2008 , 72, 790-6	82
2272	Materials, fluid dynamics, and solid mechanics aspects of coronary artery stents: a state-of-the-art review. 2008 , 86, 569-90	34
2271	2-year outcome of patients treated for bifurcation coronary disease with provisional side branch T-stenting using drug-eluting stents. 2008 , 1, 358-65	43
2270	Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. 2008 , 1, 494-503	80
2269	A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus-versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial. 2008 , 1, 524-32	30
2268	Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Libert [®] stent: 1-year results from the TAXUS ATLAS program. 2008 , 1, 699-709	67
2267	Biomarkers on admission for the prediction of cardiovascular events after primary stenting in patients with ST-elevation myocardial infarction. 2008 , 31, 572-9	10
2266	Use of drug-eluting stents in saphenous vein aortocoronary bypass graft lesions: a critical appraisal. 2008 , 21, 151-7	12
2265	Long-term clinical outcomes of the Drug-Eluting Stents in the Real World (DESIRE) Registry. 2008 , 21, 307-14	20
2264	Everolimus- and zotarolimus-eluting stents for bare metal stent in-stent restenosis treatment: a prospective study. 2008 , 21, 388-94	4
2263	Results of percutaneous coronary intervention of the unprotected left main coronary artery in 143 patients and comparison of 30-day mortality to results of coronary artery bypass grafting. 2008 , 101, 75-81	81
2262	Effectiveness of drug-eluting stent implantation for patients with unprotected left main coronary artery stenosis. 2008 , 101, 801-6	55
2261	Four-year clinical follow-up of the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital registry. 2008 , 101, 1105-11	34
2260	Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study). 2008 , 101, 1560-6	39
2259	Rates of stent thrombosis in bare-metal versus drug-eluting stents (from a large Australian multicenter registry). 2008 , 101, 1716-22	28
2258	The editor's roundtable: bare-metal stents versus drug-eluting stents-indications and complications. 2008 , 102, 32-9	
2257	Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period. 2008 , 102, 298-303	43

2256	A clinical risk score for prediction of stent thrombosis. 2008 , 102, 541-5	30
2255	Effect of prolonged thienopyridine use after drug-eluting stent implantation (from the TAXUS landmark trials data). 2008 , 102, 1017-22	15
2254	Clinical and angiographic follow-up of small vessel lesions treated with paclitaxel-eluting stents (from the TRUE Registry). 2008 , 102, 1002-8	28
2253	Impact of a 600-mg loading dose of clopidogrel on 30-day outcome in unselected patients undergoing percutaneous coronary intervention. 2008 , 102, 1318-22	16
2252	Safety and efficacy of offsite percutaneous coronary interventions in 1,348 consecutive patients in rural Tasmania. 2008 , 102, 1323-7	2
2251	Incidence of bleeding and compliance on prolonged dual antiplatelet therapy (aspirin + thienopyridine) following drug-eluting stent implantation. 2008 , 102, 1477-81	20
2250	[Statin in prevention of periprocedural myonecrosis after percutaneous coronary angioplasty: systematic review and meta-analysis]. 2008 , 57, 181-6	
2249	Pronóstico a largo plazo del uso no aprobado de stents liberadores de paclitaxel. 2008 , 61, 695-704	5
2248	Long-Term Results With the Off-Label Use of Paclitaxel-Eluting Stents. 2008 , 61, 695-704	
2247	Concerns in the SESAMI trial. 2008 , 51, 329-30; author reply 330	
2246	Defining and utilizing surrogates in the evaluation of coronary stents: what do we really want and need to know?. 2008 , 51, 33-6	5
2245	The balance of risks and benefits of drug-eluting versus bare-metal stents. 2008 , 51, 972; author reply 972-3	1
2244	Resting heart rate and cardiovascular disease: the beta-blocker-hypertension paradox. 2008 , 51, 330-1; author reply 331-2	7
2243	Reply. 2008 , 51, 330	6
2242	The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. 2008 , 51, 701-7	203
2241	Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. 2008 , 51, 708-15	96
2240	Percutaneous coronary intervention pharmacology: from a triangle to a square. 2008 , 51, 698-700	14
2239	Reply. 2008 , 51, 971-972	1

2238 Reply. **2008**, 51, 972-973

2237	A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. 2008 , 51, 1543-52	97
2236	Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model. 2008 , 51, 1844-53	57
2235	Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. 2008 , 51, 2011-6	44
2234	ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients. 2008 , 51, 2396-402	87
2233	Longest available clinical outcomes after drug-eluting stent implantation for unprotected left main coronary artery disease: the DELFT (Drug Eluting stent for LeFT main) Registry. 2008 , 51, 2212-9	135
2232	Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. 2008 , 51, 2385-95	60
2231	Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. 2008 , 52, 1134-40	404
2230	The DELFT (Drug Eluting stent for LeFT main) registry: the unknowns. 2008 , 52, 1680-1; author reply 1681	1
2229	Reply. 2008 , 52, 1681	1
2228	Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study. 2008 , 52, 1621-7	39
2227	Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial. 2008 , 52, 1957-67	92
2226	Stent thrombosis in 2008: definition, predictors, prognosis and treatment. 2008 , 101, 769-77	41
2225	Are drug-eluting stents indicated in large coronary arteries? Insights from a multi-centre percutaneous coronary intervention registry. 2008 , 130, 374-9	17
2224	Immediate and long-term outcomes of drug-eluting stent implantation for unprotected left main coronary artery disease: comparison with bare-metal stent implantation. 2008 , 155, 553-61	31
2223	Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design. 2008 , 155, 609-14	23
2222	Late thrombosis of paclitaxel-eluting stents: long-term incidence, clinical consequences, and risk factors in a cohort of 604 patients. 2008 , 155, 648-53	26
2221	Safety and effectiveness of drug-eluting stents among diabetic patients: a propensity analysis. 2008 , 156, 125-34	12

2220	Correlates of late and very late thrombosis of drug eluting stents. 2008 , 156, 141-7	29
2219	Sirolimus-eluting and paclitaxel-eluting stents for the treatment of coronary bifurcations. 2008 , 156, 745-50	23
2218	ABO blood types: influence on infarct size, procedural characteristics and prognosis. 2008 , 123, 200-5	28
2217	A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. 2008 , 371, 899-907	552
2216	Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. 2009 , 30, 916-22	304
2215	Safety of drug-coated stents. 2008 , 7, 597-606	4
2214	Drug-eluting stent thrombosis: A lesson in vascular biology. 2008 , 24, 50C-55C	2
2213	Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. 2009 , 30, 16-24	87
2212	Safety of drug-eluting stents. 2008 , 5, 316-28	17
2211	Meta-analysis shows similar risk of thrombosis after drug-eluting stent, bare-metal stent, or angioplasty. 2008 , 15, 93-100	6
2210	Value and limitations of target-vessel ischemia in predicting late clinical events after drug-eluting stent implantation. 2008 , 49, 550-6	21
2209	Current status of percutaneous coronary intervention with drug-eluting stents in Asia. <i>Circulation</i> , 2008 , 118, 2730-7	16.7 15
2208	Response to Letters Regarding Article, "Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions: Results From a Real-World Multicenter Registry" <i>Circulation</i> , 2008 , 118,	16.7
2207	Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial. 2008 , 29, 1625-34	47
2206	Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: the Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial. 2008 , 29, 2733-41	32
2205	ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007. 2009 , 30, 152-61	25
2204	Culotte stenting technique in coronary bifurcation disease: angiographic follow-up using dedicated quantitative coronary angiographic analysis and 12-month clinical outcomes. 2008 , 29, 2868-76	81
2203	Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. 2008 , 29, 1975-82	158

2202	Late stent thrombosis after drug-eluting stent implantation for acute myocardial infarction: a new red flag is raised. <i>Circulation</i> , 2008 , 118, 1117-9	16.7	37
2201	Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. 2008 , 299, 1903-13		477
2200	Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. 2008 , 337, a1331		209
2199	Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should not be continued for more than 1 year and preferably indefinitely. 2008 , 1, 226-32		3
2198	The safety of drug-eluting stents. 2008 , 2, 43-52		6
2197	Nonrandomized comparison of coronary artery bypass surgery and percutaneous coronary intervention for the treatment of unprotected left main coronary artery disease in octogenarians. <i>Circulation</i> , 2008 , 118, 2374-81	16.7	128
2196	Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents. 2008 , 299, 2868-76		77
2195	Letter by Barlis et al regarding article, "Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry. <i>Circulation</i> , 2008 , 118, e679; author reply e681	16.7	4
2194	Primary percutaneous coronary intervention for acute myocardial infarction: long-term outcome after bare metal and drug-eluting stent implantation. 2008 , 1, 103-10		36
2193	A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. 2009 , 30, 923-31		104
2192	Bivalirudin during primary PCI in acute myocardial infarction. 2008 , 358, 2218-30		1457
2191	Next-generation drug-eluting stents: a spirited step forward or more of the same. 2008 , 299, 1952-3		2
2190	Clinical outcome after primary percutaneous coronary intervention with drug-eluting and bare metal stents in patients with ST-segment elevation myocardial infarction. 2008 , 1, 176-84		26
2189	Drug-eluting versus bare metal stents in patients with st-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. <i>Circulation</i> , 2008 , 118, 1155-62	16.7	58
2188	Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. 2009 , 30, 932-9		37
2187	XIENCE V SPIRIT WOMEN clinical trial: characterization of the female population undergoing stent implantation. 2008 , 4, 439-43		11
2186	Bare-metal versus drug-eluting coronary stents. 2008 , 358, 2516; author reply 2517-8		3
2185	Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study. 2008 , 29, 3011-21		37

2184	Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. 2008 , 299, 1788-99	214
2183	Duration of antiplatelet therapy following intracoronary stenting: are changes needed?. 2008 , 10, 125-129	5
2182	One-year clinical outcomes of dialysis patients after implantation with sirolimus-eluting coronary stents. 2008 , 72, 1430-5	34
2181	Peripheral endovascular revascularization trials: high noon for uniform reporting standards. 2008 , 108, 382-5	6
2180	Systemic immunosuppressive therapy with oral Sirolimus after bare metal stent implantation: the missing alternative in the prevention of coronary restenosis after percutaneous coronary interventions. 2008 , 3, 201-8	3
2179	Impact of diabetes mellitus on early and long-term results of percutaneous drug-eluting stent implantation for unprotected left main coronary disease. 2008 , 9, 1246-53	6
2178	Bibliography. Current world literature. Clinical trials. 2008 , 23, 407-21	
2177	Outcome observations with drug-eluting stents. 2008 , 9, 110-2	1
2176	A prospective multicentre observational study on the management of unprotected left main coronary artery disease: rationale and design of the Registro Italiano sul Trattamento del tronco comune non protetto study. 2008 , 9, 826-30	1
2175	Sirolimus-eluting cobalt-chromium stents: two-year clinical results from first-in-man study on the Firebird 2TM stent. 2008 , 121, 492-497	6
2174	Impact of admission creatinine level on clinical outcomes of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention with drug-eluting stent implantation. 2008 , 121, 2379-2383	2
2173	Prospective multicenter randomized trial comparing physician versus patient transfer for primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction. 2008 , 121, 485-491	13
2172	Long term efficacy and safety of Chinese made sirolimus eluting stents: results, including off label usage, from two centres over three years. 2008 , 121, 1670-1674	3
2171	Acute coronary syndrome is an independent risk factor for late incomplete stent apposition after sirolimus-eluting stent implantation. 2008 , 121, 2504-2508	2
2170	Comparação dos stents farmacológicos vs. stents convencionais para o tratamento do infarto agudo do miocárdio com supradesnivelamento do segmento ST: resultados do Registro EINSTEIN. 2008 , 16, 279-288	1
2169	Very late stent thrombosis after drug-eluting stent implantation in a patient without aspirin and clopidogrel resistance. 2008 , 23, 556-9	3
2168	Very late stent thrombosis after discontinuation of clopidogrel therapy. 2008 , 189, 229-30	5
2167	Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization. 2009 , 5, 101-19	11

2166	Are glycoprotein inhibitors safe during percutaneous coronary intervention in patients on chronic warfarin treatment?. 2009 , 102, 1227-33		22
2165	Very late thrombosis of a drug-eluting stent after discontinuation of dual antiplatelet therapy in a patient treated with both drug-eluting and bare-metal stents. 2009 , 39, 205-8		9
2164	Incredibly late thromboses in first generation drug eluting stents: a case series. 2009 , 2, 9303		1
2163	Emprego do stent farmacológico Supralimus?, com sirolimus e polímero absorvível, no tratamento de pacientes com síndrome coronária aguda submetidos a intervenção coronária percutânea. 2009 , 17, 491-497		
2162	Percutaneous coronary intervention in perspective: drug-eluting stents as a model for regulatory review. 2009 , 2, 574-9		3
2161	Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. 2009 , 7, 17-23		4
2160	Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. 2009 , 95, 1489-94		78
2159	Platelet inhibition with cangrelor in patients undergoing PCI. 2009 , 361, 2318-29		454
2158	Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. <i>Circulation</i> , 2009 , 119, 2986-94	16.7	382
2157	Xience V everolimus-eluting coronary stent. 2009 , 6, 219-29		28
2156	Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. 2009 , 2, 339-47		94
2155	Sirolimus-eluting stent treatment at high-volume centers confers lower mortality at 6-month follow-up: results from the prospective multicenter German Cypher Registry. <i>Circulation</i> , 2009 , 120, 600-6	16.7	11
2154	Long-term follow-up on a large cohort of "full-metal jacket" percutaneous coronary intervention procedures. 2009 , 2, 416-22		42
2153	Interventional cardiology: A new drug-eluting stent that does not live up to its promise. 2009 , 6, 500-1		2
2152	The drug-eluting stent saga. <i>Circulation</i> , 2009 , 119, 653-6	16.7	6
2151	High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. <i>Circulation</i> , 2009 , 120, 2214-21	16.7	99
2150	Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study. <i>Circulation</i> , 2009 , 119, 71-8	16.7	401
2149	Three-year outcomes after sirolimus-eluting stent implantation for unprotected left main coronary artery disease: insights from the j-Cypher registry. <i>Circulation</i> , 2009 , 120, 1866-74	16.7	87

2148	Comparison of plaque sealing with paclitaxel-eluting stents versus medical therapy for the treatment of moderate nonsignificant saphenous vein graft lesions: the moderate vein graft lesion stenting with the taxus stent and intravascular ultrasound (VELETI) pilot trial. <i>Circulation</i> , 2009 , 120, 1978-86	16.7	54
2147	MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses. 2009 , 30, 1477-85		19
2146	The quest for a 'better mousetrap'. 2009 , 30, 2431-2		1
2145	Dilemma of antithrombotic therapy in anticoagulated atrial fibrillation patients squeezed between thrombosis and bleeding events: a single-centre experience. 2009 , 11, 957-60		11
2144	Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. 2009 , 30, 2714-21		199
2143	Two-year follow-up after percutaneous coronary intervention with titanium-nitride-oxide-coated stents versus paclitaxel-eluting stents in acute myocardial infarction. 2009 , 41, 599-607		19
2142	Time does not heal every wound: coronary stent thrombosis of a bare-metal stent more than one decade after its implantation. 2009 , 20, 594-7		1
2141	Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study. 2009 , 95, 1483-8		57
2140	[Perioperative antiplatelet therapy of patients with coronary stents]. 2009 , 98, 1199-210		0
2139	Percutaneous coronary intervention outcomes in a low-volume center: survival, stent thrombosis, and repeat revascularization. 2009 , 2, 671-7		4
2138	Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior descending artery: analysis of the Arterial Revascularization Therapies study part 2 (ARTS-II). 2009 , 95, 1061-6		16
2137	Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. <i>Circulation</i> , 2009 , 119, 1634-42	16.7	166
2136	Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. <i>Circulation</i> , 2009 , 119, 828-34	16.7	127
2135	Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. 2009 , 30, 2441-9		180
2134	Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries. 2009 , 2, 285-93		67
2133	Unprotected left main stenting in the real world: two-year outcomes of the French left main taxus registry. <i>Circulation</i> , 2009 , 119, 2349-56	16.7	60
2132	The problem of stent thrombosis associated with drug-eluting stents and the optimal duration of dual antiplatelet therapy. 2009 , 12, 59-64		
2131	Drug-eluting stents and glycoprotein IIb/IIIa inhibitors in vessels at low anatomic risk: a retrospective analysis of previously published data from the Basel Stent Kosten Effektivitäts Trial. 2009 , 31, 2886-93		4

2130	Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. 2009 , 103, 5-10	237
2129	Effect of previous treatment with statins on outcome of patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. 2009 , 103, 165-9	38
2128	Three-year survival following multivessel percutaneous coronary intervention with bare-metal or drug-eluting stents in unselected patients. 2009 , 103, 203-11	10
2127	Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial. 2009 , 103, 345-9	48
2126	Comparison of outcomes of drug-eluting stents versus bare-metal stents in nonstial proximal left anterior descending coronary arteries. 2009 , 103, 496-500	6
2125	One-year outcomes from the TAXUS express stent versus cypher stent. 2009 , 103, 930-6	11
2124	Effectiveness of primary percutaneous coronary interventions for stent thrombosis. 2009 , 103, 913-6	21
2123	Two-year results of paclitaxel-eluting stents in patients with medically treated diabetes mellitus from the TAXUS ARRIVE program. 2009 , 103, 1663-71	20
2122	Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction. 2009 , 104, 514-8	29
2121	Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. 2009 , 104, 525-30	46
2120	Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. 2009 , 104, 1078-82	61
2119	Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry). 2009 , 104, 1362-9	33
2118	Effect of drug-eluting stents on frequency of repeat revascularization in patients with unstable angina pectoris or non-ST-elevation myocardial infarction. 2009 , 104, 1654-9	13
2117	Reasonable duration of Clopidogrel use after drug-eluting stent implantation in Korean patients. 2009 , 104, 1668-73	14
2116	[Clinical and angiographic outcomes after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique]. 2009 , 58, 208-14	
2115	Drug-eluting or bare-metal stents in subjects over 75 years of age: what is the best therapeutic strategy? Data from 460 consecutive patients with 1-year outcome. 2009 , 10, 94-102	2
2114	Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention. 2009 , 10, 144-50	18
2113	Early and mid-term clinical outcomes with the CATANIA coronary stent system vs. bare metal stents in patients with coronary artery disease. 2009 , 10, 216-20	4

2112	Clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents versus bare-metal stents in hemodialysis patients. 2009 , 54, 299-306	37
2111	The Current Status of Coronary Drug-Eluting Stents. 2009 , 21, 18-27	1
2110	Real world safety and efficacy of the Janus Tacrolimus-Eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting STent (TEST) registry. 2009 , 73, 243-8	18
2109	Long-term clinical outcomes after drug-eluting stent implantation in unprotected left main coronary artery disease. 2009 , 73, 291-8	19
2108	Defining a new standard for IVUS optimized drug eluting stent implantation: the PRAVIO study. 2009 , 74, 348-56	19
2107	Long-term clinical and angiographic outcomes after implantation of sirolimus-eluting stents with a "modified mini-crush" technique in coronary bifurcation lesions. 2009 , 74, 76-84	7
2106	The paclitaxel-eluting Coroflex Please stent study (PECOPS I): the 3-year clinical follow-up. 2009 , 74, 674-82	6
2105	The risk of cardiac complications following noncardiac surgery in patients with drug eluting stents implanted at least six months before surgery. 2009 , 74, 837-43	29
2104	Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: results from the Prairie "Real World" Stent Registry. 2010 , 75, 93-100	21
2103	Impact of intravascular ultrasound guidance in patients with acute myocardial infarction undergoing percutaneous coronary intervention. 2010 , 75, 86-92	23
2102	Five-year clinical follow-up after implantation of the Endeavor zotarolimus-eluting stent: ENDEAVOR I, first-in-human study. 2009 , 74, 989-95	23
2101	Clinical safety and efficacy of a novel thin-strut cobalt-chromium coronary stent system: results of the real world Coroflex Blue Registry. 2010 , 75, 78-85	16
2100	Five-year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus-eluting stents: insights from the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital-(Research) Registry. 2009 , 74, 979-86	24
2099	Evaluation of drug-eluting stents' coating durability--clinical and regulatory implications. 2009 , 91, 441-51	42
2098	A novel approach to define risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents: the DERIVATION score. 2009 , 98, 240-8	12
2097	Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions: the ACROSS/TOSCA-4 (Approaches to Chronic Occlusions With Sirolimus-Eluting Stents/Total Occlusion Study of Coronary Arteries-4) trial. 2009 , 2, 97-106	64
2096	Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting. 2009 , 2, 498-503	31
2095	The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. 2009 , 2, 534-41	115

2094	In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. 2009 , 2, 767-75	11
2093	Two cases of coronary stent thrombosis very late after bare-metal stenting. 2009 , 2, 1286-7	14
2092	3-year clinical outcome of patients with chronic total occlusion treated with drug-eluting stents. 2009 , 2, 1260-5	36
2091	Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions). 2009 , 2, 1178-87	22
2090	Grayscale intravascular ultrasound: Current concepts in percutaneous coronary interventions. 2009 , 2, 259-267	
2089	[Perioperative management of patients with coronary stents in non-cardiac surgery]. 2009 , 58, 971-85	30
2088	Clinical features of early recurrent myocardial infarction. 2009 , 24, 347-51	6
2087	Resolution of late sirolimus-eluting stent thrombosis after tirofiban treatment. 2009 , 24, 388-90	3
2086	Are drug-eluting stents safe?: Definitely! Or probably... possibly? Or maybe not yet. 2009 , 86, 127-30	1
2085	A critical appraisal of the safety and efficacy of drug-eluting stents. 2009 , 85, 474-80	32
2084	Long-term clinical follow-up after sirolimus-eluting stent versus bare metal stent implantation in patients with acute coronary syndrome. 2009 , 22, 216-21	3
2083	Performance of Everolimus-Eluting Stents: Pooled Analysis from the SPIRIT Trials. 2009 , 22, S41-S47	3
2082	Future Directions of Drug-Eluting Stents. 2009 , 22, S96-S105	3
2081	Clinical manifestation and prognosis of early versus late stent thrombosis of drug-eluting stents. 2009 , 22, 228-33	8
2080	Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting. 2009 , 22, 390-7	49
2079	Predictive factors of re-restenosis after repeated sirolimus-eluting stent implantation for SES restenosis and clinical outcomes after percutaneous coronary intervention for SES restenosis. 2009 , 22, 354-61	9
2078	The carina angle-new geometrical parameter associated with periprocedural side branch compromise and the long-term results in coronary bifurcation lesions with main vessel stenting only. 2009 , 22, E1-E10	44
2077	Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. 2009 , 7, 1612-8	28

2076	Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. 2009 , 2, 291-9	136
2075	Mini-crush versus T-provisional techniques in bifurcation lesions: clinical and angiographic long-term outcome after implantation of drug-eluting stents. 2009 , 2, 185-94	29
2074	First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial. 2009 , 2, 197-204	27
2073	TAXUS Libert [®] attenuates the risk of restenosis in patients with medically treated diabetes mellitus: results from the TAXUS ATLAS program. 2009 , 2, 240-52	24
2072	The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) trial. 2009 , 2, 205-14	30
2071	Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. 2009 , 2, 303-9	60
2070	The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. 2009 , 2, 515-23	64
2069	Characterization of post-operative risk associated with prior drug-eluting stent use. 2009 , 2, 542-9	66
2068	Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries. 2009 , 2, 603-10	50
2067	Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events. 2009 , 2, 504-12	38
2066	Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. 2009 , 2, 977-85	113
2065	Randomized comparison of primary percutaneous coronary intervention with combined proximal embolic protection and thrombus aspiration versus primary percutaneous coronary intervention alone in ST-segment elevation myocardial infarction: the PREPARE (PROximal Embolic Protection in Acute Myocardial Infarction) Study. 2009 , 2, 281-90	42
2064	Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. 2009 , 2, 967-76	41
2063	No association of chromosome 9p21.3 variation with clinical and angiographic outcomes after placement of drug-eluting stents. 2009 , 2, 1149-55	23
2062	Identifying the "optimal" duration of dual antiplatelet therapy after drug-eluting stent revascularization. 2009 , 2, 1279-85	29
2061	Clinical outcomes after unrestricted implantation of everolimus-eluting stents. 2009 , 2, 1219-26	23
2060	Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry. 2009 , 2, 1227-35	51
2059	3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). 2009 , 2, 1180-9	71

2058	Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). 2009 , 2, 1248-59		107
2057	Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De		46
2056	Clinical safety of cardiac magnetic resonance imaging at 3 T early after stent placement for acute myocardial infarction. 2009 , 19, 2913-8		3
2055	Three year follow-up of the sirolimus-eluting stent and the paclitaxel-eluting stent in daily practice. 2009 , 32, E63-7		3
2054	Long-term clinical outcomes after angiographically defined very late stent thrombosis of drug-eluting stent. 2009 , 32, 526-9		4
2053	Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Libert [®] paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2. 2009 , 2, 188-95		125
2052	Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. <i>Circulation</i> , 2009 , 119, 680-6	16.7	245
2051	Impact of moderate or severe renal insufficiency on long-term outcomes in patients undergoing drug-eluting stent based coronary intervention. 2009 , 136, 72-9		26
2050	Three-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomized comparison of bare-metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study). 2009 , 157, 149-55		45
2049	Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome. 2009 , 157, 375-82		42
2048	Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. 2009 , 157, 620-4.e2		79
2047	Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction. 2009 , 157, 688-94		27
2046	Vitamin K epoxide reductase complex subunit 1 gene polymorphism is associated with atherothrombotic complication after drug-eluting stent implantation: 2-Center prospective cohort study. 2009 , 157, 908-12		9
2045	Incidence of stent thrombosis and adverse cardiac events 5 years after sirolimus stent implantation in clinical practice. 2009 , 157, 883-8		17
2044	Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. 2009 , 157, 818-24, 824.e1		92
2043	Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable angina--comparison of the effects of drug-eluting versus bare-metal stents. 2009 , 158, 271-6		33
2042	Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: results of a double-blind, placebo-controlled, randomized trial. 2009 , 158, 941-7		19
2041	Design and rationale of the TRI-stent adjudication study (TRIAS) program. 2009 , 158, 527-532.e1		11

2040	SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. 2009 , 158, 520-526.e2	37
2039	Design and rationale of the WOEST trial: What is the Optimal antiplatelet and anticoagulant therapy in patients with oral anticoagulation and coronary Stenting (WOEST). 2009 , 158, 713-8	48
2038	Rationale and design of the Patient Related Outcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. 2009 , 158, 902-909.e5	38
2037	Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. 2009 , 158, 881-886.e1	27
2036	Guidelines for reporting mortality and morbidity after cardiac valve interventions--need for a reappraisal?. 2009 , 87, 357-8; discussion 359-60	11
2035	A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. 2009 , 53, 919-28	164
2034	Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. 2009 , 53, 849-56	543
2033	9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study. 2009 , 53, 1031-9	88
2032	Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. 2009 , 53, 1399-409	541
2031	Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. 2009 , 53, 1760-8	153
2030	Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. 2009 , 53, 2324-31	116
2029	Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting) study. 2009 , 53, 2324-31	37
2028	5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. 2009 , 54, 894-902	135
2027	The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry. 2009 , 54, 269-76	55
2026	Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents 70 restenotic cases from a cohort of 718 patients: FAILS (Failure in Left Main Study). 2009 , 54, 1131-6	44
2025	Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 2009 , 54, 1293-302	133
2024	Ticagrelor versus clopidogrel in patients with acute coronary syndromes. 2009 , 361, 1045-57	4753
2023	Comparison of medium-term outcomes obtained with drug-eluting stents and coronary artery bypass grafts in an unselected population of diabetic patients with multivessel coronary disease. Propensity score analysis. 2009 , 62, 491-500	4

2022	Safety and efficacy of coronary drug-eluting stents in octogenarians. 2009 , 62, 1250-9		3
2021	Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. 2009 , 32, 749-70		54
2020	Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. <i>Circulation</i> , 2009 , 120, 391-9	16.7	388
2019	Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. 2009 , 360, 1946-59		577
2018	Four-year outcome of OPCAB no-touch with total arterial Y-graft: making the best treatment a daily practice. 2009 , 88, 796-801		45
2017	[Transferability of clinical trials results into clinical practice: examples taken from cardiology]. 2009 , 103, 360-3		
2016	Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATElet inhibition and patient Outcomes (PLATO) trial. 2009 , 157, 599-605		302
2015	Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. 2009 , 373, 309-17		755
2014	A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. 2009 , 373, 897-910		642
2013	Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. 2009 , 374, 1149-59		308
2012	Comparaci3n de los resultados cl3nicos a medio plazo de los stents farmacoactivos frente a la cirug3a de revascularizaci3n coronaria en una poblaci3n no seleccionada de pacientes diab3ticos con afecci3n multivaso. An3lisis mediante propensity score. 2009 , 62, 491-500		13
2011	Seguridad y eficacia del empleo de stents intracoronarios farmacoactivos en el paciente octogenario. 2009 , 62, 1250-1259		3
2010	Three-year prognosis of Japanese patients with ST-elevation myocardial infarction treated with sirolimus-eluting stents. 2009 , 20, 422-7		11
2009	A prospective multicentre observational study on the management of patients on oral anticoagulation undergoing coronary artery stenting: rationale and design of the ongoing warfarin and coronary stenting (WAR-STENT) registry. 2009 , 10, 200-3		7
2008	A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale. 2009 , 10, 192-9		3
2007	Impact of multivessel stenting on top of percutaneous revascularization for unprotected left main disease in the drug-eluting stent era: insights from the Turin registry. 2009 , 10, 461-8		2
2006	The Problem With Composite End Points in Cardiovascular Studies: The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention. 2009 , 2009, 306-308		
2005	Long-term outcomes of intervention for unprotected left main coronary artery stenosis: coronary stenting vs coronary artery bypass grafting. 2009 , 73, 705-12		45

2004	Clinical outcomes of sirolimus-eluting stenting after rotational atherectomy. 2009 , 73, 2042-9	30
2003	Improved long-term prognosis of elderly women in the era of sirolimus-eluting stents. 2009 , 73, 1219-27	15
2002	Partial vs full coverage for tandem lesions in culprit vessel during primary coronary intervention in patients with acute ST-elevation myocardial infarction--the PERFECT-AMI study. 2009 , 73, 2236-43	2
2001	Predictors and prognosis of stent fracture after sirolimus-eluting stent implantation. 2009 , 73, 2036-41	43
2000	Stent thrombosis and duration of dual antiplatelet therapy. 2010 , 16, 4052-63	6
1999	Recent Advancements in Pharmacological Stent Therapy Using Polymeric Materials: Opportunities and Challenges. 2010 , 7, 216-24	2
1998	C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target. 2010 , 16, 4080-8	57
1997	Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent. 2010 , 21, 46-56	57
1996	Impact of angiographic and intravascular ultrasound features on clinical outcome after sirolimus-eluting stent implantation for de-novo lesions in nondiabetic and type 2 diabetic patients. 2010 , 21, 175-81	4
1995	Clinical studies with sirolimus, zotarolimus, everolimus, and biolimus A9 drug-eluting stent systems. 2010 , 16, 4012-24	9
1994	Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials. 2010 , 31, 1071-8	23
1993	Perioperative stent thrombosis. 2010 , 2, 821-828	
1992	The role of antiplatelet therapy in the secondary prevention of coronary artery disease. 2010 , 25, 321-8	12
1991	A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease. Study design and rationale of the EXECUTIVE trial. 2010 , 11, 299-309	3
1990	Rationale and design of the Randomized comparison of XiEnce V and Multilink VisioN coronary stents in the sAme muLtivessel patient with chronic kiDnEy disease (RENAL-DES) study. 2010 , 11, 310-7	7
1989	Twelve-month outcomes in patients with diabetes implanted with a zotarolimus-eluting stent: results from the E-Five Registry. 2010 , 96, 848-53	33
1988	Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. 2010 , 74, 679-85	35
1987	A 3-year clinical outcome after percutaneous coronary intervention using sirolimus-eluting stent and off-pump coronary artery bypass grafting for the treatment of diabetic patients with multivessel disease. 2010 , 74, 671-8	35

1986	Comparison of plain balloon and cutting balloon angioplasty for the treatment of restenosis with drug-eluting stents vs bare metal stents. 2010 , 74, 1837-45	16
1985	[Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study]. 2010 , 130, 1743-50	10
1984	'Real world' comparison of drug-eluting stents vs bare metal stents in the treatment of unselected patients with acute ST-segment elevation myocardial infarction. 2010 , 74, 1111-20	20
1983	Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent) registry. 2010 , 74, 2314-21	25
1982	Long-term clinical results and predictors of adverse outcomes after drug-eluting stent implantation for bifurcation lesions in a real-world practice: the COBIS (Coronary Bifurcation Stenting) registry. 2010 , 74, 2322-8	35
1981	Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. 2010 , 104, 626-32	23
1980	TWENTE Study: The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente: study design, rationale and objectives. 2010 , 18, 360-4	13
1979	Would SYNTAX have been a positive trial if XIENCE V had been used instead of TAXUS?: A meta-analysis of a first-generation vs. a second-generation drug-eluting stent system. 2010 , 18, 451-3	20
1978	One-year clinical follow-up of a registry evaluating a percutaneous revascularisation strategy combining a pre-specified simple selection process with the use of a new thin-strut bare cobalt-chromium stent. 2010 , 18, 486-92	2
1977	Long-term clinical outcomes of drug-eluting stents vs bare-metal stents in Chinese patients. 2010 , 33, E22-9	3
1976	Clinical and angiographic outcomes of drug-eluting stents in patients with large vessel and single coronary artery lesion. 2010 , 33, 340-4	3
1975	Two-year clinical outcomes after large coronary stent (4.0 mm) placement: comparison of bare-metal stent versus drug-eluting stent. 2010 , 33, 620-625	8
1974	A meta-analysis of randomized trials on clinical outcomes of paclitaxel-eluting stents versus bare-metal stents in ST-segment elevation myocardial infarction patients. 2010 , 11, 754-61	11
1973	Long stents as a risk factor for late stent thrombosis size does matter. 2010 , 3, 390-1	3
1972	Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents. 2010 , 3, 531-9	135
1971	Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program. 2010 , 3, 742-50	11
1970	Outcomes of percutaneous coronary intervention in intermediate coronary artery disease: fractional flow reserve-guided versus intravascular ultrasound-guided. 2010 , 3, 812-7	62
1969	Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. 2010 , 3, 828-35	53

1968	Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. 2010, 3, 1043-50	83
1967	Transradial versus transfemoral method of percutaneous coronary revascularization for unprotected left main coronary artery disease: comparison of procedural and late-term outcomes. 2010, 3, 1035-42	42
1966	Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V	32
1965	The immobilization of recombinant human tropoelastin on metals using a plasma-activated coating to improve the biocompatibility of coronary stents. 2010, 31, 8332-40	84
1964	Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. 2010, 99, 165-74	143
1963	Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. 2010, 99, 345-57	29
1962	Clinical outcomes in diabetic and non-diabetic patients with drug-eluting stents: results from the first phase of the prospective multicenter German DES.DE registry. 2010, 99, 393-400	23
1961	Applications of grayscale and radiofrequency intravascular ultrasound to image atherosclerotic plaque. 2010, 17, 913-27	1
1960	Incidence and outcome of surgical procedures after sirolimus-eluting stent implantation: a report from the j-Cypher registry. 2010, 25, 29-39	15
1959	Coronary stent thrombosis in the current era: challenges and opportunities for treatment. 2010, 12, 46-57	3
1958	Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. 2010, 11, 75-86	52
1957	Coronary artery bypass grafting versus drug-eluting stent implantation for left main coronary artery disease (from a two-center registry). 2010, 105, 343-51	29
1956	The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial). 2010, 105, 475-9	44
1955	Hematocrit level as a marker of outcome in ST-segment elevation myocardial infarction. 2010, 105, 435-40	33
1954	Results of intracoronary stem cell therapy after acute myocardial infarction. 2010, 105, 804-12	93
1953	Long-term prognostic value of preprocedural C-reactive protein after drug-eluting stent implantation. 2010, 105, 826-32	23
1952	Comparison of outcomes between Zotarolimus- and sirolimus-eluting stents in patients with ST-segment elevation acute myocardial infarction. 2010, 105, 813-8	14
1951	Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial). 2010, 105, 1053-9	32

1950	Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial). 2010 , 105, 1385-94	63
1949	Long-term outcomes after percutaneous coronary intervention in patients with and without diabetes mellitus in Western Denmark. 2010 , 105, 1513-9	35
1948	Prognosis of asymptomatic coronary artery disease after percutaneous coronary intervention. 2010 , 105, 1507-12	3
1947	Angiographic predictors of recurrent stent thrombosis (from the Outcome of PCI for stent-Thrombosis Multicentre Study [OPTIMIST]). 2010 , 105, 1710-5	9
1946	Comparison of long-term (4-year) outcomes of patients with unprotected left main coronary artery narrowing treated with drug-eluting stents versus coronary-artery bypass grafting. 2010 , 105, 1728-34	34
1945	Three-year outcome of sirolimus-eluting versus bare-metal stents for the treatment of ST-segment elevation myocardial infarction (from the MISSION! Intervention Study). 2010 , 106, 4-12	37
1944	Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher Registry). 2010 , 106, 329-36	89
1943	Three-year outcomes following sirolimus- versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry). 2010 , 106, 504-10	14
1942	Effect of coronary target lesion revascularization on late cardiac events after insertion of sirolimus-eluting or bare metal stents. 2010 , 106, 774-9	3
1941	Comparison of outcomes in patients with insulin-dependent versus non-insulin dependent diabetes mellitus receiving drug-eluting stents (from the first phase of the prospective multicenter German DES.DE registry). 2010 , 106, 1201-7	22
1940	Impact of transfer for primary percutaneous coronary intervention on survival and clinical outcomes (from the HORIZONS-AMI Trial). 2010 , 106, 1218-24	11
1939	Impact of completeness of revascularization on the five-year outcome in percutaneous coronary intervention and coronary artery bypass graft patients (from the ARTS-II study). 2010 , 106, 1369-75	62
1938	Comparison of five-year outcome of octogenarians undergoing percutaneous coronary intervention with drug-eluting versus bare-metal stents (from the RESEARCH and T-SEARCH Registries). 2010 , 106, 1376-81	9
1937	Safety and efficacy of sirolimus-eluting stent implantation in patients with acute coronary syndrome in the real world. 2010 , 106, 1550-60	12
1936	Clinical and angiographic outcomes after percutaneous recanalization of chronic total saphenous vein graft occlusion using modern techniques. 2010 , 106, 1721-7	41
1935	Left main coronary disease treated by direct surgical angioplasty: long-term results. 2010 , 89, 1151-7	7
1934	Fibrinolytic therapy for very late stent thrombosis--is it a viable option?. 2010 , 11, 264.e13-5	
1933	3-year follow-up of 100 consecutive coronary bifurcation lesions treated with Taxus stents and the crush technique. 2010 , 75, 605-13	7

1932	Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0 mm registry. 2010 , 75, 179-86	11
1931	Multicentre experience with MGuard net protective stent in ST-elevation myocardial infarction: safety, feasibility, and impact on myocardial reperfusion. 2010 , 75, 715-21	25
1930	Comparison of three-year clinical outcomes between sirolimus-versus paclitaxel-eluting stents in diabetic patients: prospective randomized multicenter trial. 2010 , 76, 924-33	13
1929	Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel. 2010 , 75, 936-42	7
1928	Long-term follow-up after nonurgent percutaneous coronary intervention in unprotected left main coronary arteries. 2010 , 75, 1026-36	3
1927	Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial. 2010 , 75, 997-1003	42
1926	Outcomes after differential use of drug-eluting stents in diabetic patients: 1-year results from the DES.DE (Drug-Eluting Stent.DEutschland) registry. 2010 , 76, 50-7	3
1925	An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: a pooled analysis from the SPIRIT II and SPIRIT III trials. 2010 , 76, 60-6	33
1924	Preliminary results of the INSPIRE trial with the novel MGuard stent system containing a protection net to prevent distal embolization. 2010 , 76, 86-92	29
1923	The EXTREME registry: titanium-nitride-oxide coated stents in small coronary arteries. 2010 , 76, 281-7	5
1922	Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease. 2010 , 76, 41-9	9
1921	Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: two-year angiographic and three-year clinical results from the SPIRIT II study. 2010 , 76, 634-42	94
1920	Standardized definitions and clinical endpoints in carotid artery and supra-aortic trunk revascularization trials. 2010 , 76, 333-44	12
1919	Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial. 2010 , 76, 644-51	14
1918	Sex-specific outcomes following revascularization with zotarolimus-eluting stents: comparison of angiographic and late-term clinical results. 2010 , 76, 804-13	13
1917	The titanium nitride oxide coated stent. 2010 , 76, 288-90	2
1916	Recurrent very late thrombosis of drug-eluting stent: Optical coherence tomography findings. 2010 , 2, e166-e169	
1915	Incidence and predictors of very late (>or=4 years) major cardiac adverse events in the DESIRE (Drug-Eluting Stents in the Real World)-Late registry. 2010 , 3, 12-8	43

1914	The relationship and threshold of stent length with regard to risk of stent thrombosis after drug-eluting stent implantation. 2010 , 3, 383-9	87
1913	Impact of multiple and long sirolimus-eluting stent implantation on 3-year clinical outcomes in the j-Cypher Registry. 2010 , 3, 180-8	40
1912	Serial angiography and intravascular ultrasound: results of the SISC Registry (Stents In Small Coronaries). 2010 , 3, 191-202	11
1911	A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent. 2010 , 3, 431-8	40
1910	The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of "oculostenotic" reintervention in patients with intermediate lesions. 2010 , 3, 403-11	74
1909	Long-term impact of routinely detected early and late incomplete stent apposition: an integrated intravascular ultrasound analysis of the TAXUS IV, V, and VI and TAXUS ATLAS workhorse, long lesion, and direct stent studies. 2010 , 3, 486-94	57
1908	Long-term clinical results following stenting of the left main stem: insights from RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxis-Stent Evaluated at Rotterdam Cardiology Hospital) Registries. 2010 , 3, 584-94	42
1907	Strut coverage and vessel wall response to zotarolimus-eluting and bare-metal stents implanted in patients with ST-segment elevation myocardial infarction: the OCTAMI (Optical Coherence Tomography in Acute Myocardial Infarction) Study. 2010 , 3, 680-7	54
1906	Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2 (Estudio Español Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2). 2010 , 3, 911-9	48
1905	Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) Studies. 2010 , 3, 1220-8	40
1904	Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents. 2010 , 3, 1240-9	34
1903	A history of late and very late stent thrombosis is not associated with increased activation of the contact system, a case control study. 2010 , 8, 6	1
1902	A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: design and statistical methods of the PERSEUS clinical program. 2010 , 11, 1	37
1901	Rationale and design of EXPLORE: a randomized, prospective, multicenter trial investigating the impact of recanalization of a chronic total occlusion on left ventricular function in patients after primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. 2010 , 11, 89	48
1900	Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. 2010 , 8, 351-9	113
1899	Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. 2010 , 8, 250-6	274
1898	Acute and subacute stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: incidence, predictors and clinical outcome. 2010 , 8, 2385-93	43
1897	Coronary stenting with the sirolimus-eluting stent in clinical practice: final results from the prospective multicenter German Cypher Stent Registry. 2010 , 23, 18-25	15

1896	Acute coronary syndromes in treatment-naïve black South africans with human immunodeficiency virus infection. 2010 , 23, 70-7	29
1895	Paclitaxel-eluting stents for chronically occluded saphenous vein grafts (EOS) study. 2010 , 23, 40-5	9
1894	Paclitaxel-Eluting Stents for Chronically Occluded Saphenous Vein Grafts (EOS) Study. 2010 ,	
1893	Safety and efficacy of bivalirudin for percutaneous coronary intervention with rotational atherectomy. 2010 , 23, 223-9	5
1892	Aggressive plaque modification with rotational atherectomy and/or cutting balloon before drug-eluting stent implantation for the treatment of calcified coronary lesions. 2010 , 23, 240-8	43
1891	Predictor of stent thrombosis in patients treated with turbostratic carbon-coated stent implantation for acute myocardial infarction. 2010 , 23, 554-9	3
1890	Stent thrombosis following 2 drug-eluting stent implantations for coronary bifurcation lesion: a single-center analysis. 2010 , 23, 346-51	0
1889	Prediction of clinical outcomes in patients with unprotected left main trifurcation lesions treated by drug-eluting stents: importance of 2-stent technique and SYNTAX score. 2010 , 23, 352-7	9
1888	Protein C and/or protein S deficiency and occurrence of stent thrombosis: a hitherto unrecognized association. 2010 , 23, 560-4	3
1887	Long-term (4-year) outcomes and predictors of adverse cardiac events after sirolimus-eluting stent implantation in unprotected left main coronary artery. 2010 , 51, 377-82	3
1886	Fortschritte in der Thrombozytenfunktionsdiagnostik. 2010 , 30, 217-229	6
1885	Impacto de stents farmacológicos em pacientes com doença arterial coronária estível submetidos a intervençõ coronária percutânea na prática diária do mundo real. 2010 , 18, 392-399	
1884	Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update. 2010 , 6, 855-67	9
1883	The effect of cilostazol on stent thrombosis after drug-eluting stent implantation. 2010 , 40, 10-5	6
1882	Efficacy of sirolimus-eluting stents compared with paclitaxel-eluting stents in an unselected population with coronary artery disease: 24-month outcomes of patients in a prospective non-randomized registry in Southern Turkey. 2010 , 7, 191-6	2
1881	Coronary stent thrombosis in patients with chronic renal insufficiency. 2010 , 61, 297-303	3
1880	Very long-term (15 to 20 years) clinical and angiographic outcome after coronary bare metal stent implantation. 2010 , 3, 468-75	73
1879	Rationale and design of a randomized clinical comparison of everolimus-eluting (Xience v/Promus) and sirolimus-eluting (cypher select+) coronary stents in unselected patients with coronary heart disease. 2010 , 116, 73-8	17

1878	Paclitaxel-eluting versus sirolimus-eluting stents in diabetes mellitus: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. 2010 , 3, 42-9		13
1877	Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. 2010 , 304, 1339-49		130
1876	Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). <i>Circulation</i> , 2010 , 122, 52-61	16.7	197
1875	Long-term outcome of adjunctive celecoxib treatment after paclitaxel-eluting stent implantation for the complex coronary lesions: two-year clinical follow-up of COREA-TAXUS trial. 2010 , 3, 243-8		7
1874	CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. 2010 , 31, 3046-53		118
1873	Altered plasma fibrin clot properties are associated with in-stent thrombosis. 2010 , 30, 276-82		49
1872	Role of the paclitaxel-eluting stent and tirofiban in patients with ST-elevation myocardial infarction undergoing postfibrinolysis angioplasty: the GRACIA-3 randomized clinical trial. 2010 , 3, 297-307		28
1871	Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. <i>Circulation</i> , 2010 , 122, 2301-12	16.7	268
1870	Comparison of the long-term safety and efficacy of drug-eluting and bare-metal stent implantation in saphenous vein grafts. 2010 , 3, 249-56		16
1869	Strut coverage and vessel wall response to a new-generation paclitaxel-eluting stent with an ultrathin biodegradable abluminal polymer: Optical Coherence Tomography Drug-Eluting Stent Investigation (OCTDESI). 2010 , 3, 367-75		56
1868	Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. 2010 , 303, 754-62		632
1867	Drug-eluting versus bare-metal stents in large coronary arteries. 2010 , 363, 2310-9		203
1866	Elevated CK-MB values after routine angioplasty predicts worse long-term prognosis in low-risk patients. 2010 , 44, 69-75		2
1865	Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. 2010 , CD004587		45
1864	Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). 2010 , 31, 1311-8		179
1863	Clinical outcome of coronary stenting after thoracic radiotherapy: a case-control study. 2010 , 96, 678-82		18
1862	Sirolimus-eluting stent versus balloon angioplasty for sirolimus-eluting stent restenosis: Insights from the j-Cypher Registry. <i>Circulation</i> , 2010 , 122, 42-51	16.7	34
1861	Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Libert [®] paclitaxel-eluting stent in de novo native coronary artery lesions. 2010 , 3, 556-64		46

1860	Genous endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. 2010 , 31, 1055-64	96
1859	Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. 2010 , 31, 1172-80	209
1858	Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. 2010 , 31, 59-66	85
1857	Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. 2010 , 31, 582-7	48
1856	Circulating endothelial progenitor cell levels and function in patients who experienced late coronary stent thrombosis. 2010 , 31, 2625-32	31
1855	Comparison of sirolimus-eluting and bare metal stent for treatment of patients with total coronary occlusions: results of the GISSOC II-GISE multicentre randomized trial. 2010 , 31, 2014-20	48
1854	ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. 2010 , 31, 2482-91	69
1853	Late and very late drug-eluting stent malapposition: serial 2-year quantitative IVUS analysis. 2010 , 3, 335-40	22
1852	Current status of the Xience V [®] everolimus-eluting coronary stent system. 2010 , 8, 1363-74	9
1851	Nano- and Biotechnological Approaches in Current and Future Generation of Cardiovascular Stents. 2010 , 6, 469-478	7
1850	Benefits of and safety concerns associated with drug-eluting coronary stents. 2010 , 8, 449-70	20
1849	Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. 2010 , 363, 930-42	582
1848	Scaling new heights in quality improvement: the PINNACLE (Practice Innovation And Clinical Excellence) program. 2010 , 56, 15-7	2
1847	Drug-eluting stents: issues of late stent thrombosis. 2010 , 28, 97-105	16
1846	Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial. 2010 , 26, 2077-85	8
1845	Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. 2010 , 362, 1663-74	700
1844	A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. 2010 , 55, 543-54	193
1843	Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years. 2010 , 55, 613-6	19

1842	Increased rate of stent thrombosis and target lesion revascularization after filter protection in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: 15-month follow-up of the DEDICATION (Drug Elution and Distal Protection in ST Elevation Myocardial Infarction) trial. 2010, 55, 867-71	30
1841	Intravascular ultrasound findings in patients with very late stent thrombosis after either drug-eluting or bare-metal stent implantation. 2010, 55, 1936-42	115
1840	5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. 2010, 55, 1093-101	172
1839	Stent thrombosis: the effect of intention on perception. 2010, 55, 1943-4	2
1838	Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization: a systematic review and meta-analysis. 2010, 55, 1854-66	113
1837	Sirolimus- versus paclitaxel-eluting stents for the treatment of coronary bifurcations results: from the COBIS (Coronary Bifurcation Stenting) Registry. 2010, 55, 1743-50	48
1836	Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. 2010, 55, 2710-6	162
1835	Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial. 2010, 56, 272-7	171
1834	Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial. 2010, 56, 264-71	55
1833	Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial. 2010, 56, 641-5	63
1832	New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. 2010, 56, 1542-51	86
1831	Stent thrombosis. 2010, 56, 1357-65	312
1830	In-stent restenosis in the drug-eluting stent era. 2010, 56, 1897-907	520
1829	Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. 2010, 56, 1597-604	69
1828	Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). 2010, 56, 2084-9	77
1827	Thrombus aspiration for the treatment of definite stent thrombosis. 2010, 103, 33-8	3
1826	Hybrid revascularization, comprising coronary artery bypass graft with exclusive arterial conduits followed by early drug-eluting stent implantation, in multivessel coronary artery disease. 2010, 103, 502-11	24
1825	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. 2010, 103, 13-28	232

1824	Effect of stent thrombosis on the risk-benefit balance of drug-eluting stents and bare metal stents. 2010 , 63, 528-35		
1823	Very late restenosis of a paclitaxel-eluting stent implanted to treat previous in-stent restenosis of a bare metal stent. 2010 , 63, 1101-3		
1822	Sudden cardiac death in a case of undiagnosed pericardial agenesis. 2010 , 63, 1103-5		2
1821	Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. 2010 , 363, 1597-607		4801
1820	Incidencia de trombosis de stents coronarios en el «mundo real». 2010 , 17, 99-105		
1819	Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. 2010 , 363, 136-46		519
1818	Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. <i>Circulation</i> , 2010 , 122, 2131-41	16.7	392
1817	Drug-eluting stents for the treatment of acute myocardial infarction: the view to the HORIZONS. 2010 , 19, 11-8		1
1816	Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: data from the REAL registry. 2010 , 140, 154-60		18
1815	Long-term follow-up of patients with sirolimus-eluting stents for treatment of bare-metal in-stent restenosis. 2010 , 140, 219-25		4
1814	Renal function and drug-eluting stent. 2010 , 142, 92-4		9
1813	Clinical outcomes of drug-eluting stent use in patients with ST elevation myocardial infarction. 2010 , 143, 283-8		6
1812	Long-term clinical outcome with titanium-nitride-oxide-coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population. 2010 , 144, 42-6		17
1811	Sirolimus- vs. paclitaxel-eluting stents in patients undergoing off-label percutaneous coronary intervention. 2010 , 145, 299-300		
1810	Long-term clinical outcome and prognosis after treatment of the first generation drug-eluting stent thrombosis. 2010 , 145, 564-6		4
1809	Involvement of aldosterone-mineralocorticoid receptor system in advanced glycation end product (AGE)-elicited plasminogen activator inhibitor-1 (PAI-1) expression in diabetes. 2010 , 145, 566-7		3
1808	One-year clinical outcome after treatment of bare-metal stent in-stent restenosis with the paclitaxel-eluting stent in an unselected cohort. 2010 , 145, 608-9		
1807	Absence of metal allergy in patients with very late drug-eluting stent thrombosis: a pilot study. 2010 , 145, 629-30		7

1806	Coronary ischemia and percutaneous intervention. 2010 , 19, 12-21		1
1805	Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. 2010 , 103, 151-9		114
1804	Long-term outcome of percutaneous catheter intervention for de novo coronary bifurcation lesions with drug-eluting stents or bare-metal stents. 2010 , 159, 454-61		19
1803	Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP. 2010 , 159, 434-8		8
1802	The outcome of primary percutaneous coronary intervention for stent thrombosis causing ST-elevation myocardial infarction. 2010 , 159, 672-6		24
1801	Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation. 2010 , 159, 891-898.e1		35
1800	Iatrogenic left main coronary artery dissection: incidence, classification, management, and long-term follow-up. 2010 , 159, 1147-53		54
1799	Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVALuate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). 2010 , 160, 65-72		65
1798	Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents. 2010 , 160, 355-61		16
1797	Real-world outcome of coronary bifurcation lesions in the drug-eluting stent era: results from the 4,314-patient Italian Society of Invasive Cardiology (SICI-GISE) Italian Multicenter Registry on Bifurcations (I-BIGIS). 2010 , 160, 535-542.e1		38
1796	Serial angiographic findings and prognosis of stent fracture site without early restenosis after sirolimus-eluting stent implantation. 2010 , 160, 775.e1-9		6
1795	Fondaparinux with UnfracTionated heparin dURING Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with aspirin and clopidogrel. 2010 , 160, 101-10		16
1794	Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions.		132
1793	Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. 2010 , 160, 795-803.e2		19
1792	Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. <i>Circulation</i> , 2010 , 121, 512-8	16.7	444
1791	Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. <i>Circulation</i> , 2010 , 121, 2645-53	16.7	458
1790	Stent thrombosis--risk assessment and prevention. 2010 , 28, e92-100		17
1789	Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. 2010 , 213, 256-62		48

1788	One-year clinical outcome after provisional T-stenting for bifurcation lesions with the endothelial progenitor cell capturing stent compared with the bare-metal stent. 2010 , 213, 525-31	9
1787	Influencia de la trombosis del stent en la relación riesgo-beneficio de los stents farmacoactivos y los stents convencionales. 2010 , 63, 528-535	2
1786	Reestenosis muy tardã de un stent farmacoactivo recubierto de paclitaxel empleado como tratamiento de una previa reestenosis intra-stent de un stent convencional. 2010 , 63, 1101-1103	
1785	Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. 2010 , 375, 201-9	560
1784	Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. 2010 , 375, 283-93	531
1783	Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. 2010 , 375, 1090-9	174
1782	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. 2010 , 376, 1233-43	624
1781	Long-term outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice: a Canadian experience. 2010 , 26, e40-4	7
1780	Coronary stents: factors contributing to perioperative major adverse cardiovascular events. 2010 , 105 Suppl 1, i3-15	101
1779	Vigorous exercise as a triggering mechanism for late stent thrombosis: A description of three cases. 2010 , 21, 72-6	10
1778	The comparative safety of bare-metal and drug-eluting intracoronary stents. 2010 , 7, 611-24	4
1777	Competing risk analysis of events 10 years after revascularization. 2010 , 44, 279-88	7
1776	Clinical safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents in patients with coronary artery disease. 2011 , 43, 75-9	
1775	Biolimus-eluting biodegradable polymer-coated stent versus bare metal stent in acute ST-elevation and non-ST elevation myocardial infarction: Justification for biodegradable polymer-coated stent in acute coronary syndrome (JANICE) registry. 2011 , 13, 43-7	
1774	Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development. 2011 , 20, 119-33	11
1773	Angiographic and long-term clinical outcome of the sleeve technique in treating in-stent restenotic bifurcation lesions: a preliminary experience. 2011 , 13, 159-63	2
1772	No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. 2011 , 32, 1605-13	158
1771	Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform. Report of a policy conference of the European Society of Cardiology. 2011 , 32, 1673-86	53

1770	RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. 2011 , 32, 2541-54	142
1769	Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization?. <i>Circulation</i> , 2011 , 123, 779-97	16.7 327
1768	Intravascular ultrasound results from the NEVO ResElution-I trial: a randomized, blinded comparison of sirolimus-eluting NEVO stents with paclitaxel-eluting TAXUS Libert'stents in de novo native coronary artery lesions. 2011 , 4, 146-54	13
1767	Pronóstico a medio plazo del intervencionismo percutáneo electivo sobre el tronco común de la coronaria izquierda. Experiencia multicéntrica. 2011 , 46, 143-149	1
1766	Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. 2011 , 57, 390-8	245
1765	FAME and coronary stent investigations: is there a kink in the wire?. 2011 , 57, 115-6; author reply 116	2
1764	With the "universal definition," measurement of creatine kinase-myocardial band rather than troponin allows more accurate diagnosis of periprocedural necrosis and infarction after coronary intervention. 2011 , 57, 653-61	88
1763	Reply. 2011 , 57, 116	
1762	Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. 2011 , 57, 538-45	306
1761	Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population: a report from the e-SELECT (Multi-Center Post-Market Surveillance) registry. 2011 , 57, 1445-54	42
1760	Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. 2011 , 57, 253-69	662
1759	Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization. 2011 , 57, 2143-51	78
1758	The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention). 2011 , 57, 2221-32	84
1757	Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis. 2011 , 57, 2309-16	43
1756	A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. 2011 , 57, 1700-8	170
1755	Bleeding avoidance strategies. Consensus and controversy. 2011 , 58, 1-10	126
1754	6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm. 2011 , 58, 258-64	39
1753	Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. 2011 , 58, 704-11	192

1752	Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. 2011 , 57, 1778-83	121
1751	High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. 2011 , 58, 467-73	181
1750	Learning to walk before we run: the mechanics of medical intervention for peripheral arterial disease. 2011 , 58, 1077-9	2
1749	Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. 2011 , 58, 1569-77	223
1748	Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. 2011 , 58, 1844-54	123
1747	2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice. 2011 , 4, 887-95	29
1746	Long-term outcome of percutaneous coronary intervention for chronic total occlusions. 2011 , 4, 952-61	213
1745	1-year outcome of TRIAS HR (TRI-stent adjudication study-high risk of restenosis) a multicenter, randomized trial comparing genous endothelial progenitor cell capturing stents with drug-eluting stents. 2011 , 4, 896-904	40
1744	Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. 2011 , 4, 1057-66	302
1743	Sirolimus-eluting coronary stents in octogenarians: a 1-year analysis of the worldwide e-SELECT Registry. 2011 , 4, 982-91	9
1742	Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. 2011 , 4, 1119-28	28
1741	Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Disease in Patients With Stable Coronary Disease) Trials. 2011 , 4, 1101-15	69
1740	Impact of intravascular ultrasound imaging on early and late clinical outcomes following percutaneous coronary intervention with drug-eluting stents. 2011 , 4, 974-81	90
1739	Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second generation everolimus-eluting and paclitaxel-eluting stents in real-life practice)	82
1738	A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study). 2011 , 4, 1298-309	48
1737	One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent. 2011 , 104, 604-10	11
1736	Impact of abciximab in elderly patients with high-risk acute coronary syndrome undergoing percutaneous coronary intervention: an observational registry study. 2011 , 28, 369-78	1
1735	Comprehensive Cardiovascular Medicine in the Primary Care Setting. 2011 ,	

1734 Thrombose de stent. **2011**, 2011, 31-34

1733	Simple or complex stenting for bifurcation coronary lesions: a patient-level pooled-analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. 2011 , 4, 57-64	118
1732	Apixaban with antiplatelet therapy after acute coronary syndrome. 2011 , 365, 699-708	765
1731	Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2)	70
1730	Impact of intravascular ultrasound guidance on long-term clinical outcomes in patients treated with drug-eluting stent for bifurcation lesions: data from a Korean multicenter bifurcation registry. 2011 , 161, 180-7	82
1729	A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study. 2011 , 161, 650-656.e1	22
1728	Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. 2011 , 161, 391-6	44
1727	Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. 2011 , 161, 605-10	28
1726	Value of the SYNTAX score in patients treated by primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: The MI SYNTAXscore study. 2011 , 161, 771-81	89
1725	Rationale and design of the clinical evaluation of the Resolute Zotarolimus-Eluting Coronary Stent System in the treatment of de novo lesions in native coronary arteries (the RESOLUTE US clinical trial). 2011 , 161, 807-14	18
1724	Changes in reference vessel diameter in ST-segment elevation myocardial infarction after primary percutaneous coronary intervention: implications for appropriate stent sizing. 2011 , 162, 173-7	7
1723	Long-term clinical outcome in patients with small vessel disease treated with drug-eluting versus bare-metal stenting. 2011 , 162, 907-13	20
1722	Mode of death after contemporary percutaneous coronary intervention: a report from the Evaluation of Drug Eluting Stents and Ischemic Events registry. 2011 , 162, 914-21	10
1721	Relationship between angiographic dynamic and densitometric assessment of myocardial reperfusion and survival in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: the harmonizing outcomes with revascularization and stents in AMI (HORIZONS-AMI) trial. 2011 , 162, 1844-51	19
1720	Risk of target lesion failure in relationship to vessel angiographic geometry and stent conformability using the second generation of drug-eluting stents. 2011 , 162, 1069-1079.e2	13
1719	Impact of female sex on long-term outcomes in patients with ST-elevation myocardial infarction treated by primary percutaneous coronary intervention. 2011 , 27, 749-55	20
1718	Residual platelet reactivity after aspirin and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing percutaneous coronary intervention. 2011 , 22, 471-7	13
1717	Focused clinical review: periprocedural management of antiplatelet therapy in patients with coronary stents. 2011 , 20, 438-45	7

1716	High on treatment platelet reactivity and stent thrombosis. 2011 , 20, 525-31	10
1715	Stent thrombosis: nightmare of the interventional cardiology era. 2011 , 148, e51-2	3
1714	A new approach to percutaneous coronary revascularization in patients requiring undeferrable non-cardiac surgery. 2011 , 146, 399-403	12
1713	Long-term safety and efficacy of sirolimus- vs. paclitaxel-eluting stent implantation for acute ST-elevation myocardial infarction: 3-year follow-up of the PROSIT trial. 2011 , 147, 253-7	25
1712	Left ventricular support device for cardiogenic shock during myocardial infarction due to stent thrombosis: a single centre experience. 2011 , 148, 337-40	4
1711	Renal dysfunction and high levels of hsCRP are additively associated with hard endpoints after percutaneous coronary intervention with drug eluting stents. 2011 , 149, 174-181	22
1710	Sirolimus- vs. paclitaxel-eluting stents for the treatment of unprotected left main coronary artery stenosis: complete 2-year follow-up of a two-center registry. 2011 , 151, 89-95	7
1709	High-risk PCI in acute coronary syndromes with Impella LP 2.5 device support. 2011 , 153, 59-63	24
1708	What is optimal revascularization strategy in patients with multivessel coronary artery disease in non-ST-elevation myocardial infarction? Multivessel or culprit-only revascularization. 2011 , 153, 148-53	38
1707	Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials. 2011 , 150, 84-9	30
1706	The doubtful association between blood lipid changes and progression of coronary calcification. 2011 , 153, 224-5	
1705	Prasugrel and bivalirudin for primary angioplasty: early results on stent thrombosis and bleeding. 2011 , 153, 222-4	11
1704	Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. 2011 , 32, 2125-34	417
1703	Long-term safety and efficacy of drug-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized trials. 2011 , 217, 149-57	21
1702	Elevated plasma asymmetric dimethylarginine level in acute myocardial infarction patients as a predictor of poor prognosis and angiographic impaired reperfusion. 2011 , 219, 304-10	21
1701	Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. 2011 , 377, 1241-7	192
1700	Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. 2011 , 378, 693-703	217
1699	Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. 2011 , 378, 1940-8	283

1698	Drug-eluting coronary stents - focus on improved patient outcomes. 2011 , 2, 161-74	10
1697	Two-year clinical outcomes of patients with long segments drug-eluting stents: comparison of sirolimus-eluting stent with paclitaxel-eluting stent. 2011 , 26, 1299-304	4
1696	Two-year outcome of Turkish patients treated with Zotarolimus versus Paclitaxel eluting stents in an unselected population with coronary artery disease in the real world: a prospective non-randomized registry in southern Turkey. 2011 , 8, 68-73	2
1695	Clinical outcomes by geographic region for patients implanted with the zotarolimus-eluting stent. 2011 , 96, 353-62	1
1694	Stents farmacológicos liberadores de Everolimus Xience™ V no tratamento de pacientes com lesões coronárias complexas na prática diária: resultados iniciais do registro brasileiro BRAVO. 2011 , 19, 357-366	2
1693	Comparação randomizada entre o stent eluidor de paclitaxel de nova geração sem polímero e o stent eluidor de paclitaxel com polímero durável em pacientes com doença arterial coronária: resultados da análise angiográfica e ultrassonográfica seriada do estudo PAX-A. 2011 , 19, 379-391	2
1692	Culprit-Lesion-Only Versus Multivessel Revascularization Using Drug-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: A Korean Acute Myocardial Infarction Registry-Based Analysis. 2011 , 41, 718-25	30
1691	Análise ultrassonográfica tardia do stent eluidor de sirolimus Firebird™. 2011 , 19, 286-291	1
1690	Comparison of clinical outcomes of hydrophilic and lipophilic statins in patients with acute myocardial infarction. 2011 , 26, 294-303	33
1689	Is increased platelet turnover responsible for low responsiveness to different thienopyridines? A case report of recurrent stent thromboses. 2011 , 106, 182-4	12
1688	The impact of moderate to severe renal insufficiency on patients with acute myocardial infarction. 2011 , 41, 308-12	1
1687	Comparing two-stent strategies for bifurcation coronary lesions: which vessel should be stented first, the main vessel or the side branch?. 2011 , 26, 1031-40	5
1686	Association on cardiovascular interventions of PCS Current status of drug-eluting stents and drug-eluting balloons in patients with stable coronary artery disease: An expert consensus document of the Association for Percutaneous Cardiovascular Interventions and Polish Cardiac Society. 2011 , 1, 20-55	
1685	Coronary bifurcation stenting with dedicated Tryton side-branch stent. Early and 6-month results of 40 patients. 2011 , 1, 1-7	
1684	Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events. 2011 , 106, 230-9	38
1683	Drug-Eluting Stents. 2011 , 427-448	5
1682	Prognostic significance of mean platelet volume on admission in an unselected cohort of patients with non ST-segment elevation acute coronary syndrome. 2011 , 106, 132-40	32
1681	The genetic basis of platelet responsiveness to clopidogrel. A critical review of the literature. 2011 , 106, 203-10	11

1680	A retrospective analysis of consecutive patients undergoing nonurgent percutaneous coronary intervention comparing bare metal stents with drug-eluting stents using the National Institute for Clinical Excellence criteria. 2011 , 22, 32-9	5
1679	Complete resolution of very late stent thrombosis with systemic thrombolysis. 2011 , 12, 765-7	1
1678	Impact of smoking on acute phase outcomes of myocardial infarction. 2011 , 22, 217-22	18
1677	Intravascular Ultrasound: Its Use and Limitations in Cardiac Catheterization Laboratory. 2011 , 1, 67-71	
1676	Elevated serum uric acid predicts angiographic impaired reperfusion and 1-year mortality in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention. 2011 , 59, 931-7	24
1675	From treating complex coronary artery disease to promoting cardiovascular health: therapeutic transitions and challenges, 2010-2020. 2011 , 90, 509-18	17
1674	Coronary stent thrombosis: incidence, predictors and triggering mechanisms. 2011 , 3, 581-588	2
1673	Safety and efficacy of exercise training after coronary stenting in patients with stable coronary artery disease. 2011 , 75, 2379-86	7
1672	Clinical and angiographic outcomes with sirolimus-eluting stent for coronary bifurcation lesions. The J-PMS study. 2011 , 75, 306-14	6
1671	Comparison of drug-eluting stent with bare metal stent for distal de novo unprotected left main coronary artery stenosis. A propensity score-matched cohort study. 2011 , 75, 290-8	5
1670	High plasma interleukin-6 is associated with drug-eluting stent thrombosis: possible role of inflammatory cytokines in the development of stent thrombosis from the Korea Stent Thrombosis Registry. 2011 , 75, 1350-7	13
1669	Long-term benefit of the TAXUS Libert [®] stent in small vessels and long lesions. TAXUS ATLAS program. 2011 , 75, 1120-9	9
1668	Efficacy of paclitaxel-eluting stent in patients with impaired glucose tolerance--comparison with sirolimus-eluting stent. 2011 , 75, 868-73	2
1667	Inter- and intra-observer variability for assessment of the synergy between percutaneous coronary intervention with TAXUS and cardiac surgery (SYNTAX) score and association of the SYNTAX score with clinical outcome in patients undergoing unprotected left main stenting in the real world. 2011 , 75, 1130-7	27
1666	Characteristics and predictors of drug-eluting stent thrombosis: results from the multicenter 'Korea Stent Thrombosis (KoST)' registry. 2011 , 75, 1626-32	26
1665	Prognostic value of N-terminal pro-B-type natriuretic peptide in patients with acute coronary syndromes undergoing left main percutaneous coronary intervention. 2011 , 75, 2648-53	9
1664	Inhibitory interaction between calcium channel blocker and clopidogrel. -Efficacy of cilostazol to overcome it-. 2011 , 75, 2581-9	13
1663	Comparison of paclitaxel-, sirolimus-, and zotarolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction and metabolic syndrome. 2011 , 75, 2120-7	11

1662	Coronary stenting with the GenousâBio-Engineered R StentâIn elderly patients. 2011 , 75, 2590-7	9
1661	Retrospective comparison of the clinical and angiographic outcomes of the sirolimus-eluting stent and the bare-metal stent in 2031 nonrandomized consecutive de novo native coronary lesions. 2011 , 50, 2463-70	6
1660	Clinical outcomes and the risk factors of coronary artery aneurysms that developed after drug-eluting stent implantation. 2011 , 75, 861-7	20
1659	Effectiveness of paclitaxel-eluting stents in complex clinical patients. -Insights from the TAXUS Japan Postmarket surveillance study.-. 2011 , 75, 2573-80	12
1658	Lower fetuin-A predicts angiographic impaired reperfusion and mortality in ST-elevation myocardial infarction. 2011 , 59, 816-22	9
1657	Prevalence and predictors of premature discontinuation of dual antiplatelet therapy after drug-eluting stent implantation: importance of social factors in Asian patients. 2011 , 41, 623-9	9
1656	A case-control study on platelet reactivity in patients with coronary stent thrombosis. 2011 , 9, 909-16	18
1655	Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial. 2011 , 24, 105-11	25
1654	Does occlusion duration influence procedural and clinical outcome of patients who underwent percutaneous coronary intervention for chronic total occlusion?. 2011 , 24, 223-31	11
1653	Two-year clinical outcomes with paclitaxel-eluting coronary stents in patients with chronic total occlusions: analysis from the TAXUS ARRIVE program. 2011 , 24, 232-40	3
1652	Twelve-month outcomes after coronary stenting with the GenousâBio-engineered R StentâIn diabetic patients from the e-HEALING registry. 2011 , 24, 285-94	8
1651	Low stent thrombosis risk with the XIENCE Vâ Everolimus-Eluting Coronary Stent: evidence from randomized and single-arm clinical trials. 2011 , 24, 326-41	8
1650	The real world experience of the everolimus-eluting coronary stent system: audit of everolimus-eluting coronary stents. 2011 , 24, 241-6	2
1649	Do patients with drug-eluting stent thrombosis have a similar prognosis to patients presenting with st-Elevation myocardial infarction of de novo lesions?. 2011 , 24, 320-5	5
1648	Two-Year outcomes after utilization of the TAXUS paclitaxel-eluting stent in bifurcations and multivessel stenting in the ARRIVE registries. 2011 , 24, 342-50	2
1647	Long-term clinical and angiographic results of Sirolimus-Eluting Stent in Complex Coronary Chronic Total Occlusion Revascularization: the SECTOR registry. 2011 , 24, 426-36	28
1646	Spot drug-eluting stenting for long coronary stenoses: long-term results of a randomized clinical study. 2011 , 24, 437-41	1
1645	Three-year clinical follow-up of an unselected patient population treated with the genous endothelial progenitor cell capturing stent. 2011 , 24, 442-9	9

1644	Early angio-guided complete revascularization versus culprit vessel PCI followed by ischemia-guided staged PCI in STEMI patients with multivessel disease. 2011 , 24, 535-41	23
1643	One-year outcomes with angiographic follow-up of paclitaxel-eluting balloon for the treatment of in-stent restenosis: insights from Spanish multicenter registry. 2011 , 24, 518-28	25
1642	Long-term clinical outcome of thin-strut cobalt-chromium stents in the drug-eluting stent era: results of the COBALT (comparison of bare-metal stents in all-comers' lesion treatment) registry. 2011 , 24, 496-504	12
1641	Three-year clinical outcome with the Endeavorâ€Žotarolimus-eluting stent in primary percutaneous coronary intervention for ST elevation myocardial infarction: the Endeavorâ€Žprimary PCI study (E-PPCI). 2011 , 24, 542-8	3
1640	Retrospective comparison of clinical and angiographic outcomes after primary stenting using sirolimus-eluting and bare-metal stents in nonrandomized consecutive 568 patients with first ST-segment elevated myocardial infarctions. 2011 , 57, 44-52	13
1639	Stent thrombosis and drug-eluting stents. 2011 , 58, 92-8	27
1638	Stent thrombosis of drug eluting stent: pathological perspective. 2011 , 58, 84-91	59
1637	Nonsteroidal antiinflammatory drug use and cardiovascular risks after coronary stent implantation. 2011 , 31, 458-68	8
1636	Usefulness of mean platelet volume as a biomarker for long-term outcomes after percutaneous coronary intervention. 2011 , 107, 204-9	59
1635	Two-year safety and effectiveness of sirolimus-eluting stents (from a prospective registry). 2011 , 107, 528-34	4
1634	Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial). 2011 , 107, 833-40	35
1633	Comparison of dual drug-eluting Cilotax stent and paclitaxel-eluting Taxus Liberte stent in native coronary artery lesions. 2011 , 107, 990-4	11
1632	Early and late (one year) outcomes following transcatheter aortic valve implantation in patients with severe aortic stenosis (from the United States REVIVAL trial). 2011 , 107, 1058-64	64
1631	Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention. 2011 , 107, 1597-603	20
1630	Comparison of everolimus-eluting stent with paclitaxel-eluting stent in long chronic total occlusions. 2011 , 107, 1768-71	27
1629	Relation of fractional flow reserve after drug-eluting stent implantation to one-year outcomes. 2011 , 107, 1763-7	60
1628	Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents. 2011 , 107, 1757-62	6
1627	Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). 2011 , 107, 1751-6	4

1626	Comparison of drug-eluting versus bare metal stents in cardiac allograft vasculopathy. 2011 , 108, 665-8	20
1625	Propensity-matched patient-level comparison of the TAXUS Libert [®] and TAXUS element (ION) paclitaxel-eluting stents. 2011 , 108, 828-37	15
1624	Long-term clinical outcomes of percutaneous coronary intervention for chronic total occlusions in patients with versus without diabetes mellitus. 2011 , 108, 924-31	36
1623	Predictors and implications of coronary infarct artery patency at initial angiography in patients with acute myocardial infarction (from the CADILLAC and HORIZONS-AMI Trials). 2011 , 108, 918-23	39
1622	Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy). 2011 , 108, 1232-7	35
1621	Comparison of angioscopic findings and three-year cardiac events between sirolimus-eluting stent and bare-metal stent in acute myocardial infarction. 2011 , 108, 1238-43	9
1620	Impact of smoking on outcomes of patients with ST-segment elevation myocardial infarction (from the HORIZONS-AMI Trial). 2011 , 108, 1387-94	24
1619	Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study). 2011 , 108, 1556-63	34
1618	Rate of nuisance bleedings and impact on compliance to prasugrel in acute coronary syndromes. 2011 , 108, 1710-3	31
1617	Comparison of direct stenting with conventional stent implantation in acute myocardial infarction. 2011 , 108, 1697-703	33
1616	Usefulness of thrombus aspiration for the treatment of coronary stent thrombosis. 2011 , 108, 1721-7	15
1615	[Decreasing incidence of stent thrombosis]. 2011 , 60, 338-46	
1614	Reliability using the universal classification of acute myocardial infarction compared to ST-segment classification. 2011 , 12, 210-6	1
1613	Long-term follow-up of multivessel percutaneous coronary intervention with drug-eluting stents for de novo lesions with correlation to the SYNTAX score. 2011 , 12, 220-7	4
1612	The clinical evaluation of the Endeavor zotarolimus-eluting coronary stent in Japanese patients with de novo native coronary artery lesions: primary results and 3-year follow-up of the Endeavor Japan study. 2011 , 12, 273-9	3
1611	Clopidogrel in acute coronary syndromes: where are we now?. 2011 , 105, 766-73	5
1610	Multivessel vs single-vessel revascularization in patients with non-ST-segment elevation acute coronary syndrome and multivessel disease in the drug-eluting stent era. 2011 , 34, 160-5	29
1609	Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. 2011 , 34, 332-8	37

1608	Long-term outcomes of sirolimus-eluting stents vs. paclitaxel-eluting stents in unprotected left main coronary artery bifurcation lesions. 2011 , 34, 378-83	7
1607	Long-term outcome of percutaneous coronary intervention: the significance of native coronary artery disease progression. 2011 , 34, 588-92	8
1606	CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. 2011 , 4, 422-8	98
1605	Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. 2011 , 4, 429-36	79
1604	Effect of gender difference on platelet reactivity. 2011 , 19, 451-7	57
1603	Dedicated bifurcation analysis: dedicated devices. 2011 , 27, 181-8	4
1602	Two hour bivalirudin infusion after PCI for ST elevation myocardial infarction. 2011 , 31, 401-6	10
1601	Clinical outcome and quality of life after interventional treatment of left main disease with drug-eluting-stents in comparison to CABG in elderly and younger patients. 2011 , 100, 439-46	26
1600	Comparison between on-label versus off-label use of drug-eluting coronary stents in clinical practice: results from the German DES.DE-Registry. 2011 , 100, 701-9	10
1599	Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation. 2011 , 100, 765-71	24
1598	Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. 2011 , 100, 907-14	7
1597	Efficacy of paclitaxel-eluting stent implantation in hemodialysis patients. 2011 , 26, 582-9	14
1596	[Coronary stent thrombosis: what's new in 2011?]. 2011 , 36, 241-53	2
1595	Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis. 2011 , 4, 155-64	57
1594	Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with Balloon angioplasty). 2011 , 4, 14-23	94
1593	5-Year follow-up of coronary revascularization in diabetic patients with multivessel coronary artery disease: insights from ARTS (arterial revascularization therapy study)-II and ARTS-I trials. 2011 , 4, 317-23	48
1592	Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). 2011 , 4, 543-50	84
1591	Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: analysis from the HORIZONS-AMI (Harmonizing Outcomes with RevascularizatiON and Stents in Acute Myocardial Infarction) trial. 2011 , 4, 760-8	28

1590	Medikamente freisetzende Koronarstents und mit Medikamenten beschichtete Ballonkatheter. 2011 , 5, 411-435	11
1589	Potential difficulty for accurate categorization of drug-eluting stent thrombosis without coronary angiography: unignorable involvement of the cases with new onset acute myocardial infarction occurred in target vessels. 2011 , 26, 109-16	
1588	Comparison of real-world clinical outcomes between Cypher- and Taxus-eluting stents: the GARA-GARA study. 2011 , 26, 202-8	4
1587	Very late stent thrombosis and neointimal plaque rupture after implantation of sirolimus-eluting stents: observations with angiography, IVUS and OCT. 2011 , 26, 263-8	2
1586	Calcified plaque rupture and very late stent thrombosis after bare-metal stent implantation. 2011 , 26, 252-9	3
1585	Sirolimus versus paclitaxel coronary stents in clinical practice. 2011 , 77, 5-12	8
1584	EuroSCORE is a good global predictor of long-term outcomes in high-risk but not in low-risk patients after unprotected left main angioplasty. 2011 , 77, 625-32	5
1583	Clinical outcomes following predilatation with a novel 1.25-mm diameter angioplasty catheter. 2011 , 77, 510-4	3
1582	Long-term risk of clinical events from stenting side branches of coronary bifurcation lesions with drug-eluting and bare-metal stents: an observational meta-analysis. 2011 , 77, 202-12	17
1581	Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients. 2011 , 77, 494-501	12
1580	Six-month clinical follow-up of the Tryton side branch stent for the treatment of bifurcation lesions: a two center registry analysis. 2011 , 77, 798-806	29
1579	Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial. 2011 , 77, 1012-7	28
1578	One-year clinical outcome in an unselected patient population treated with the Genousâ endothelial progenitor cell capturing stent. 2011 , 77, 809-17	10
1577	Extended follow-up safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: two-year follow-up from the E-Five Registry. 2011 , 77, 993-1000	10
1576	Usage patterns and 1-year outcomes with the TAXUS Libertstent: results of the TAXUS OLYMPIA registry. 2011 , 77, 979-92	2
1575	Rationale and design of the randomized, multicenter EREMUS trial, a study that investigates how to achieve low restenosis and early reendothelialization after percutaneous coronary interventions. 2011 , 78, 32-7	
1574	Long-term outcome of provisional side-branch T-stenting for the treatment of unprotected distal left main coronary artery disease. 2011 , 77, 765-72	4
1573	Comparison of zotarolimus- versus everolimus-eluting stents in the treatment of coronary bifurcation lesions. 2011 , 78, 1086-92	11

1572	Two-year follow-up of the Genous [®] endothelial progenitor cell capturing stent versus the Taxus Libert [®] stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study. 2011 , 78, 189-95	29
1571	Acute and 16-month outcomes of a new stent: the first-in-man evaluation of the Medtronic S9 (integrity) stent. 2011 , 78, 898-908	8
1570	Incidence, predictors, management, immediate and long-term outcomes following grade III coronary perforation. 2011 , 4, 87-95	141
1569	Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abiraterone and Paclitaxel-Coated Stent in Myocardial Infarction) trial. 2011 , 4, 111-119	111
1568	Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. 2011 , 4, 176-82	73
1567	Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. 2011 , 4, 149-54	176
1566	5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. 2011 , 4, 24-9	100
1565	Very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction: a 15-year single-center experience. 2011 , 4, 30-8	61
1564	The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions. 2011 , 4, 168-75	44
1563	Randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIA Yukon trial. 2011 , 4, 452-9	27
1562	Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach. 2011 , 4, 327-35	57
1561	The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial. 2011 , 4, 432-41	83
1560	Autopsy validation study of the academic research consortium stent thrombosis definition. 2011 , 4, 554-9	30
1559	Percutaneous coronary intervention of unprotected left main coronary artery disease as culprit lesion in patients with acute myocardial infarction. 2011 , 4, 618-26	44
1558	Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial. 2011 , 4, 672-82	18
1557	A patient-level pooled analysis assessing the impact of the SYNTAX (synergy between percutaneous coronary intervention with taxus and cardiac surgery) score on 1-year clinical outcomes in 6,508 patients enrolled in contemporary coronary stent trials. 2011 , 4, 645-53	63
1556	Prognostic significance of coronary thrombus in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. 2011 , 4, 769-77	27
1555	Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial Program. 2011 , 4, 530-42	50

1554	High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. 2011 , 97, 1943-50		40
1553	Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. 2011 , 32, 205-17		510
1552	Randomized trial of stents versus bypass surgery for left main coronary artery disease. 2011 , 364, 1718-27		456
1551	Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. 2011 , 4, 463-73		21
1550	Randomized comparison of final kissing balloon dilatation versus no final kissing balloon dilatation in patients with coronary bifurcation lesions treated with main vessel stenting: the Nordic-Baltic Bifurcation Study III. <i>Circulation</i> , 2011 , 123, 79-86	16.7	219
1549	Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. <i>Circulation</i> , 2011 , 123, 1745-56	16.7	193
1548	High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. 2011 , 97, 983-90		52
1547	Dual antiplatelet therapy duration: what are the drivers?. 2011 , 26 Suppl 1, S4-14		5
1546	Novel approaches for preventing or limiting events in diabetic patients (Naples-diabetes) trial: a randomized comparison of 3 drug-eluting stents in diabetic patients. 2011 , 4, 121-9		33
1545	One-year clinical outcome of interventionalist- versus patient-transfer strategies for primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results from the REVERSE-STEMI study. 2011 , 4, 355-62		7
1544	Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials. 2011 , 4, 371-7		45
1543	Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. 2011 , 305, 1097-105		959
1542	Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. <i>Circulation</i> , 2011 , 123, 2736-47	16.7	2467
1541	Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. <i>Circulation</i> , 2011 , 124, 893-900	16.7	163
1540	Cost-effectiveness of drug-eluting stents versus bare metal stents in clinical practice. 2011 , 4, 408-15		21
1539	Impact of angiographic complete revascularization after drug-eluting stent implantation or coronary artery bypass graft surgery for multivessel coronary artery disease. <i>Circulation</i> , 2011 , 123, 2373-81	16.7	87
1538	Urban and rural implementation of pre-hospital diagnosis and direct referral for primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction. 2011 , 32, 430-6		132
1537	Very Late Stent Thrombosis of Sirolimus-eluting Stent 59 Months After Implantation: A First Report from The Middle-East and Review of Literature. 2011 , 12, 22-5		3

1536	Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel. 2011 , 39, 2012-9	15
1535	Value of age, creatinine, and ejection fraction (ACEF score) in assessing risk in patients undergoing percutaneous coronary interventions in the 'All-Comers' LEADERS trial. 2011 , 4, 47-56	85
1534	Paclitaxel-eluting stents compared with bare metal stents in diabetic patients with acute myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. 2011 , 4, 130-8	8
1533	Sirolimus-eluting stent implantation for ostial left anterior descending coronary artery lesions: three-year outcome from the j-Cypher Registry. 2011 , 4, 362-70	12
1532	Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. 2011 , 4, 585-94	91
1531	When stable becomes unstable: the perils of impersonal medicine. <i>Circulation</i> , 2011 , 123, 335-41	16.7 0
1530	Impact of leukocyte count on mortality and bleeding in patients with myocardial infarction undergoing primary percutaneous coronary interventions: analysis from the Harmonizing Outcome with Revascularization and Stent in Acute Myocardial Infarction trial. <i>Circulation</i> , 2011 , 123, 2829-37, 7 p following 2837	16.7 47
1529	Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease. 2011 , 97, 1338-42	63
1528	Incidence and predictors of major perioperative adverse cardiac and cerebrovascular events in non-cardiac surgery. 2011 , 107, 879-90	102
1527	Drug-eluting stents in patients at high risk of restenosis: assessment for France. 2011 , 27, 108-17	2
1526	High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. 2011 , 306, 1215-23	304
1525	Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year. 2011 , 120, 43-9	6
1524	The future of clinical trials in secondary prevention after acute coronary syndromes. 2011 , 32, 1583-9	22
1523	SYNTAX score and Clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of Sirolimus-eluting stent compared with paclitaxel-eluting stent for coronary revascularization (SIRTAX) trial. 2011 , 32, 3115-27	109
1522	Prognostic implications of creatine kinase-MB elevation after percutaneous coronary intervention: results from the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. 2011 , 4, 474-80	35
1521	Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUTY Trial. 2011 , 4, 577-84	34
1520	Non-cardiac surgery in patients with coronary stents: the RECO study. 2011 , 97, 1566-72	90
1519	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. 2011 , 13, 723-46	166

1518	Impact of drug-eluting stents and diabetes mellitus in patients with coronary bifurcation lesions: a survey from the Italian Society of Invasive Cardiology. 2011 , 4, 72-9		4
1517	Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. 2011 , 343, d4588		190
1516	Intraplaque haemorrhages as the trigger of plaque vulnerability. 2011 , 32, 1977-85, 1985a, 1985b, 1985c		235
1515	Long-term clinical outcomes of overlapping heterogeneous drug-eluting stents compared with homogeneous drug-eluting stents. 2011 , 97, 1501-6		13
1514	Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial. 2012 , 5, 698-704		42
1513	Troponin criteria for myocardial infarction after percutaneous coronary intervention. 2012 , 172, 502-8		78
1512	Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET). <i>Circulation</i> , 2012 , 126, 1225-36	16.7	125
1511	No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting. 2012 , 5, 82-8, S1-2		34
1510	Serial assessment of coronary artery response to paclitaxel-eluting stents using optical coherence tomography. 2012 , 5, 30-8		24
1509	POLAR Registry (Promus eluting stent registry in Latin America): 1 year Follow-up Results. 2012 , 20, 29-34		
1508	Impact of the SYNTAX Score on Risk Stratification after Percutaneous Coronary Intervention in Non-Selected Patients. 2012 , 20, 35-40		
1507	Third universal definition of myocardial infarction. <i>Circulation</i> , 2012 , 126, 2020-35	16.7	2259
1506	Comparison of 5-year clinical outcomes between sirolimus-versus paclitaxel-eluting stent: Korean multicenter network analysis of 9000-patient cohort. 2012 , 5, 174-84		12
1505	The impact of successful manual thrombus aspiration on in-stent restenosis after primary PCI: angiographic and clinical follow-up. 2012 , 23, 487-91		16
1504	Very late stent thrombosis: current concepts. 2012 , 27, 634-41		21
1503	Impact of chronic kidney disease on long-term clinical outcomes after percutaneous coronary intervention with drug-eluting or bare-metal stents. 2012 , 11, 152-9		8
1502	Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant Surgeons, American Society of Transplantation, and National Kidney Foundation. <i>Circulation</i> , 2012 , 126, 617-63	16.7	181
1501	Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and Paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions. 2012 , 5, 150-6		29

1500	Long-Term (>10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. <i>Circulation</i> , 2012 , 125, 2343-53	16.7	171
1499	Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. 2012 , 345, e5170		160
1498	Final kissing ballooning and long-term clinical outcomes in coronary bifurcation lesions treated with 1-stent technique: results from the COBIS registry. 2012 , 98, 225-31		84
1497	Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. 2012 , 33, 977-87		114
1496	Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). 2012 , 33, 606-13		267
1495	Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. <i>Circulation</i> , 2012 , 125, 2015-26	16.7	526
1494	Clinical outcomes and treatment after drug-eluting stent failure: the absence of traditional risk factors for in-stent restenosis. 2012 , 5, 12-9		17
1493	Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry. 2012 , 5, 805-12		28
1492	Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. 2012 , 33, 1214-22		296
1491	The impact of anemia on long-term clinical outcome in patients undergoing revascularization with the unrestricted use of drug-eluting stents. 2012 , 5, 202-10		50
1490	Peri-procedural myocardial infarction: time for re-evaluation of its definition and use as an endpoint in coronary stent trials. 2012 , 98, 1397-9		1
1489	Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). <i>Circulation</i> , 2012 , 125, 1246-55	16.7	131
1488	Third universal definition of myocardial infarction. 2012 , 33, 2551-67		2064
1487	Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. 2012 , 33, 768-75		157
1486	The intra-aortic balloon pump in high-risk percutaneous coronary intervention: is counterpulsation counterproductive?. 2012 , 4, 211-234		4
1485	Impact of coronary bifurcation angle on clinical outcomes after percutaneous coronary intervention in real-world practice: results from the COBIS registry. 2012 , 122, 216-24		12
1484	Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack. 2012 , 43, 2376-81		38
1483	Tong-xin-luo capsule for patients with coronary heart disease after percutaneous coronary intervention. 2012 ,		

1482	Incidence, predictors, and 30-day outcomes of new-onset atrial fibrillation after primary percutaneous coronary intervention: insight into the RISK-PCI trial. 2012 , 23, 1-8	26
1481	Clinical Profile and Late Follow-up of Patients with Bare-metal Stent Thrombosis. 2012 , 20, 379-385	
1480	Transradial Percutaneous Coronary Intervention in Patients with ST-Elevation Acute Myocardial Infarction. 2012 , 20, 282-287	1
1479	Long-term Clinical and Angiographic Follow-up of the New Non-Polymeric Paclitaxel-Eluting Stent for the Treatment of De Novo Coronary Lesions: Outcomes of the PAX-B Study. 2012 , 20, 146-154	2
1478	Evaluation of the XIENCE [®] Everolimus-Eluting Coronary Stent System in the Female Latin American Population of the SPIRIT Women Single-Arm Study: One-year Clinical Follow-up Data. 2012 , 20, 239-246	
1477	Twelve-month clinical outcomes after coronary stenting with the Genous Bio-engineered R Stent in patients with a bifurcation lesion: from the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) registry. 2012 , 23, 201-7	7
1476	Differences in cardiovascular risk factors and clinical outcomes between Western European and Southeast Asian patients treated with the Genous Bio-engineered R stent: an e-HEALING worldwide registry substudy. 2012 , 23, 271-7	9
1475	The HEART study: a real-world experience using the CID Chrono Carbostent in primary and rescue PCI. 2012 , 13, 775-82	1
1474	Monitoring the safety of medicines used off-label. 2012 , 91, 787-95	23
1473	Effect of serum gamma-glutamyl transferase levels on myocardial perfusion and long-term prognosis after primary angioplasty in patients with acute ST-elevation myocardial infarction. 2012 , 60, 1186-93	16
1472	Retrospective comparison of midterm clinical and angiographic outcomes after the implantation of paclitaxel- and sirolimus-eluting stents for de novo coronary complex lesions in nonrandomized Japanese patients. 2012 , 51, 2695-701	5
1471	Guidewire-assisted cannulation of the common bile duct for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. 2012 , 12, CD009662	27
1470	Perioperative management after coronary stenting: role of risk assessment and the antiplatelet conundrum. 2012 , 4, 245-252	1
1469	Prognostic significance of neutrophil gelatinase-associated lipocalin in ST-segment elevation myocardial infarction. 2012 , 60, 508-13	19
1468	Three-year follow-up of sirolimus-eluting stents vs. bare metal stents for acute myocardial infarction. 2012 , 76, 65-70	7
1467	Impact of platelet reactivity to adenosine diphosphate before implantation of drug-eluting stents on subsequent adverse cardiac events in patients with stable angina. 2012 , 76, 641-9	8
1466	Impact of calcification on the long-term outcomes of sirolimus-eluting stent implantation: subanalysis of the Cypher Post-Marketing Surveillance Registry. 2012 , 76, 57-64	31
1465	In vivo optical coherence tomography of very late drug-eluting stent thrombosis compared with late in-stent restenosis. 2012 , 76, 390-8	20

1464	Heparin bridging vs. uninterrupted oral anticoagulation in patients with Atrial Fibrillation undergoing Coronary Artery Stenting. Results from the AFCAS registry. 2012 , 76, 1363-8	34	
1463	Sirolimus eluting coronary stent implantation in patients on maintenance hemodialysis: the OUCH study (outcome of cypher stent in hemodialysis patients). 2012 , 76, 1856-63	18	
1462	Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. 2012 , 76, 2673-80	15	
1461	Bare metal stent thrombosis in patients with acute coronary syndrome. 2012 , 76, 634-40	6	
1460	First-in-man study of simvastatin-eluting stent in de novo coronary lesions: the SIMVASTENT study. 2012 , 76, 1109-14	13	
1459	Impact of positive peri-stent vascular remodeling after sirolimus-eluting and paclitaxel-eluting stent implantation on 5-year clinical outcomes: intravascular ultrasound analysis from the Poststent Optimal Stent Expansion Trial multicenter randomized trial. 2012 , 76, 1102-8	5	
1458	Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. 2012 , 379, 1705-11	285	
1457	Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. 2012 , 379, 1393-402	727	
1456	Stent thrombosis: has the firestorm been extinguished?. 2012 , 379, 1368-9	10	
1455	Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. 2012 , 10, 1999-2005	102	
1454	Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study. 2012 , 25, 565-75	5	
1453	Long-term safety of drug-eluting stents in patients on warfarin treatment. 2012 , 44, 271-8	14	
1452	Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. <i>Circulation</i> , 2012 , 125, 505-13	16.7	450
1451	Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. 2012 , 308, 2507-16	148	
1450	Stents and antiplatelet therapy. 2012 , 47, 114-24	3	
1449	Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. 2012 , 5, 357-64	116	
1448	A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). 2012 , 60, 1340-8	468	
1447	Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. 2012 , 380, 1482-90	332	

1446	Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. 2012 , 380, 1396-405	124
1445	Utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention for type C lesions. 2012 , 25, 452-9	9
1444	Transcatheter "thrombin-blood patch" injection: a novel and effective approach to treat catheterization-related arterial perforation. 2012 , 80, 1025-32	8
1443	Long-term clinical outcomes following sirolimus-eluting stent implantation in patients with acute myocardial infarction. A meta-analysis of randomized trials. 2012 , 101, 885-93	20
1442	Assessment of an asymmetrical coating stent with sirolimus released from abluminal matrix in porcine model. 2012 , 101, 917-27	10
1441	Clinical presentation and short-term outcome of acute coronary syndrome in native young Saudi population. 2012 , 24, 169-75	4
1440	Comparison of the Prognostic Predictive Value of the TIMI, PAMI, CADILLAC, and GRACE Risk Scores in STEACS Undergoing Primary or Rescue PCI. 2012 , 65, 227-233	1
1439	Long-term Follow-up After Percutaneous Treatment of the Unprotected Left Main Stenosis in High Risk Patients Not Suitable for Bypass Surgery. 2012 , 65, 530-537	
1438	Very Late Stent Thrombosis With Newer Drug-Eluting Stents: No Longer an Issue?. 2012 , 65, 595-598	
1437	SeQuentPlease World Wide Registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. 2012 , 60, 1733-8	158
1436	Different cardiac biomarkers to detect peri-procedural myocardial infarction in contemporary coronary stent trials: impact on outcome reporting. 2012 , 98, 1424-30	22
1435	Post-discharge clinical and angiographic outcomes of patients presenting within 48h of STEMI treated with paclitaxel- or sirolimus-eluting stents. 2012 , 60, 174-9	6
1434	Predicting clopidogrel response using DNA samples linked to an electronic health record. 2012 , 91, 257-63	81
1433	First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. 2012 , 5, 620-32	163
1432	Caracterización de la restenosis de stents coronarios convencionales y liberadores de medicamentos en pacientes incluidos en el registro DRug Eluting STent (DREST). 2012 , 19, 121-131	2
1431	Comparison of the prognostic predictive value of the TIMI, PAMI, CADILLAC, and GRACE risk scores in STEACS undergoing primary or rescue PCI. 2012 , 65, 227-33	22
1430	Long-term follow-up after percutaneous treatment of the unprotected left main stenosis in high risk patients not suitable for bypass surgery. 2012 , 65, 530-7	9
1429	Very late stent thrombosis with newer drug-eluting stents: no longer an issue?. 2012 , 65, 595-8	16

1428	Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. <i>Circulation</i> , 2012 , 125, 1110-21	16.7	280
1427	Impact of incomplete stent apposition on long-term clinical outcome after drug-eluting stent implantation. 2012 , 33, 1334-43		76
1426	Third universal definition of myocardial infarction. 2012 , 9, 620-33		146
1425	Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BASel Stent Kosten Effektivit�s Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. 2012 , 163, 136-41.e1		11
1424	Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study trial 2012 , 163, 104-11		12
1423	Rationale and design of the TAXUS Libert� Post-Approval Study: examination of patients receiving the TAXUS Libert� stent with concomitant prasugrel therapy in routine interventional cardiology practice. 2012 , 163, 142-8.e6		4
1422	Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. 2012 , 163, 383-91, 391.e1-5		29
1421	A high loading dose of clopidogrel reduces myocardial infarct size in patients undergoing primary percutaneous coronary intervention: a magnetic resonance imaging study. 2012 , 163, 500-7		22
1420	Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: results from long-term follow-up of the Occluded Artery Trial (OAT) cohort. 2012 , 163, 563-71		32
1419	DUrable polymer-based sTent CHallenge of Promus ElemEnt versus ReSolute integrity (DUTCH PEERS): rationale and study design of a randomized multicenter trial in a Dutch all-comers population. 2012 , 163, 557-62		21
1418	The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Libert� paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. 2012 , 163, 867-875.e1		44
1417	Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents. 2012 , 163, 876-886.e2		20
1416	Rationale and design of the Cangrelor versus standard therapy to aCHieve optimal Management of Platelet InhibitIO N PHOENIX trial. 2012 , 163, 768-776.e2		64
1415	Long-term clinical and angiographic outcomes of patients with sirolimus-eluting stent fracture. 2012 , 158, 83-7		4
1414	Comparison of the safety between first- and second-generation drug eluting stents: meta-analysis from 19 randomized trials and 16,924 patients. 2012 , 160, 181-6		8
1413	A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: final results of the ZoMaxx II trial. 2012 , 157, 96-101		4
1412	Very late stent thrombosis after drug eluting stent: management therapy guided by intravascular ultrasound imaging. 2012 , 154, 349-51		1
1411	Comparison of drug-eluting versus bare-metal stents after rotational atherectomy for the treatment of calcified coronary lesions. 2012 , 154, 373-6		22

1410	Super late stent thrombosis occurred at 8 years after drug-eluting stent implantation. 2012 , 159, e53-5	2
1409	Cardiac troponin I reduces hypoxia/reoxygenation-induced myocardial cell injury in vitro. 2012 , 158, 120-2	2
1408	Biodegradable polymer versus permanent polymer sirolimus-eluting stents in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. 2012 , 158, 118-20	1
1407	Prognostic models for cardiovascular events after successful primary percutaneous coronary intervention. 2012 , 158, 168-70	2
1406	Drug eluting stents based on Poly(ethylene carbonate): optimization of the stent coating process. 2012 , 80, 562-70	33
1405	Freeing the vessel from metallic cage: what can we achieve with bioresorbable vascular scaffolds?. 2012 , 27, 141-54	21
1404	Design and rationale of the MR-INFORM study: stress perfusion cardiovascular magnetic resonance imaging to guide the management of patients with stable coronary artery disease. 2012 , 14, 65	65
1403	The 'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfty & effectiveness of drug-elUting stents & antiplatelet REgimen' (HOST-ASSURE) trial: study protocol for a randomized controlled trial. 2012 , 13, 29	8
1402	Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. 2012 , 60, 2481-9	707
1401	Restenosis after PCI. Part 1: pathophysiology and risk factors. 2011 , 9, 53-62	189
1400	Stent thrombosis: an overview. 2012 , 10, 599-615	12
1399	French Ministry of Health prospective multicentre study using bio-active stents coated with titanium nitride oxide: the EVIDENCE registry. 2012 , 105, 60-7	9
1398	Zotarolimus-eluting stent versus sirolimus-eluting and paclitaxel-eluting stents for percutaneous coronary intervention: a meta-analysis of randomized trials. 2012 , 105, 544-56	4
1397	Red versus white thrombi in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: clinical and angiographic outcomes. 2012 , 164, 553-60	42
1396	Optimized duration of clopidogrel therapy following treatment with the Endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial: rationale and design of a large-scale, randomized, multicenter study. 2012 , 164, 810-6.e3	16
1395	Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy. 2012 , 164, 817-24.e13	16
1394	The 'all comer' Coroflex Please drug-eluting stent registry in Europe and Asia - an overall and transcontinental assessment of the 10-month major adverse cardiac events. 2012 , 64, 453-61	3
1393	Coronary artery disease progression late after successful stent implantation. 2012 , 59, 793-9	50

1392	Randomized trial of optimal treatment strategies for in-stent restenosis after drug-eluting stent implantation. 2012 , 59, 1093-100	38
1391	A multicenter randomized trial comparing amphilius- with paclitaxel-eluting stents in de novo native coronary artery lesions. 2012 , 59, 1371-6	85
1390	Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. 2012 , 59, 1362-70	165
1389	Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. 2012 , 59, 1752-9	48
1388	A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. 2012 , 59, 1350-61	197
1387	Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial. 2012 , 60, 381-7	112
1386	Intraprocedural thrombotic events during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes are associated with adverse outcomes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 2012 , 59, 1745-51	36
1385	First results of the DEB-AMI (drug eluting balloon in acute ST-segment elevation myocardial infarction) trial: a multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes. 2012 , 59, 2327-37	96
1384	Impact of ischemia-guided revascularization with myocardial perfusion imaging for patients with multivessel coronary disease. 2012 , 60, 181-90	54
1383	Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. 2012 , 60, 434-80	253
1382	Clinical and angiographic outcomes of patients treated with everolimus-eluting stents or first-generation Paclitaxel-eluting stents for unprotected left main disease. 2012 , 60, 1217-22	35
1381	2-year patient-related versus stent-related outcomes: the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) Trial. 2012 , 60, 1140-7	41
1380	Reduction in mortality as a result of direct transport from the field to a receiving center for primary percutaneous coronary intervention. 2012 , 60, 1223-30	55
1379	Third universal definition of myocardial infarction. 2012 , 60, 1581-98	2143
1378	Angiographic stent thrombosis at coronary bifurcations: short- and long-term prognosis. 2012 , 5, 57-63	15
1377	Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging. 2012 , 5, 12-20	251
1376	No evidence of "obesity paradox" after treatment with drug-eluting stents in a routine clinical practice: results from the prospective multicenter German DES.DE (German Drug-Eluting Stent) Registry. 2012 , 5, 162-9	58
1375	Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. 2012 , 5, 131-40	127

1374	Long-term comparison of everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes. 2012 , 5, 145-54	15
1373	Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study. 2012 , 5, 313-22	18
1372	Impact of sex on clinical and angiographic outcomes among patients undergoing revascularization with drug-eluting stents. 2012 , 5, 301-10	57
1371	Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction. 2012 , 5, 259-67	60
1370	Pathology of drug-eluting versus bare-metal stents in saphenous vein bypass graft lesions. 2012 , 5, 666-74	41
1369	A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. 2012 , 5, 281-8	69
1368	Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). 2012 , 5, 728-37	69
1367	Drug-eluting stent for left main coronary artery disease. The DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. 2012 , 5, 718-27	102
1366	Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction: a propensity score-matched analysis. 2012 , 5, 936-45	14
1365	Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction. 2012 , 5, 1043-51	48
1364	Clinical impact of second-generation everolimus-eluting stent compared with first-generation drug-eluting stents in diabetes mellitus patients: insights from a nationwide coronary intervention register. 2012 , 5, 1141-9	44
1363	Impact of insulin resistance on post-procedural myocardial injury and clinical outcomes in patients who underwent elective coronary interventions with drug-eluting stents. 2012 , 5, 1159-67	33
1362	Randomized comparison of conservative versus aggressive strategy for provisional side branch intervention in coronary bifurcation lesions: results from the SMART-STRATEGY (Smart Angioplasty Research Team-Optimal Strategy for Side Branch Intervention in Coronary Bifurcation Lesions) randomized trial. 2012 , 5, 1133-40	38
1361	Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes. 2012 , 5, 1097-105	79
1360	CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. 2012 , 5, 1280-7	81
1359	Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. 2012 , 5, 1231-8	27
1358	On OCT and finding the uncovered tracks. 2012 , 5, 83-6	2
1357	Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. 2012 , 5, S53-61	77

1356	ST peak during primary percutaneous coronary intervention predicts final infarct size, left ventricular function, and clinical outcome. 2012 , 45, 708-16	5
1355	Late (3 years) follow-up of successful versus unsuccessful revascularization in chronic total coronary occlusions treated by drug eluting stent. 2012 , 110, 948-53	31
1354	Comparison of frequency of periprocedural myocardial infarction in patients with and without diabetes mellitus to those with previously unknown but elevated glycated hemoglobin levels (from the TWENTE Trial). 2012 , 110, 1561-7	20
1353	Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus- and sirolimus-eluting stents (from the SORT OUT IV trial). 2012 , 110, 1585-91	44
1352	Bleeding complications with regional adaptation of a prolonged bivalirudin regimen for ST-elevation acute myocardial infarction. 2012 , 110, 1607-12	6
1351	Relation of body mass index to risk of stent thrombosis after percutaneous coronary intervention. 2012 , 110, 1592-7	8
1350	Adverse cardiac events in patients with coronary stents undergoing noncardiac surgery: a systematic review. 2012 , 204, 494-501	20
1349	In vivo biocompatibility of a plasma-activated, coronary stent coating. 2012 , 33, 7984-92	53
1348	Optimal visualization of five different stent layers during and after percutaneous coronary intervention for recurrent in-stent restenosis using optical coherence tomography (OCT). 2012 , 13, 292-4	
1347	Twelve-month results of a paclitaxel releasing balloon in patients presenting with in-stent restenosis First-in-Man (PEPPER) trial. 2012 , 13, 260-4	29
1346	Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses. 2012 , 13, 307-10	7
1345	Safety and efficacy of the cobalt chromium PRO-Kinetik coronary stent system: results of the MULTIBENE study. 2012 , 13, 316-20	6
1344	Extracellular matrix molecules facilitating vascular biointegration. 2012 , 3, 569-87	15
1343	Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. 2012 , 172, 1537-45	52
1342	Rivaroxaban in patients with a recent acute coronary syndrome. 2012 , 366, 9-19	1357
1341	Six-month clinical outcomes of the Tryton Side Branch Stent for the treatment of bifurcation lesions. 2012 , 20, 439-46	14
1340	Prognostic impact of diabetes mellitus and hypertension for mid-term outcome of patients with acute myocardial infarction who underwent percutaneous coronary intervention. 2012 , 60, 257-63	23
1339	Comparison between sirolimus- and paclitaxel-eluting stents for the treatment of older patients affected by coronary artery disease: results from a single-center allcomers registry. 2012 , 27, 553-8	8

1338	Complete versus incomplete revascularization for treatment of multivessel coronary artery disease in the drug-eluting stent era. 2012 , 27, 433-42	28
1337	Microembolization and myonecrosis during elective percutaneous coronary interventions in diabetic patients: an intracoronary Doppler ultrasound study with 2-year clinical follow-up. 2012 , 107, 289	18
1336	Use of troponin to diagnose periprocedural myocardial infarction: effect on composite endpoints in the British Bifurcation Coronary Study (BBC ONE). 2012 , 98, 1431-5	8
1335	Bare metal stent thrombosis and in-stent neoatherosclerosis. 2012 , 5, 47-54	52
1334	A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. 2012 , 60, 2473-80	213
1333	Impact of total occlusion of an infarct-related artery on long-term mortality in acute non-ST-elevation myocardial infarction patients who underwent early percutaneous coronary intervention. 2012 , 53, 160-4	22
1332	Pathological perspective of drug-eluting stent thrombosis. 2012 , 2012, 219389	11
1331	Stent thrombosis: incidence, predictors and new technologies. 2012 , 2012, 956962	44
1330	The relevance of P2Y(12)-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: a clinical follow-up. 2012 , 107, 189-91	5
1329	Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials. 2012 , 2012, 126369	21
1328	The avantgarde carbostent in patients scheduled for undelayable noncardiac surgery. 2012 , 2012, 372371	2
1327	A history of early stent thrombosis is associated with prolonged clot lysis time. 2012 , 107, 513-20	35
1326	A case of acute stent thrombosis with heparin-induced thrombocytopenia immediately after percutaneous coronary intervention. 2012 , 18, 43-48	
1325	Risk assessment for percutaneous coronary intervention of the unprotected left main coronary artery in a real-world population. 2012 , 67, 503-13	2
1324	DES Overview: A Historical and Current Review of Pivotal Clinical Trial Programs. 2012 ,	
1323	Long-term safety and efficacy of sirolimus- and Paclitaxel-eluting stents in patients with acute myocardial infarction: four-year observational study. 2012 , 42, 266-73	1
1322	Comparison of safety and efficacy of paclitaxel-eluting stents with durable versus biodegradable polymer implanted in saphenous vein graft lesions. Nine-month angiographic and intravascular ultrasound follow-up. 2012 , 4, 269-274	
1321	Mid-term clinical outcomes of ACS and non-ACS patients treated with everolimus-eluting stents. 2012 , 53, 215-20	1

1320	Comparison of long-term clinical outcomes between sirolimus-eluting stents and paclitaxel-eluting stents following rotational atherectomy. 2012 , 53, 149-53	28
1319	Acute and long-term angiographic outcomes of side branch stenosis after randomized treatment of zotarolimus-, sirolimus-, and paclitaxel-eluting stent for coronary artery stenosis. 2012 , 27, 1499-506	5
1318	Perfil clínico e evoluç�o tardia de pacientes com trombose de stent n�o-farmacol�gico. 2012 , 20, 379-385	
1317	A comparison of two brands of clopidogrel in patients with drug-eluting stent implantation. 2012 , 42, 458-63	3
1316	Effects of 600 mg versus 300 mg loading dose of clopidogrel in Asian patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: long-term follow-up study. 2012 , 53, 906-14	3
1315	Avaliaç�o do stent coron�rio eluidor de everolimus XIENCE TM V na cpopulaç�o feminina latino-americana do estudo de braç�o r�ndico SPIRIT Women: acompanhamento cl�nico de um ano. 2012 , 20, 239-246	
1314	Coronary pressure-derived fractional flow reserve measurements: recommendations for standardization, recording, and reporting as a core laboratory technique. Proposals for integration in clinical trials. 2012 , 5, 312-7	40
1313	Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions. 2012 , 108, 318-27	31
1312	Contemporary clinical characteristics, treatment, and outcomes of angiographically confirmed coronary stent thrombosis: results from a multicenter California registry. 2012 , 79, 550-6	16
1311	Resolute Italian study in all comers: immediate and one-year outcomes. 2012 , 79, 567-74	8
1310	Bench top evaluation and clinical experience with the Szabo technique: new questions for a complex lesion. 2012 , 79, 378-89	21
1309	Seven-year safety and efficacy of the unrestricted use of drug-eluting stents in saphenous vein bypass grafts. 2012 , 79, 912-8	10
1308	Retroperitoneal hemorrhage after percutaneous coronary intervention in the current practice era: clinical outcomes and prognostic value of abdominal/pelvic computed tomography. 2012 , 80, 29-36	20
1307	Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study. 2012 , 80, 408-16	6
1306	Percutaneous left main coronary disease treatment without on-site surgery back-up in patients with acute coronary syndromes: immediate and 2-year outcomes. 2012 , 79, 979-87	7
1305	Lack of long-term clinical benefit of thrombus aspiration during primary percutaneous coronary intervention with paclitaxel-eluting stents or bare-metal stents: post-hoc analysis of the PASSION-trial. 2012 , 79, 870-7	2
1304	Unprotected left main coronary artery stenting with zotarolimus (Endeavor) drug-eluting stents: a single center retrospective experience. 2012 , 80, E15-22	8
1303	Frequency and impact of bleeding in elective coronary stent clinical trials--utility of three commonly used definitions. 2012 , 80, E23-9	3

1302	Incidence of periprocedural myocardial infarction following stent implantation: comparison between first- and second-generation drug-eluting stents. 2012 , 80, 524-30	8
1301	Long-term clinical outcomes in patients treated with drug-eluting compared to bare-metal stents for the treatment of transplant coronary artery disease. 2012 , 80, 533-8	9
1300	The XIENCE nano everolimus eluting coronary stent system for the treatment of small coronary arteries: the SPIRIT Small Vessel trial. 2012 , 80, 546-53	37
1299	MGUard versus bAre-metal stents plus manual thRombectomy in ST-elevation myocarDial infarction pAtieNts-(GUARDIAN) trial: study design and rationale. 2012 , 79, 1118-26	15
1298	Comparison of the efficacy and safety of paclitaxel-eluting coroflex please stents and paclitaxel-eluting stents in patients with coronary artery disease: a randomized PIPA trial. 2012 , 80, 799-806	2
1297	Comparison of the predictive value of EuroSCORE, SYNTAX score, and clinical SYNTAX score for outcomes of patients undergoing percutaneous coronary intervention for unprotected left main coronary artery disease. 2012 , 80, 222-30	17
1296	Early beneficial effects of drug-eluting stents in vein grafts wane during long term follow-up: a case-control study. 2012 , 80, 1112-7	3
1295	Outcomes in patients with renal impairment undergoing percutaneous coronary intervention and implantation of the Endeavor zotarolimus-eluting stent: 1- and 2-year data from the E-Five Registry. 2012 , 80, 885-92	3
1294	A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial. 2012 , 80, 1138-46	78
1293	Randomized study comparing everolimus- and sirolimus-eluting stents in patients with bifurcation lesions treated by provisional side-branch stenting. 2012 , 80, 1165-70	24
1292	Contemporary occurrence of stent thrombosis in clinical practice: better never than late. 2012 , 79, 557-8	1
1291	Comparison of vascular remodeling in patients treated with sirolimus-versus zotarolimus-eluting stent following acute myocardial infarction. 2012 , 35, 49-54	4
1290	Impact of acute coronary syndrome classification and procedural technique on clinical outcomes in patients with coronary bifurcation lesions treated with drug-eluting stents. 2012 , 35, 610-8	7
1289	In This Issue. 2012 , 91, 151-151	
1288	Five-year outcomes of Cypherâ€coronary stent: report from J-PMS Study. 2012 , 27, 63-71	14
1287	The impact of preprocedural hemoglobin A1c on the efficacy of sirolimus-eluting and paclitaxel-eluting stents. 2012 , 27, 72-83	3
1286	Optical coherence tomography findings of very late stent thrombosis after drug-eluting stent implantation. 2012 , 28, 715-23	22
1285	Plasma fibrinogen levels and restenosis after primary percutaneous coronary intervention. 2012 , 33, 308-17	10

1284	New anticoagulants in ischemic heart disease. 2012 , 14, 450-6	3
1283	Coronary stent choice in patients with acute myocardial infarction. 2012 , 14, 477-85	2
1282	Early double stent thrombosis associated with clopidogrel hyporesponsiveness. 2012 , 20, 38-41	2
1281	Applying the National Institute for Clinical Excellence criteria to patients treated with the Genousâ Bio-engineered R stentâa sub-study of the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) worldwide registry. 2012 , 27, 360-9	7
1280	Concurrent drug eluting/bare metal stent implantation during percutaneous coronary intervention in target vessel: outcomes and 1-year follow-up. 2012 , 101, 281-8	7
1279	Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. 2012 , 101, 461-7	41
1278	Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. 2012 , 35, 165-74	43
1277	Natural history of side branches jailed by drug-eluting stents. 2012 , 25, 37-46	10
1276	Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents following successful PCI in non-ST-elevation myocardial infarction: findings from the Guthrie Health Off-Label Stent (GHOST) Registry. 2012 , 25, 28-36	5
1275	Impact of the combined left ventricular systolic and renal dysfunction on one-year outcomes after primary percutaneous coronary intervention. 2012 , 25, 132-9	5
1274	Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents in ST elevation myocardial infarction: findings from the Guthrie Health Off-label Stent (GHOST) Registry. 2012 , 25, 118-25	4
1273	One-year clinical outcomes after sirolimus-eluting coronary stent implantation for acute myocardial infarction in the worldwide e-SELECT registry. 2012 , 25, 253-61	2
1272	Glycosylated hemoglobin and outcomes in diabetic patients with acute myocardial infarction after successful revascularization with stent placement: findings from the guthrie health off-label stent (GHOST) investigators. 2012 , 25, 262-9	13
1271	A modified provisional stenting approach to coronary bifurcation lesions: clinical application of the "jailed-balloon technique". 2012 , 25, 289-96	30
1270	Treatment of coronary bifurcation lesions with drug-eluting stents: insights from the first phase of the prospective multicenter german drug-eluting stent registry. 2012 , 25, 344-52	3
1269	Comparison of three-year clinical outcomes with nonextended versus extended dual antiplatelet therapy between first- and second-generation drug-eluting stent implantation in patients with acute myocardial infarction: data from the infarct prognosis study registry. 2012 , 25, 245-52	
1268	Bridging therapy after recent stent implantation: case report and review of data. 2012 , 13, 30-8	9
1267	Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. 2012 , 109, 214-8	65

1266	Outcome of percutaneous coronary intervention utilizing drug-eluting stents in patients with reduced left ventricular ejection fraction. 2012 , 109, 344-51	17
1265	Influence of diabetes mellitus on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. 2012 , 109, 629-35	43
1264	Meta-analysis of long-term outcomes for drug-eluting stents versus bare-metal stents in primary percutaneous coronary interventions for ST-segment elevation myocardial infarction. 2012 , 109, 932-40	22
1263	Long-term outcomes with use of intravascular ultrasound for the treatment of coronary bifurcation lesions. 2012 , 109, 960-5	37
1262	Diabetes mellitus, myocardial reperfusion, and outcome in patients with acute ST-elevation myocardial infarction treated with primary angioplasty (from HORIZONS AMI). 2012 , 109, 1111-6	36
1261	Antithrombotic management and 1-year outcome of patients on oral anticoagulation undergoing coronary stent implantation (from the Registro Regionale Angioplastiche Emilia-Romagna Registry). 2012 , 109, 1411-7	26
1260	Long-term outcomes of percutaneous coronary interventions with stent implantation in patients ≥80 years old. 2012 , 109, 1717-21	20
1259	Long-term outcomes of heart transplantation recipients with transplant coronary artery disease who develop in-stent restenosis after percutaneous coronary intervention. 2012 , 109, 1729-32	8
1258	Impact of routine angiographic follow-up after percutaneous coronary intervention with drug-eluting stents in the SPIRIT III randomized trial at three years. 2012 , 110, 21-9	18
1257	Outcomes according to presentation with versus without cardiogenic shock in patients with left main coronary artery stenosis and acute myocardial infarction. 2012 , 110, 36-9	9
1256	Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention. 2012 , 110, 30-5	16
1255	Effects of thiazolidinediones on cardiovascular events in patients with type 2 diabetes mellitus after drug-eluting stent implantation: a retrospective cohort study using the national health insurance database in Taiwan. 2012 , 34, 885-93	5
1254	Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial. 2012 , 271, 257-63	38
1253	Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. 2012 , 10, 529-42	73
1252	Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practice. 2012 , 25, 482-92	18
1251	Clinical impact of thrombus aspiration during primary percutaneous coronary intervention: results from Korea Acute Myocardial Infarction Registry. 2012 , 59, 249-57	19
1250	Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events. 2012 , 42, 266-74	12
1249	Coronary chronic total occlusions: mid-term comparison of clinical outcome following the use of the guided-STAR technique and conventional anterograde approaches. 2012 , 79, 20-7	59

1248	Sustained clinical safety and efficacy of a biodegradable-polymer coated sirolimus-eluting stent in "real-world" practice: three-year outcomes of the CREATE (Multi-Center Registry of EXCEL Biodegradable Polymer Drug Eluting Stents) study. 2012 , 79, 211-6	14
1247	Duration of dual antiplatelet therapy and outcomes after coronary stenting with the Genousâ bio-engineered R stentâIn patients from the e-HEALING registry. 2012 , 79, 243-52	7
1246	Stent thrombosis: understanding and managing a critical problem. 2012 , 14, 91-107	5
1245	Everolimus-eluting stents for treatment of chronic total coronary occlusions. 2012 , 101, 23-8	19
1244	Real-world experience of drug-eluting stents in saphenous vein grafts compared to native coronary arteries: results from the prospective multicenter German DES.DE registry. 2012 , 101, 201-8	3
1243	Impact of intravascular ultrasound-guided percutaneous coronary intervention on long-term clinical outcomes in a real world population. 2013 , 81, 407-16	45
1242	Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction. 2013 , 81, E9-14	6
1241	Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions. 2013 , 81, 285-91	84
1240	Impact of different stent alloys on human vascular response to everolimus-eluting stent: an optical coherence tomography study: the OCTEVEREST. 2013 , 81, 510-8	23
1239	Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial. 2013 , 81, E23-8	42
1238	Mean platelet volume may predict early clinical outcome after coronary artery bypass grafting. 2013 , 8, 91	14
1237	Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. 2013 , 14, 56	10
1236	Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention. 2013 , 69, 771-7	19
1235	Late and very late stent thrombosis in patients with second-generation drug-eluting stents. 2013 , 29, 1488-94	19
1234	Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. 2013 , 381, 836-44	285
1233	Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction). 2013 , 6, 548-53	32
1232	Angiographic and clinical outcomes after implantation of drug eluting stents in bifurcation lesions with crush or kissing stent technique. 2013 , 26, 145-52	4
1231	Treatment of coronary bifurcation lesions: stent-covering of the side branch with and without PCI of the side branch: a retrospective analysis of all consecutive patients. 2013 , 13, 27	4

1230	Impact of the clinical syntax score on 5-year clinical outcomes after sirolimus-eluting stents implantation. 2013 , 28, 258-66	7
1229	Blood compatibility of a new zwitterionic bare metal stent with hyperbranched polymer brushes. 2013 , 1, 5036-5044	20
1228	Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: a proposed alternative regimen. 2013 , 165, 444-7	18
1227	Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial. 2013 , 26, 221-7	2
1226	A critical analysis of clinical outcomes reported in stem cell trials for acute myocardial infarction: some thoughts for design of future trials. 2013 , 15, 341	8
1225	Incidence, predictors, morphological characteristics, and clinical outcomes of stent edge dissections detected by optical coherence tomography. 2013 , 6, 800-13	109
1224	Optical coherence tomography guided in-stent thrombus removal in patients with acute coronary syndromes. 2013 , 29, 989-96	13
1223	Comparison of clinical efficacy and safety of clopidogrel resinate with clopidogrel bisulfate in patients undergoing percutaneous coronary intervention. 2013 , 27, 441-9	2
1222	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. 2013 , 382, 1714-22	405
1221	Evaluation of XIENCE V everolimus-eluting and Taxus Express2 paclitaxel-eluting coronary stents in patients with jailed side branches from the SPIRIT IV trial at 2 years. 2013 , 111, 1580-6	2
1220	Increased risk of minor bleeding and antiplatelet therapy cessation in patients with acute coronary syndromes and low on-aspirin platelet reactivity. A prospective cohort study. 2013 , 36, 22-30	6
1219	Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trial. 2013 , 28, 424-33	11
1218	Outcome of percutaneous coronary intervention with drug-eluting stents in unprotected left main versus non-left main native coronary artery disease: results from the prospective multicenter German DES.DE registry. 2013 , 102, 679-86	5
1217	Clinical outcomes of different first- and second-generation drug-eluting stents in routine clinical practice: results from the prospective multicenter German DES.DE registry. 2013 , 102, 371-81	10
1216	Prognosis of patients with atrial fibrillation undergoing percutaneous coronary intervention receiving drug eluting stents. 2013 , 102, 289-97	22
1215	Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. 2013 , 382, 1981-92	234
1214	Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. 2013 , 382, 614-23	606
1213	Health economic evaluation of the use of drug-eluting stents : First results from the Drug-Eluting Stent Registry (DES.de). 2012 , 38, 57	1

1212	Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents. 2013 , 6, 504-12	46
1211	The risk of stent thrombosis is multifactorial and may remain for long. 2013 , 8, e64-e65	
1210	Drug eluting stent implantation in patients requiring concomitant vitamin K antagonist therapy. One-year outcome of the worldwide e-SELECT registry. 2013 , 168, 2522-7	1
1209	Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy. 2013 , 165, 704-9	55
1208	Very long-term outcomes following drug-eluting stent implantation for unprotected left main coronary artery stenosis: a single center experience. 2013 , 66, 24-33	9
1207	The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease. 2013 , 6, 1153-9	31
1206	Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial. 2013 , 61, 2406-2416	59
1205	Predictors of reocclusion after successful drug-eluting stent-supported percutaneous coronary intervention of chronic total occlusion. 2013 , 61, 545-50	137
1204	Early and long-term outlook of percutaneous coronary intervention for bifurcation lesions in young patients. 2013 , 167, 2995-9	4
1203	Safety and effectiveness of the Genous [®] Endothelial progenitor cell-capture stent in the first year following ST-elevation acute myocardial infarction: A single center experience and review of the literature. 2013 , 14, 338-42	2
1202	Clinical Efficacy and Safety of SeQuent Please Paclitaxel-Eluting Balloon in a Real-World Single-Center Registry of South-East Asian Patients. 2013 , 1, 37-41	6
1201	Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease. 2013 , 106, 554-61	11
1200	Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease. 2013 , 62, 2075-82	61
1199	Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). 2013 , 6, 314-22	144
1198	Long-term efficacy of sirolimus-eluting stent for small vessel disease--subanalysis of Cypher Stent Japan Post-Marketing Surveillance Registry. 2013 , 61, 31-7	2
1197	Complementary prognostic utility of myocardial blush grade and ST-segment resolution after primary percutaneous coronary intervention: analysis from the HORIZONS-AMI trial. 2013 , 166, 676-83	20
1196	Intra-procedural stent thrombosis: a new risk factor for adverse outcomes in patients undergoing percutaneous coronary intervention for acute coronary syndromes. 2013 , 6, 36-43	39
1195	Antiplatelet therapy after Genous EPC-capturing coronary stent implantation: the ARGENTO study: a prospective, multicenter registry. 2013 , 167, 757-61	10

1194	OCT analysis in patients with very late stent thrombosis. 2013 , 6, 695-703	69
1193	Gender-related differences of diabetic patients undergoing percutaneous coronary intervention with drug-eluting stents: a real-life multicenter experience. 2013 , 168, 139-43	11
1192	Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice. 2013 , 14, 289-93	2
1191	Usefulness of intravascular ultrasound to predict outcomes in short-length lesions treated with drug-eluting stents. 2013 , 112, 642-6	14
1190	Long-term clinical outcomes after unprotected left main coronary artery stenting in an all-comers patient population. 2013 , 82, E411-8	3
1189	Comparison of long-term outcomes in STEMI and NSTEMI-ACS after coronary stent placement: an analysis in a real world BMS and DES population. 2013 , 167, 2082-7	8
1188	Impact of metabolic syndrome on clinical outcomes after new generation drug-eluting stent implantation: the 'obesity paradox' phenomenon is still apparent. 2013 , 23, 307-13	12
1187	One-year clinical outcomes of percutaneous treatment with drug-eluting balloons: Results from a multicenter registry. 2013 , 32, 361-369	3
1186	Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries. 2013 , 61, 536-44	43
1185	Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. 2013 , 167, 2018-23	94
1184	Relation between white blood cell count and final infarct size in patients with ST-segment elevation acute myocardial infarction undergoing primary percutaneous coronary intervention (from the INFUSE AMI trial). 2013 , 112, 1860-6	14
1183	High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting. 2013 , 167, 1877-81	27
1182	Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen). 2013 , 6, 932-42	29
1181	Cause of death within 30 days of percutaneous coronary intervention in an era of mandatory outcome reporting. 2013 , 62, 409-15	46
1180	Complex coronary artery disease: would outcomes from the SYNTAX (synergy between percutaneous coronary intervention with taxus and cardiac surgery) trial have differed with newer-generation drug-eluting stents?. 2013 , 6, 1023-5	2
1179	Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES versus BMS alone to Eliminate Restenosis (CEREA-DES). 2013 , 34, 1740-8	19
1178	Post myocardial infarction cardiogenic shock: a review of current therapies. 2013 , 28, 151-65	16
1177	The paclitaxel-eluting PTCA-balloon in combination with a cobalt-chromium stent in two different sequences to treat de novo coronary artery lesions: an angiographic follow up study. 2013 , 65, 510-7	10

1176	A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. 2013 , 166, 527-33	95
1175	Serial morphological and functional assessment of drug-eluting balloon for in-stent restenotic lesions: mechanisms of action evaluated with angiography, optical coherence tomography, and fractional flow reserve. 2013 , 6, 569-76	31
1174	Short-term and long-term clinical impact of stent thrombosis and graft occlusion in the SYNTAX trial at 5 years: Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery trial. 2013 , 62, 2360-2369	47
1173	Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. 2013 , 167, 430-5	31
1172	Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. 2013 , 6, 1166-75	38
1171	Bivalirudin started during emergency transport for primary PCI. 2013 , 369, 2207-17	372
1170	Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. 2013 , 62, 2261-73	693
1169	The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent. 2013 , 6, 334-43	71
1168	Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial. 2013 , 166, 669-75	18
1167	Predictors of cardiac death in patients with coronary chronic total occlusion not revascularized by PCI. 2013 , 168, 1402-9	63
1166	Predictors and outcomes of side branch occlusion after main vessel stenting in coronary bifurcation lesions: results from the COBIS II Registry (CORONARY Bifurcation Stenting). 2013 , 62, 1654-1659	155
1165	Comparison of sirolimus-, paclitaxel-, and everolimus-eluting stent in unprotected left main coronary artery percutaneous coronary intervention. 2013 , 25, 75-8	
1164	Serial assessment of vessel interactions after drug-eluting stent implantation in unprotected distal left main coronary artery disease using frequency-domain optical coherence tomography. 2013 , 6, 1035-45	15
1163	Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery disease after treatment with sirolimus-eluting stents: insights from the j-Cypher registry. 2013 , 6, 654-63	16
1162	Stent thrombosis with drug-eluting stents: is the paradigm shifting?. 2013 , 62, 1915-1921	92
1161	First- versus second-generation drug-eluting stents for the treatment of coronary bifurcations. 2013 , 14, 311-5	19
1160	Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 10-year follow-up of a randomized trial. 2013 , 6, 20-6	52
1159	A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease). 2013 , 6, 1012-22	22

1158	Differential 1-year clinical outcomes for ST-segment elevation myocardial infarction related to stent thrombosis or saphenous vein graft thrombosis. 2013 , 82, 193-200	4
1157	First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries). 2013 , 6, 1026-34	27
1156	Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.	61
1155	Clinical outcome after crush versus culotte stenting of coronary artery bifurcation lesions: the Nordic Stent Technique Study 36-month follow-up results. 2013 , 6, 1160-5	42
1154	Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial. 2013 , 168, 3736-40	74
1153	Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial (EUROMAX): an international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation myocardial infarction treated with primary percutaneous coronary intervention. 2013 , 168, 3418-24	12
1152	Comparison of 9-month angiographic outcomes of Resolute zotarolimus-eluting and everolimus-eluting stents in a real world setting of coronary intervention in Korea. 2013 , 13, 65	6
1151	Optical coherence tomography derived cut-off value of uncovered stent struts to predict adverse clinical outcomes after drug-eluting stent implantation. 2013 , 29, 1255-63	41
1150	Angiographic and clinical comparison of novel Orsiro Hybrid sirolimus-eluting stents and Resolute Integrity zotarolimus-eluting stents in all-comers with coronary artery disease (ORIENT trial): study protocol for a randomized controlled trial. 2013 , 14, 398	5
1149	Avoiding stent thrombosis: advances in technique, antiplatelet pharmacotherapy and stent design. 2013 , 5, 179-201	
1148	The favorable price evolution between bare metal stents and drug eluting stents increases the cost effectiveness of drug eluting stents. 2013 , 168, 1466-71	11
1147	C-reactive protein and prognosis in women and men with coronary artery disease after percutaneous coronary intervention. 2013 , 14, 264-9	9
1146	Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction. 2013 , 47, 230-5	
1145	Comparison of 3-year clinical outcomes between Resolute zotarolimus- and sirolimus-eluting stents for long coronary artery stenosis. 2013 , 26, 378-83	2
1144	Procedural success and long-term outcomes of aspiration thrombectomy for the treatment of stent thrombosis. 2013 , 82, 1048-53	10
1143	Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention. 2013 , 24, 183-8	10
1142	Clinical endpoint adjudication in a contemporary all-comers coronary stent investigation: methodology and external validation. 2013 , 34, 53-9	8
1141	Very Long-term Outcomes Following Drug-eluting Stent Implantation for Unprotected Left Main Coronary Artery Stenosis: A Single Center Experience. 2013 , 66, 24-33	1

1140	Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. 2013 , 381, 461-7	277
1139	Clinical outcomes after bare-metal stenting in diabetic patients with lesions carrying a low risk of restenosis. 2013 , 81, 26-33	2
1138	Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. 2013 , 69, 1103-12	49
1137	Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. 2013 , 381, 1107-15	1191
1136	Stent thrombosis is a major concern in clinical practice: A single Saudi center experience. 2013 , 25, 233-8	3
1135	The Japanese experience with sirolimus-eluting stent implantation in the infarct-related artery: five years of observation from the J-PMS study. 2013 , 61, 321-5	1
1134	Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study. 2013 , 170, 36-42	22
1133	A propensity score matched analysis to determine if second-generation drug-eluting stents outperform first-generation drug-eluting stents in a complex patient population. 2013 , 170, 43-8	5
1132	Long-term outcomes of patients receiving zotarolimus-eluting stents in ST elevation myocardial infarction, non-ST elevation acute coronary syndrome, and stable angina: data from the Resolute program. 2013 , 168, 3522-6	8
1131	Balance of Ischemia and Bleeding in Selecting an Antithrombotic Regimen. 2013 , 2, 515-525	
1130	Comparison of first- and second-generation drug-eluting stents in saphenous vein grafts used as aorto-coronary conduits. 2013 , 112, 318-22	19
1129	Three year clinical outcomes with zotarolimus (Endeavor) drug-eluting stents in an unrestricted contemporary practice. 2013 , 168, 595-6	2
1128	Chronic kidney disease and percutaneous coronary interventions with drug-eluting stents: does the K/DOQI classification matter?. 2013 , 166, 530-3	1
1127	Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. 2013 , 6, 999-1009	164
1126	One-year outcomes of percutaneous coronary intervention with the 38-mm Resolute zotarolimus-eluting stent. 2013 , 112, 1335-41	14
1125	Characteristics of patients and types of lesions in patients with drug-eluting or bare-metal stent implantation in small coronary arteries: from the FU-Registry. 2013 , 61, 117-21	11
1124	Triple, simultaneous, very late coronary stent thrombosis. 2013 , 32, 247-252	3
1123	[Very late bare-metal stent thrombosis 10 years after the implantation: a case report]. 2013 , 62, 435-7	1

1122	Efficacy and safety of zotarolimus-eluting stents compared with sirolimus-eluting stents in patients undergoing percutaneous coronary interventions--a meta-analysis of randomized controlled trials. 2013 , 167, 2126-33	8
1121	Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. 2013 , 6, 1267-74	216
1120	The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. 2013 , 6, 325-33	56
1119	Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). 2013 , 6, 1275-81	31
1118	Partial subacute thrombosis of drug eluting stent in CT coronarography and IVUS image. 2013 , 55, e264-e270	
1117	Incidence, correlates, and significance of abnormal cardiac enzyme rises in patients treated with surgical or percutaneous based revascularisation: a substudy from the Synergy between Percutaneous Coronary Interventions with Taxus and Cardiac Surgery (SYNTAX) Trial. 2013 , 168, 5287-92	13
1116	Two-year follow-up of outcomes of second-generation everolimus-eluting stents versus first-generation drug-eluting stents for stenosis of saphenous vein grafts used as aortocoronary conduits. 2013 , 112, 61-7	24
1115	One-year clinical outcomes of percutaneous treatment with drug-eluting balloons: results from a multicenter registry. 2013 , 32, 361-9	9
1114	Triple, simultaneous, very late coronary stent thrombosis. 2013 , 32, 247-52	5
1113	Approach to coronary bifurcation lesions using the everolimus-eluting stent: comparison between a simple strategy and a complex strategy with T-stenting. 2013 , 66, 636-43	3
1112	Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program. 2013 , 6, 357-68	74
1111	Prehospitalization antiplatelet therapy and outcomes after saphenous vein graft intervention. 2013 , 111, 153-8	4
1110	Initial clinical experience with an everolimus eluting platinum chromium stent (Promus Element) in unselected patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). 2013 , 167, 146-50	23
1109	Long-term outcomes following off-label use of sirolimus-eluting stent. 2013 , 62, 151-7	1
1108	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. 2013 , 382, 1879-88	102
1107	Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trial. 2013 , 167, 1632-7	6
1106	Impact of intravascular ultrasound guidance in routine percutaneous coronary intervention for conventional lesions: data from the EXCELLENT trial. 2013 , 167, 721-6	35
1105	Safety and efficacy of biodegradable polymer-coated biolimus-eluting stents. 2013 , 65, 207-212	3

1104	Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial. 2013 , 166, 1035-42	45
1103	Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. 2013 , 168, 5162-6	28
1102	Five-year clinical outcome of titanium-nitride-oxide-coated bioactive stents versus paclitaxel-eluting stents in patients with acute myocardial infarction: long-term follow-up from the TITAX AMI trial. 2013 , 168, 1214-9	27
1101	Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. 2013 , 167, 2882-8	23
1100	Additional side branch stent placement in patients with long side branch lesions treated with the Tryton dedicated bifurcation side branch stent. 2013 , 168, 3059-62	
1099	Abordaje de las lesiones bifurcadas con stent liberador de everolimus: comparaci3n entre estrategias simple y compleja con T-stenting. 2013 , 66, 636-643	13
1098	Clinical outcome of patients with de novo coronary bifurcation lesions treated with the Tryton Side Branch Stent. The SAFE-TRY prospective multicenter single arm study. 2013 , 168, 5323-8	4
1097	Prehospital statin therapy and one-year mortality in patients with stable coronary artery disease undergoing percutaneous coronary intervention. 2013 , 24, 145-50	2
1096	Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial. 2013 , 6, 664-70	25
1095	Usefulness of monocyte chemoattractant protein-1 to predict no-reflow and three-year mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. 2013 , 112, 187-93	14
1094	Polymer-free sirolimus-eluting versus polymer-based paclitaxel-eluting stents: an individual patient data analysis of randomized trials. 2013 , 66, 435-42	2
1093	Bare-metal stenting of large coronary arteries in ST-elevation myocardial infarction is associated with low rates of target vessel revascularization. 2013 , 165, 591-9	9
1092	Thrombocytopenia in patients with atrial fibrillation on oral anticoagulation undergoing percutaneous coronary intervention. 2013 , 112, 493-8	9
1091	Intravascular ultrasound predictors for edge restenosis after newer generation drug-eluting stent implantation. 2013 , 111, 1408-14	61
1090	Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction: Insights from the EXAMINATION trial. 2013 , 168, 2632-6	10
1089	Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes. 2013 , 61, 808-16	107
1088	AV delay optimization improves atrial transport in patients with restrictive diastolic dysfunction. 2013 , 168, 2908-9	
1087	Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. 2013 , 381, 661-9	152

1086	Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERordable Stent Coating) randomized, noninferiority trial. 2013 , 6, 777-89	254
1085	Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. 2013 , 167, 575-84	128
1084	Two-year follow-up of percutaneous coronary intervention using EucaTax or Cypher. 2013 , 14, 284-8	2
1083	Intravascular ultrasound assessed incomplete stent apposition and stent fracture in stent thrombosis after bare metal versus drug-eluting stent treatment the Nordic Intravascular Ultrasound Study (NIVUS). 2013 , 168, 1010-6	24
1082	Comparison between zotarolimus-eluting stents and first generation drug-eluting stents in the treatment of patients with acute ST-segment elevation myocardial infarction. 2013 , 166, 118-25	7
1081	Propensity-matched lesion-based comparison of midterm outcomes of TAXUS Express and TAXUS Libert [®] stents for de novo native coronary stenosis. 2013 , 62, 289-95	3
1080	Comparison of outcomes using the sirolimus-eluting stent in calcified versus non-calcified native coronary lesions in patients on- versus not on-chronic hemodialysis (from the j-Cypher registry). 2013 , 112, 647-55	30
1079	Comparison of long-term outcomes between everolimus-eluting and sirolimus-eluting stents in small vessels. 2013 , 111, 973-8	11
1078	The use and clinical outcomes of rotablation in challenging cases in the drug-eluting stent era. 2013 , 76, 71-7	14
1077	Recurrent very late drug-eluting stent thrombosis. 2013 , 168, e111-2	
1076	Comparison of outcomes of patients with ST-segment elevation myocardial infarction with versus without previous coronary artery bypass grafting (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial). 2013 , 111, 1377-86	18
1075	Contemporary analysis of incidence and outcomes of stent thrombosis presenting as ST elevation myocardial infarction in a primary percutaneous coronary intervention cohort. 2013 , 112, 1347-54	5
1074	A gender-specific analysis of association between hyperuricaemia and cardiovascular events in patients with coronary artery disease. 2013 , 23, 1195-201	32
1073	Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents. 2013 , 112, 1843-8	7
1072	Documento de consenso de expertos. Tercera definici3n universal del infarto de miocardio. 2013 , 66, 132.e1-132.e15	14
1071	Three-year follow-up of the MULTICentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STent or Bare-Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY). 2013 , 165, 134-41	24
1070	Frequency, mechanisms, and implications of late peri-stent contrast staining: analysis (from the HORIZONS-AMI Trial). 2013 , 111, 1587-92	7
1069	Impact of tissue prolapse after stent implantation on short- and long-term clinical outcomes in patients with acute myocardial infarction: an intravascular ultrasound analysis. 2013 , 166, 646-51	28

1068	Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: validity, pitfalls, and future approaches. 2013 , 165, 644-54, 654.e1	8
1067	Intravascular ultrasound assessment of drug-eluting stent coverage of the coronary ostium and effect on outcomes. 2013 , 111, 1401-7	15
1066	Evaluation of a policy of selective drug-eluting stent implantation for patients at high risk of restenosis. 2013 , 22, 523-32	7
1065	Five-year outcomes in patients with chronic total coronary occlusion treated with drug-eluting vs bare-metal stents: a case-control study. 2013 , 29, 945-50	13
1064	Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes. 2013 , 62, 158-64	26
1063	Comparison of procedural success and long-term outcomes of stent thrombosis in coronary bypass grafts versus native coronary arteries. 2013 , 111, 689-94	
1062	Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: a randomized trial. 2013 , 166, 920-6	25
1061	Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease. 2013 , 111, 804-10	33
1060	Stents liberadores de rapamicina sin polímero frente a stents liberadores de paclitaxel con polímero: un análisis de datos de pacientes procedentes de ensayos aleatorizados. 2013 , 66, 435-442	10
1059	Long-term outcome after angiographically proven coronary stent thrombosis. 2013 , 111, 1289-94	15
1058	Medical therapy of coronary artery disease after percutaneous intervention. 2013 , 13, 287-93	10
1057	Everolimus versus sirolimus-eluting stents for the treatment of sirolimus-eluting stent restenosis. 2013 , 165, 568-9	1
1056	Nonemergency PCI at hospitals with or without on-site cardiac surgery. 2013 , 368, 1498-508	39
1055	Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. 2013 , 61, 2060-6	185
1054	Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. 2013 , 381, 639-50	507
1053	Drug-eluting stents versus coronary artery bypass graft surgery in left main coronary artery disease: a meta-analysis of early outcomes from randomized and nonrandomized studies. 2013 , 145, 738-47	16
1052	The neutrophil to lymphocyte ratio was associated with impaired myocardial perfusion and long term adverse outcome in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. 2013 , 228, 203-10	91
1051	Stent thrombosis and platelet reactivity. 2013 , 55, e151-e157	

1050	Management and outcome of spontaneous coronary artery dissection: conservative therapy versus revascularization. 2013 , 168, 2907-8	22
1049	Pharmacotherapy for the reduction of stent thrombosis. 2013 , 11, 567-76	1
1048	Drug-eluting coronary-artery stents. 2013 , 368, 254-65	499
1047	A randomized, controlled, multicenter trial to evaluate the safety and efficacy of Zotarolimus- vs. Paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries: five-year results from the ZOMAXX I trial. 2013 , 82, 1039-47	6
1046	High-speed rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: the randomized ROTAXUS (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease) trial. 2013 , 6, 10-9	256
1045	Safety and efficacy of everolimus- versus sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials. 2013 , 165, 241-50.e4	55
1044	Late and very late coronary stent thrombosis: Intravascular ultrasound findings and associations with antiplatelet therapy. 2013 , 82, 1056-65	9
1043	Sirolimus-eluting stents reduce long-term mortality compared with bare metal stents in ST-segment elevation myocardial infarction: a meta-analysis of randomized controlled trials. 2013 , 167, 162-7	3
1042	Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. 2013 , 165, 964-971.e1	238
1041	Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. 2013 , 102, 799-806	22
1040	A randomized comparison of sirolimus- vs. paclitaxel-eluting stents for treatment of bifurcation lesions by single stent and kissing balloon: results of the SINGLE KISS trial. 2013 , 166, 187-92	7
1039	Periprocedural myocardial infarction is not associated with an increased risk of long-term cardiac mortality after coronary bifurcation stenting. 2013 , 167, 1251-6	14
1038	Single-stent crossover technique from distal unprotected left main coronary artery to the left circumflex artery. 2013 , 82, 757-64	9
1037	Causes of death in patients ≥5 years of age with non-ST-segment elevation acute coronary syndrome. 2013 , 112, 1-7	29
1036	Late thrombosis after double versus single drug-eluting stent in the treatment of coronary bifurcations: a meta-analysis of randomized and observational Studies. 2013 , 6, 687-95	61
1035	The long-term clinical outcome of T-stenting and small protrusion technique for coronary bifurcation lesions. 2013 , 6, 554-61	21
1034	Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. 2013 , 381, 651-60	243
1033	Randomized comparison of clinical outcomes between intravascular ultrasound and angiography-guided drug-eluting stent implantation for long coronary artery stenoses. 2013 , 6, 369-76	101

1032	A prospective, randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions: the AVIO trial. 2013 , 165, 65-72	147
1031	Prasugrel monitoring and bleeding in real world patients. 2013 , 111, 38-44	37
1030	Prevalence of left and balanced coronary arterial dominance decreases with increasing age of patients at autopsy. A postmortem coronary angiograms study. 2013 , 22, 49-53	24
1029	Trends in the outcomes of percutaneous coronary intervention with the routine incorporation of fractional flow reserve in real practice. 2013 , 34, 3353-61	71
1028	Prevalence, correlation and clinical outcome of intra-procedural stent thrombosis in patients undergoing primary percutaneous coronary intervention for acute coronary syndrome. 2013 , 26, 215-20	10
1027	Placement of Tryton Side Branch Stent only; a new treatment strategy for Medina 0,0,1 coronary bifurcation lesions. 2013 , 82, E395-402	9
1026	Two-year outcomes after deployment of XIENCE V everolimus-eluting stents in patients undergoing percutaneous coronary intervention of bifurcation lesions: a report from the SPIRIT V single arm study. 2013 , 82, E163-72	9
1025	Safety and efficacy outcomes of overlapping second-generation everolimus-eluting stents versus first-generation drug-eluting stents. 2013 , 112, 1093-8	24
1024	Association among leukocyte count, mortality, and bleeding in patients with non-ST-segment elevation acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] trial). 2013 , 111, 1237-45	12
1023	Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. 2013 , 29, 1334-45	81
1022	Forming vascular networks within functional cardiac tissue constructs. 2013 , 3, 138-143	1
1021	Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial. 2013 , 99, 1267-74	30
1020	Ischemic postconditioning during primary percutaneous coronary intervention: the effects of postconditioning on myocardial reperfusion in patients with ST-segment elevation myocardial infarction (POST) randomized trial. <i>Circulation</i> , 2013 , 128, 1889-96	16.7 140
1019	Healing responses after bifurcation stenting with the dedicated TRYTON Side-Branch Stent in combination with XIENCE-V stents: a clinical, angiography, fractional flow reserve, and optical coherence tomography study: the PYTON (Prospective evaluation of the TRYTON Side-Branch Stent with an additional XIENCE-V everolimus-eluting stent in coronary bifurcation lesions)	15
1018	Impact of coronary microvascular function on long-term cardiac mortality in patients with acute ST-segment-elevation myocardial infarction. 2013 , 6, 207-15	63
1017	The advantages of a consultant led primary percutaneous coronary intervention service on patient outcome. 2013 , 106, 989-94	2
1016	Long-term safety of drug-eluting stents. 2013 , 11, 1359-78	5
1015	Stent-oriented versus patient-oriented outcome in patients undergoing early percutaneous coronary intervention for acute coronary syndrome: 2-year report from the BASE-ACS trial. 2013 , 45, 488-93	14

1014	Randomized study to assess the effect of thrombus aspiration on flow area in patients with ST-elevation myocardial infarction: an optical frequency domain imaging study--TROFI trial. 2013 , 34, 1050-60	89
1013	Early application of an intra-aortic balloon pump in patients with ST-segment elevation acute myocardial infarction scheduled for elective percutaneous coronary intervention. 2013 , 41, 754-61	0
1012	Percutaneous Coronary Intervention using Transradial Access in Elderly vs. Non-Elderly Patients. 2013 , 21, 36-42	1
1011	Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. <i>Circulation</i> , 2013 , 128, 1055-65	16.7 99
1010	Prognostic value of uric acid in patients with Type 2 diabetes mellitus and coronary artery disease. 2013 , 124, 259-68	11
1009	CLINICAL AND ANGIOGRAPHIC CHARACTERISTICS OF PATIENTS WITH STENT THROMBOSIS. 2013 , 5-11	
1008	Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. 2013 , 18, 555-9	12
1007	Experience with biodegradable polymer coated sirolimus-eluting coronary stent system in "real-life" percutaneous coronary intervention: 24-month data from the manipal-s registry. 2013 , 7, 1959-63	3
1006	Risk factors for coronary drug-eluting stent thrombosis: influence of procedural, patient, lesion, and stent related factors and dual antiplatelet therapy. 2013 , 2013, 748736	13
1005	Ten years of percutaneous coronary intervention in a low-volume military treatment facility: a quality improvement project. 2013 , 178, 1029-35	1
1004	Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease. 2013 , 24, 542-8	3
1003	Final 5-year results of the TAXUS ATLAS, TAXUS ATLAS Small Vessel, and TAXUS ATLAS Long Lesion clinical trials of the TAXUS Libert [®] paclitaxel-eluting stent in de-novo coronary artery lesions. 2013 , 24, 61-8	8
1002	Gender differences in clinical outcomes after percutaneous coronary interventions with zotarolimus-eluting stents: insights from the Korean Endeavor Registry. 2013 , 346, 479-85	1
1001	Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V [®] everolimus-eluting stents: one-year results from the XIENCE V USA study. 2013 , 82, E385-94	4
1000	Leukocyte count is a modulating factor for the mortality benefit of bivalirudin in ST-segment-elevation acute myocardial infarction: the HORIZONS-AMI trial. 2013 , 6, 518-26	15
999	Impaired Coronary Autoregulation Is Associated With Long-term Fatal Events in Patients With Stable Coronary Artery Disease. 2013 , 6, 329-35	44
998	Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). 2013 , 34, 909-19	95
997	Impact of altitude on predicting midterm outcome in patients with ST elevation myocardial infarction. 2013 , 19, 382-8	2

996	Cigarette smoking is paradoxically associated with low mortality risk after acute myocardial infarction. 2013 , 15, 1230-8		13
995	Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. <i>Circulation</i> , 2013 , 128, 141-51	16.7	247
994	Timing of mortality after severe bleeding and recurrent myocardial infarction in patients with ST-segment-elevation myocardial infarction. 2013 , 6, 391-8		23
993	Outcomes for clinical studies assessing drug and revascularization therapies for claudication and critical limb ischemia in peripheral artery disease. <i>Circulation</i> , 2013 , 127, 1241-50	16.7	23
992	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. 2013 , 347, f6530		166
991	Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention. 2013 , 23, 558-62		10
990	Impact of stress hyperglycemia on in-hospital stent thrombosis and prognosis in nondiabetic patients with ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention. 2013 , 24, 352-6		14
989	Safety and feasibility of intra-arterial bivalirudin bolus administration during primary angioplasty. 2013 , 24, 419-21		
988	Six-year clinical outcomes of first-generation drug-eluting stents: a propensity-matched analysis. 2013 , 24, 440-8		3
987	Dual antiplatelet therapy can be discontinued at three months after implantation of zotarolimus-eluting stent in patients with coronary artery disease. 2013 , 2013, 518968		4
986	Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials. 2013 , 6, 378-90		63
985	Randomized comparison of sirolimus-eluting and everolimus-eluting coronary stents in the treatment of total coronary occlusions: results from the chronic coronary occlusion treated by everolimus-eluting stent randomized trial. 2013 , 6, 21-8		53
984	Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. 2013 , 34, 894-902d		20
983	Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRAFFICER) trial. 2013 , 34, 1723-31		34
982	Long-term clinical outcomes with the use of a modified provisional jailed-balloon stenting technique for the treatment of nonleft main coronary bifurcation lesions. 2013 , 82, E637-46		21
981	Risk of long-term dual antiplatelet therapy following drug-eluting stent implantation in octogenarians. 2013 , 26, 114-22		3
980	Is postdilatation with a noncompliant balloon necessary after coronary stent deployment during primary angioplasty?. 2013 , 26, 325-31		14
979	Angiographic and clinical outcomes of everolimus-eluting stent in the treatment of extra long stenoses (AEETES). 2013 , 26, 22-8		7

978	Monitoring persistent platelet reactivity in patients with unprotected left main stenting. 2013 , 26, 578-85	4
977	One-year outcome of small-vessel disease treated with sirolimus-eluting stents: a subgroup analysis of the e-SELECT registry. 2013 , 26, 163-72	5
976	Assessment of efficacy and safety of combining "paclitaxel" eluting balloon and "limus" eluting stent in the same lesion. 2013 , 26, 259-63	7
975	Uric acid and prognosis in angiography-proven coronary artery disease. 2013 , 43, 256-66	31
974	Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. 2013 , 347, f6625	208
973	MGuard mesh-covered stent for treatment of ST-segment elevation myocardial infarction with high thrombus burden despite manual aspiration. 2013 , 26, 1-7	8
972	Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial. 2013 , 82, E769-76	13
971	Long-term clinical follow-up after drug-eluting stent implantation for bare metal in-stent restenosis. 2013 , 26, 271-7	1
970	Effect of the ABCC3 -211C/T polymorphism on clopidogrel responsiveness in patients with percutaneous coronary intervention. 2013 , 40, 504-9	9
969	A comparative study of bivalirudin plus clopidogrel versus bivalirudin plus prasugrel in primary angioplasty using propensity score matching. 2013 , 26, 463-9	5
968	Impact of scheduled angiographic follow-up in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. 2013 , 26, 319-24	9
967	Clinical outcomes following percutaneous coronary intervention with drug-eluting stents versus bare metal stents in patients on chronic hemodialysis. 2013 , 26, 351-8	12
966	Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. 2013 , 99, 98-105	60
965	Drug-eluting vs. conventional balloon for side branch dilation in coronary bifurcations treated by provisional T stenting. 2013 , 26, 454-62	22
964	Volume-outcomes relationship in the era of modern coronary intervention-results from the prospective multicenter German DES.DE Registry. 2013 , 82, E788-97	5
963	Procedural effectiveness of a novel 1.20 mm diameter angioplasty catheter: clinical and angiographic outcomes. 2013 , 26, 131-6	0
962	Combined paclitaxel-eluting balloon and Genous cobalt-chromium alloy stent utilization in de novo coronary stenoses (PEGASUS). 2013 , 26, 556-60	3
961	An audit of outcomes after same-day discharge post-PCI in acute coronary syndrome and elective patients. 2013 , 26, 570-7	17

960	Telephone contact to improve adherence to dual antiplatelet therapy after drug-eluting stent implantation. 2013 , 99, 562-9	43
959	Long-term follow-up of coronary venous bypass graft lesions treated with a new generation drug-eluting stent with bioabsorbable polymer. 2013 , 26, 425-33	2
958	An evidence-based review of the impact of periprocedural myocardial infarction in carotid revascularization. 2013 , 82, 709-14	5
957	Nine-month angiographic and intravascular ultrasound outcomes after resolute zotarolimus-eluting stent implantation for the treatment of in-stent restenosis. 2013 , 26, 543-9	
956	Retrospective multicenter observational study of the interventional management of coronary disease in the very elderly: the NINETY. 2013 , 82, 414-21	8
955	In-hospital and one year outcomes with drug-eluting versus bare metal stents in large native coronary arteries: a report from the Evaluation of Drug-Eluting Stents and Ischemic Events registry. 2013 , 82, E356-64	3
954	Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program. 2013 , 99, 626-33	26
953	Arterial repair 4 months after zotarolimus-eluting stent implantation observed on angioscopy. 2013 , 77, 1186-92	12
952	Incidence and predictors for late target lesion revascularization after sirolimus-eluting stent implantation. 2013 , 77, 988-94	9
951	Vaporizing thrombus with excimer laser before coronary stenting improves myocardial reperfusion in acute coronary syndrome. 2013 , 77, 1445-52	25
950	Difference in clinical and angiographic characteristics of very late stent thrombosis between drug-eluting and bare-metal stent implantations. 2013 , 77, 1453-60	10
949	Long-term outcome of drug-eluting vs. bare-metal stents in patients with acute myocardial infarction. Subgroup analysis of the nagoya acute myocardial infarction study (NAMIS). 2013 , 77, 2024-31	8
948	Seven-year clinical outcomes of unprotected left main coronary artery stenting with drug-eluting stent and bare-metal stent. 2013 , 77, 2497-504	12
947	Consideration of dual anti-platelet therapy duration after drug-eluting stent implantation in a Japanese population: a five-year follow-up after sirolimus-eluting stent implantation. 2013 , 52, 703-11	3
946	Women treated with second-generation zotarolimus-eluting resolute stents and everolimus-eluting xience V stents: insights from the gender-stratified, randomized, controlled TWENTE trial. 2013 , 82, 396-405	6
945	Stent thrombosis after coronary stent implantation: a protective effect of high-dose statin therapy?. 2013 , 126, 115-21	5
944	Clinical Outcome of Diabetic Patients Treated by Percutaneous Coronary Intervention Using Drug-Eluting and Bare Metal Stents. 2013 , 21, 359-366	
943	Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries. 2013 , 81, 793-9	31

942	Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. 2013 , 81, 1127-33	5
941	In Vitro Dissolution Testing of Drug-Eluting Stents. 2013 , 14, 67-75	6
940	Comparison of 3-year clinical outcomes between classic crush and modified mini-crush technique in coronary bifurcation lesions. 2013 , 82, 370-6	2
939	Preclinical Evaluation of Coronary Stents: Focus on Safety Issues. 2013 , 11, 74-99	12
938	Development of a high-volume, multiple-operator program for percutaneous chronic total coronary occlusion revascularization: procedural, clinical, and cost-utilization outcomes. 2013 , 82, 1-8	47
937	Angiographically confirmed stent thrombosis in contemporary practice: insights from intravascular ultrasound. 2013 , 81, 782-90	15
936	Bleeding outcomes after routine transradial primary angioplasty for acute myocardial infarction using eptifibatid and unfractionated heparin: a single-center experience following the HORIZONS-AMI trial. 2013 , 82, E138-47	5
935	Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study. 2013 , 81, E237-44	6
934	The independent value of a direct stenting strategy on early and late clinical outcomes in patients undergoing elective percutaneous coronary intervention. 2013 , 81, 949-56	0
933	Impact of incomplete revascularization in patients undergoing PCI for unprotected left main stem stenosis. 2013 , 81, 939-46	12
932	Coronary reperfusion and clinical outcomes after thrombus aspiration during primary percutaneous coronary intervention: findings from the HORIZONS-AMI trial. 2013 , 82, 594-601	8
931	Minimizing complications following stent implantation: outcomes and follow-up. 2013 , 5, 301-317	2
930	Clinical outcome after surgical or percutaneous revascularization in coronary bypass graft failure. 2013 , 14, 438-45	18
929	Incidence of definite stent thrombosis or in-stent restenosis after drug-eluting stent implantation for treatment of coronary in-stent restenosis: from Western Denmark Heart Registry. 2013 , 81, 260-5	11
928	Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation. 2013 , 110, 560-8	31
927	Comparison of long-term clinical and 1-year angiographic outcomes after primary stenting (-12 hours) and late reperfusion (12 hours-) using sirolimus-eluting stents for ST-segment elevated myocardial infarctions: a propensity score matching analysis. 2013 , 52, 1303-10	3
926	Usefulness of the SYNTAX and clinical SYNTAX scores in predicting clinical outcome after unrestricted use of sirolimus- and everolimus-eluting Stents. 2013 , 77, 2912-21	19
925	Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes. 2013 , 109, 744-54	24

924	Event detection using population-based health care databases in randomized clinical trials: a novel research tool in interventional cardiology. 2013 , 5, 357-61	21
923	Prognostic value of post-procedural aPTT in patients with ST-elevation myocardial infarction treated with primary PCI. 2013 , 109, 961-70	11
922	Efficacy and safety of a biodegradable polymer sirolimus-eluting stent in primary percutaneous coronary intervention: a randomized controlled trial. 2013 , 9, 1040-8	4
921	Safety and efficacy of biolimus-eluting stent with biodegradable polymer: insights from EINSTEIN (Evaluation of Next-generation drug-eluting STent IN patients with coronary artery disease) Registry. 2013 , 11, 350-6	5
920	Clinical significance of histological features of thrombi in patients with myocardial infarction. 2013 , 101, 502-10	
919	A prospective, randomized comparison of promus everolimus-eluting and TAXUS Liberte paclitaxel-eluting stent systems in patients with coronary artery disease eligible for percutaneous coronary intervention: the PROMISE study. 2013 , 28, 1609-14	5
918	Postoperative care and follow-up after coronary stenting. 2013 , 110, 72-81; quiz 82	9
917	Trans-radial versus trans-femoral intervention for the treatment of coronary bifurcations: results from Coronary Bifurcation Stenting Registry. 2013 , 28, 388-95	6
916	Seven-year clinical outcomes of sirolimus-eluting stent versus bare-metal stent: a matched analysis from a real world, single center registry. 2013 , 28, 396-401	4
915	Relationship between angiographic late loss and 5-year clinical outcome after drug-eluting stent implantation. 2013 , 54, 41-7	
914	Resolute Integrity drug eluting stent safety and efficacy for the treatment of coronary artery disease. 2013 , 23	
913	CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population. 2013 , 8, e59344	17
912	Two-year results of an open-label randomized comparison of everolimus-eluting stents and sirolimus-eluting stents. 2014 , 8, e64424	10
911	Efficacy and safety of biodegradable polymer biolimus-eluting stents versus durable polymer drug-eluting stents: a meta-analysis. 2013 , 8, e78667	10
910	Von Willebrand factor antigen predicts response to double dose of aspirin and clopidogrel by PFA-100 in patients undergoing primary angioplasty for ST elevation myocardial infarction. 2013 , 2013, 313492	3
909	Left ventricular thrombus and subsequent thromboembolism, comparison of anticoagulation, surgical removal, and antiplatelet agents. 2013 , 20, 73-93	58
908	Clinical Coronary In-Stent Restenosis Follow-Up after Treatment and Analyses of Clinical Outcomes. 2015 , 104, 375-86	4
907	Early stent thrombosis. Aetiology, treatment, and prognosis. 2014 , 10, 221-5	7

906	Red blood cell distribution width and long-term outcome in patients undergoing percutaneous coronary intervention in the drug-eluting stenting era: a two-year cohort study. 2014, 9, e94887	19
905	Safety and efficacy of biodegradable drug-eluting vs. bare metal stents: a meta-analysis from randomized trials. 2014, 9, e99648	4
904	Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention. 2014, 9, e102701	21
903	Stent thrombosis is the primary cause of ST-segment elevation myocardial infarction following coronary stent implantation: a five year follow-up of the SORT OUT II study. 2014, 9, e113399	8
902	Efficacy and safety of biodegradable polymer biolimus A9-eluting stent versus durable polymer everolimus-eluting stent in diabetic patients: a prospective non-randomized single-centre long-term comparison. 2014, 69, 523-31	3
901	Long-term prognostic value of admission haemoglobin A1c (HbA1c) levels in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. 2014, 10, 166-74	5
900	Comparison of full lesion coverage versus spot drug-eluting stent implantation for coronary artery stenoses. 2014, 55, 584-91	2
899	Drug-eluting versus bare metal stents after rotational atherectomy: clinical outcome in a single centre. 2014, 69, 611-7	3
898	Prospective and systematic analysis of unexpected requests for non-cardiac surgery or other invasive procedures during the first year after drug-eluting stent implantation. 2014, 55, 345-52	9
897	Stent thrombosis in patients with coronary artery disease treated with biodegradable polymer drug-eluting stents: an update meta-analysis. 2014, 55, 213-8	10
896	Impact of rivaroxaban on stent thrombosis and secondary prevention of cardiovascular events in acute coronary syndrome. 2014, 103	
895	Southern Saskatchewan Ticagrelor Registry experience. 2014, 8, 1427-35	8
894	The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting. 2014, 112, 1174-81	24
893	Clinical impact of Q-wave presence on electrocardiogram at presentation of patients with ST-segment elevation myocardial infarction undergoing primary coronary intervention. 2014, 55, 404-8	6
892	Evaluaci3n econ3mica del stent medicado vs. convencional para pacientes con infarto agudo de miocardio con elevaci3n del ST en Colombia. 2014, 21, 364-371	
891	Performance of the Titanium-Nitride-Oxide Coated Stent in Patients with Multivessel Coronary Artery Disease. 2014, 22, 143-148	3
890	Efficacy and safety of tirofiban-supported primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: results of propensity analysis using the Clinical Center of Serbia STEMI Register. 2014, 3, 56-66	15
889	Usefulness of mean platelet volume as a biomarker for long-term clinical outcomes after percutaneous coronary intervention in Korean cohort: a comparable and additive predictive value to high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide. 2014, 25, 427-32	22

888	A high ratio of ADP-TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone. 2014 , 103, 968-75		7
887	A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel. 2014 , 25, 612-8		23
886	Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials. 2014 , 21, 644-53		18
885	Prospective, multi-center evaluation of a silicon carbide coated cobalt chromium bare metal stent for percutaneous coronary interventions: two-year results of the ENERGY Registry. 2014 , 15, 381-7		7
884	Similar five-year outcome with paclitaxel- and sirolimus-eluting coronary stents. 2014 , 48, 148-55		8
883	Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial. 2014 , 35, 2812-20		45
882	Very late stent thrombosis related to incomplete neointimal coverage or neoatherosclerotic plaque rupture identified by optical coherence tomography imaging. 2014 , 15, 24-31		30
881	Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. 2014 , 349, g6427		71
880	Response to letter regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial". <i>Circulation</i> , 2014 , 129, e494-5	16.7	2
879	Biocompatibility of Coronary Stents. 2014 , 7, 769-786		25
878	Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. 2014 , 100, 1158-64		144
877	Evaluation of long-term clinical and health service outcomes following coronary artery revascularisation in Western Australia (WACARP): a population-based cohort study protocol. 2014 , 4, e006337		6
876	A clinical update on the use of resolute stents with dual anti-platelet therapy interruption. 2014 , 6, 453-462		
875	A Randomized Comparison between Everolimus-Eluting Stent and Cobalt Chromium Stent in Patients with Acute ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention Using Routine Intravenous Eptifibatide: The X-MAN (Xience vs. Multi-Link Stent in Acute Myocardial Infarction) Trial, A Pilot Study. 2014 , 23, 93-100		
874	Late results (>10 years) of intracoronary beta brachytherapy for diffuse in-stent restenosis. 2014 , 33, 609-16		4
873	Serial optical frequency domain imaging in STEMI patients: the follow-up report of TROFI study. 2014 , 15, 987-95		28
872	Bivalirudin use and one-month outcome in the context of contemporary antiplatelet treatment: insights from the Greek Antiplatelet Registry. 2014 , 32, 120-6		3
871	A randomized comparison of novel biodegradable polymer- and durable polymer-coated cobalt-chromium sirolimus-eluting stents. 2014 , 7, 1352-60		27

870	Meta-analysis of bioabsorbable versus durable polymer drug-eluting stents in 20,005 patients with coronary artery disease: an update. 2014 , 83, E193-206	25
869	Bivalirudin use in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Insights from the prospective, multi-centre EUROVISION registry. 2014 , 16, 127-31	1
868	New strategies for developing cardiovascular stent surfaces with novel functions (Review). 2014 , 9, 029017	15
867	Dual antiplatelet therapy over 6 months increases the risk of bleeding after biodegradable polymer-coated sirolimus eluting stents implantation: insights from the CREATE study. 2014 , 27, 119-26	5
866	Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study. 2014 , 7, 1117-27	35
865	Predictors and outcomes of recurrent stent thrombosis: results from a multicenter registry. 2014 , 7, 1105-13	18
864	Comparison of the safety and efficacy of biodegradable polymer biolimus-eluting stents and durable polymer everolimus-eluting stents: propensity score-matched analysis. 2014 , 27, 399-407	1
863	Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives. 2014 , 12, 963-76	
862	Optimal duration of dual antiplatelet therapy following treatment with the endeavor zotarolimus-eluting stent in real-world Japanese patients with coronary artery disease (OPERA): study design and rationale. 2014 , 84, 368-74	2
861	Incidence, angiographic features and outcomes of patients presenting with subtle ST-elevation myocardial infarction. 2014 , 168, 884-90	24
860	Comparison of biodegradable polymer versus durable polymer sirolimus-eluting stenting in patients with acute st-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the RESOLVE study. 2014 , 27, 131-41	6
859	Long-term clinical outcomes following drug-eluting stent implantation for unprotected distal trifurcation left main disease: the Milan-New Tokyo (MITO) registry. 2014 , 83, 530-8	15
858	Impact of chronic total occlusion revascularization in patients with acute myocardial infarction treated by primary percutaneous coronary intervention. 2014 , 114, 1794-800	19
857	One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry. 2014 , 37, 357-64	76
856	Low-dose heparin for elective percutaneous coronary intervention. 2014 , 27, 58-62	6
855	Clinical and angiographic outcomes with everolimus eluting stents for the treatment of cardiac allograft vasculopathy. 2014 , 27, 73-9	11
854	Impact of in-hospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention. 2014 , 168, 862-8.e1	6
853	Impact of diabetes mellitus and metabolic syndrome on acute and chronic on-clopidogrel platelet reactivity in patients with stable coronary artery disease undergoing drug-eluting stent placement. 2014 , 168, 940-7.e5	12

852	New generation drug-eluting stents for ST-elevation myocardial infarction: a new paradigm for safety. 2014 , 84, 955-62	8
851	Percutaneous coronary intervention for acute coronary syndrome due to graft failure: use of bare-metal and drug-eluting stents and subsequent long-term clinical outcome. 2014 , 83, 203-9	4
850	Very late hazard with stenting versus balloon angioplasty for ST-elevation myocardial infarction: a 16-year single-center experience. 2014 , 27, 21-8	18
849	Cangrelor: a novel intravenous antiplatelet agent with a questionable future. 2014 , 34, 1061-76	15
848	Clinical outcomes of biodegradable polymer drug-eluting stents for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials. 2014 , 37, 440-53	5
847	Performance of the resolute zotarolimus-eluting stent in small vessels. 2014 , 84, 17-23	17
846	Impact of occluded culprit arteries on long-term clinical outcome in patients with non-ST-elevation myocardial infarction: 48-month follow-up results in the COREA-AMI Registry. 2014 , 27, 12-20	12
845	Influence of a paclitaxel coated balloon in combination with a bare metal stent on restenosis and endothelial function: comparison with a drug eluting stent and a bare metal stent. 2014 , 84, 323-31	21
844	Transradial versus transfemoral method of two-stent implantation for true bifurcation lesions: comparison of immediate and long-term outcomes. 2014 , 27, 99-107	4
843	Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. 2014 , 4, e005781	20
842	Comparison of procedural and long-term outcomes between transradial and transfemoral approach in one-stage intervention for triple vessel coronary artery disease. 2014 , 27, 108-16	1
841	Extended follow-up following "full-metal jacket" percutaneous coronary interventions with drug-eluting stents. 2014 , 84, 1042-50	18
840	RAPSTROM—First-in-man study long-term results of a biodegradable polymer sustained-release sirolimus-eluting stent in de novo coronary stenoses. 2014 , 27, 373-80	2
839	Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age. 2014 , 83, 182-9	21
838	Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial). 2014 , 83, 418-24	19
837	Impact of bifurcation stent technique on clinical outcomes in patients with a Medina 0,0,1 coronary bifurcation lesion: results from the COBIS (CORonary Bifurcation Stenting) II registry. 2014 , 84, E43-50	6
836	Hypercoagulation assessed by thromboelastography is neither related to infarct size nor to clinical outcome after primary percutaneous coronary intervention. 2014 , 20, 825-31	1
835	Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials. 2014 , 9, 1110-20	17

834	CES1A -816C as a genetic marker to predict greater platelet clopidogrel response in patients with percutaneous coronary intervention. 2014 , 63, 178-83	16
833	Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents. 2014 , 25, 405-11	12
832	Second-generation versus first-generation drug-eluting stents for the treatment of patients with acute coronary syndromes and obstructive coronary artery disease. 2014 , 25, 208-14	10
831	Should primary percutaneous coronary intervention be the routine reperfusion strategy in octogenarians presenting with ST elevation myocardial infarction?. 2014 , 15, 53-9	5
830	Genetic risk of restenosis after percutaneous coronary interventions in the era of drug-eluting stents. 2014 , 25, 658-64	5
829	Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis. 2014 , 25, 638-44	5
828	Long-term comparison of sirolimus-eluting and bare-metal stents in ST-segment elevation myocardial infarction. 2014 , 25, 378-83	4
827	The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease. 2014 , 24, 204-10	32
826	Factor XI rs2036914 gene polymorphism and occurrence of adverse events after percutaneous coronary intervention. A prospective evaluation. 2014 , 177, 711-3	3
825	Prospective 'real world' registry for the use of the 'PCB only' strategy in small vessel de novo lesions. 2014 , 100, 311-6	65
824	Outcome in patients with left-sided native-valve infective endocarditis and isolated large vegetations. 2014 , 37, 626-33	8
823	Perioperative management of the patient with a coronary artery stent. 2014 , 121, 1093-8	7
822	Clinical use of optical coherence tomography to identify angiographic silent stent thrombosis. 2014 , 48, 156-60	2
821	Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5,834 patients. 2014 , 21, 411-24	20
820	Randomized comparison between polymer-free versus polymer-based paclitaxel-eluting stent: two-year final clinical results. 2014 , 7, 312-21	12
819	Thrombin-inhibiting nanoparticles rapidly constitute versatile and detectable anticlotting surfaces. 2014 , 25, 395101	17
818	Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus. 2014 , 25, 348-56	16
817	Current cigarette smoking is an independent risk factor for subacute stent thrombosis in acute myocardial infarction patients. 2014 , 63, 358-64	16

816	Three-year follow-up of patients with bifurcation lesions treated with sirolimus- or everolimus-eluting stents: SEAside and CORpal cooperative study. 2014 , 67, 797-803	3
815	Ten-year clinical follow-up after sirolimus-eluting stent implantation. 2014 , 167, 893-9	5
814	Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial. 2014 , 15, 69-75	10
813	Seguimiento de 3 años de pacientes con lesiones de bifurcación tratados con stents liberadores de sirolimus o everolimus: estudio de colaboración de SEAside y CORpal. 2014 , 67, 797-803	14
812	Long-term outcomes of percutaneous coronary interventions or coronary artery bypass grafting for left main coronary artery disease in octogenarians (from a Drug-Eluting stent for Left main Artery registry substudy). 2014 , 113, 2007-12	23
811	Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). 2014 , 63, 619-629	73
810	One-year outcomes from an all-comers chinese population of patients implanted with the resolute zotarolimus-eluting stent. 2014 , 113, 613-20	14
809	Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. 2017 , 13, 459-466	65
808	Potentially increased incidence of scaffold thrombosis in patients treated with Absorb BVS who terminated DAPT before 18 months. 2017 , 13, e177-e184	18
807	Impact of residual SYNTAX score on clinical outcomes after incomplete revascularisation percutaneous coronary intervention: a large single-centre study. 2017 , 13, 1185-1193	12
806	One-year clinical results of the Italian diffuse/multivessel disease ABSORB prospective registry (IT-DISAPPEARS). 2017 , 13, 424-431	13
805	Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III. 2017 , 13, 432-439	76
804	A randomised comparison of biodegradable polymer- and permanent polymer-coated platinum-chromium everolimus-eluting coronary stents in China: the EVOLVE China study. 2017 , 13, 1210-1217 ⁹	
803	Clinical outcomes after percutaneous coronary intervention with the COMBO stent versus Resolute Integrity and PROMUS Element stents: a propensity-matched analysis. 2017 , 13, 1202-1209	9
802	First-in-human evaluation of a novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial. 2017 , 13, 415-423	21
801	First serial optical coherence tomography assessment at baseline, 12 and 24 months in STEMI patients treated with the second-generation Absorb bioresorbable vascular scaffold. 2018 , 13, e2201-e2209	5
800	Everolimus-eluting bioresorbable scaffolds in patients with coronary artery disease: results from the German-Austrian ABSORB RegIstRy (GABI-R). 2017 , 13, 1311-1318	13
799	Characteristics and outcome of patients with complex coronary lesions treated with bioresorbable scaffolds: three-year follow-up in a cohort of consecutive patients. 2018 , 14, e1011-e1019	13

798	Final five-year outcomes after implantation of biodegradable polymer-coated biolimus-eluting stents versus durable polymer-coated sirolimus-eluting stents. 2017 , 13, 1336-1344	10
797	One-year clinical outcomes after unrestricted implantation of the Absorb bioresorbable scaffold (RAI registry). 2018 , 14, e546-e553	5
796	Outcome of percutaneous coronary intervention with the Absorb bioresorbable scaffold: data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). 2017 , 13, 1303-1310	3
795	First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial. 2018 , 13, 2026-2035	13
794	State of the art: coronary angiography. 2017 , 13, 634-643	17
793	State of the art: coronary artery stents - past, present and future. 2017 , 13, 706-716	41
792	Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: insights from five-year follow-up of the EXAMINATION trial. 2018 , 13, 1939-1945	5
791	Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT. 2017 , 13, 1168-1176	34
790	Long-term safety of bioresorbable scaffolds: insights from a network meta-analysis including 91 trials. 2018 , 13, 1904-1913	12
789	A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. 2018 , 14, 692-699	7
788	Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy. 2018 , 13, 1923-1930	27
787	Characteristics of stent thrombosis in bifurcation lesions analysed by optical coherence tomography. 2018 , 13, e2174-e2181	3
786	Comparison of everolimus-eluting bioresorbable vascular scaffolds and metallic stents: three-year clinical outcomes from the ABSORB China randomised trial. 2018 , 14, e554-e561	17
785	Acute and one-year clinical outcomes following implantation of bioresorbable vascular scaffolds: the ABSORB UK Registry. 2018 , 13, 1554-1560	3
784	A prospective randomised trial comparing the novel ridaforolimus-eluting BioNIR stent to the zotarolimus-eluting Resolute stent: six-month angiographic and one-year clinical results of the NIREUS trial. 2018 , 14, 86-93	9
783	Procedural and one-year outcomes of patients treated with orbital and rotational atherectomy with mechanistic insights from optical coherence tomography. 2019 , 14, 1760-1767	19
782	Angiographic and clinical performance of a paclitaxel-coated balloon compared to a second-generation sirolimus-eluting stent in patients with in-stent restenosis: the BIOLUX randomised controlled trial. 2018 , 14, 1096-1103	17
781	Long-term consequences of optical coherence tomography findings during percutaneous coronary intervention: the Centro Per La Lotta Contro L'infarto - Optimization Of Percutaneous Coronary Intervention (CLI-OPCI) LATE study. 2018 , 14, e443-e451	19

780	Establishment of healing profile and neointimal transformation in the new polymer-free biolimus A9-coated coronary stent by longitudinal sequential optical coherence tomography assessments: the EGO-BIOFREEDOM study. 2018 , 14, 780-788	13
779	Safety and efficacy of polymer-free biolimus-eluting stents in all-comer patients: the RUDI-FREE study. 2018 , 14, 772-779	14
778	Biolimus A9 polymer-free coated stents in high bleeding risk patients undergoing complex PCI: evidence from the LEADERS FREE randomised clinical trial. 2018 , 14, e418-e425	14
777	Relation between bioresorbable scaffold sizing using QCA-Dmax and long-term clinical outcomes in 1,232 patients from three study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). 2018 , 14, e1057-e1066	3
776	Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI. 2018 , 14, e426-e433	19
775	Long-term clinical outcomes after bioresorbable and permanent polymer drug-eluting stent implantation: final five-year results of the CENTURY II randomised clinical trial. 2018 , 14, e343-e351	17
774	Bioabsorbable polymer everolimus-eluting stents in patients with acute myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry. 2018 , 14, e562-e569	4
773	Ten-year clinical outcome of patients treated with a drug-eluting stent in the proximal left anterior descending artery segment compared with patients stented in other non-left main coronary segments. 2018 , 14, 764-771	5
772	Impact of retrograde approach on long-term clinical outcomes of patients undergoing coronary chronic total occlusion interventions. 2018 , 14, e1183-e1191	7
771	Bioresorbable vascular scaffolds in coronary chronic total occlusions: clinical, vasomotor and optical coherence tomography findings at three-year follow-up (ABSORB-CTO study). 2019 , 15, 99-107	5
770	Impact of the one-year angioscopic findings on long-term clinical events in 504 patients treated with first-generation or second-generation drug-eluting stents: the DESNOTE-X study. 2019 , 15, 631-639	9
769	Randomised comparison of a biodegradable polymer ultra-thin sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients with de novo native coronary artery lesions: the merIT-V trial. 2018 , 14, e1207-e1214	10
768	Very long-term outcome of coronary covered stents: a report from the SCAAR registry. 2019 , 14, 1660-1667	13
767	Clinical outcomes of state-of-the-art percutaneous coronary revascularisation in patients with three-vessel disease: two-year follow-up of the SYNTAX II study. 2019 , 15, e244-e252	38
766	Safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: three-year clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. 2020 , 15, e1375-e1382	18
765	Diabetes and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: a pre-specified analysis from the randomised TROPICAL-ACS trial. 2019 , 15, e513-e521	6
764	BIOFLOW-IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months. 2019 , 15, e1006-e1013	24
763	A multicentre, randomised controlled clinical study of drug-coated balloons for the treatment of coronary in-stent restenosis. 2020 , 16, e328-e334	8

762	Incidence and predictors of stent thrombosis after endovascular revascularisation of the superficial femoral artery. 2019 , 15, e1107-e1114	8
761	First-in-man randomised comparison of the Angiolite durable fluoroacrylate polymer-based sirolimus-eluting stent versus a durable fluoropolymer-based everolimus-eluting stent in patients with coronary artery disease: the ANGIOLITE trial. 2019 , 15, e1081-e1089	4
760	Incidence and predictors of outcomes after a first definite coronary stent thrombosis. 2020 , 16, e344-e350	6
759	Treatment with a dedicated bifurcation sirolimus-eluting cobalt-chromium stent for distal left main coronary artery disease: rationale and design of the POLBOS LM study. 2020 , 16, 654-662	2
758	The obesity paradox revisited: body mass index and -long-term outcomes after PCI from a large pooled patient-level database. 2020 , 15, 1199-1208	12
757	Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). 2019 , 15, e990-e998	67
756	Defining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. 2020 , 15, 1190-1198	5
755	First-in-human evaluation of a novel sirolimus-eluting ultra-high molecular weight APTITUDE bioresorbable scaffold: 9- and 24-month imaging and clinical results of the RENASCENT II trial. 2020 , 16, e133-e140	5
754	Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial. 2020 , 15, 1527-1533	19
753	Clinical outcomes of calcified nodules detected by optical coherence tomography: a sub-analysis of the CLIMA study. 2020 , 16, 380-386	5
752	Impact of coronary lesion complexity in percutaneous coronary intervention: one-year outcomes from the large, multicentre e-Ultimaster registry. 2020 , 16, 603-612	10
751	Twelve-month clinical and imaging outcomes of the uncaging coronary DynamX bioadaptor system. 2020 , 16, e974-e981	3
750	Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. 2018 , 13, 1574-1586	26
749	Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. 2010 , 6, 437-46	6
748	Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. 2010 , 6, 447-53	100
747	Early experience with a new approach for percutaneous intervention of totally occluded saphenous vein graft: is the flow the best thrombolytic?. 2010 , 6, 461-6	7
746	Impact of arterial injury on neointimal hyperplasia after implantation of drug-eluting stents in coronary arteries: an intravascular ultrasound study. 2010 , 6, 467-74	5
745	The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. 2015 , 10, 1396-401	119

744	Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials. 2015 , 10, 1425-31	14
743	Validation of residual SYNTAX score with second-generation drug-eluting stents: one-year results from the prospective multicentre SEEDS study. 2014 , 10, 65-73	20
742	Everolimus-eluting versus sirolimus-eluting coronary stents in patients with and without diabetes mellitus. 2014 , 10, 74-82	10
741	Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes. 2014 , 10, 83-9	2
740	Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial. 2014 , 10, 204-11	13
739	Outcomes after revascularisation with everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes and stable angina pectoris: a substudy of the SORT OUT IV trial. 2014 , 10, 212-23	8
738	Comparison of bivalirudin and heparin in patients undergoing rotational atherectomy: a subanalysis of the randomised ROTAXUS trial. 2014 , 10, 458-65	4
737	ST peak during percutaneous coronary intervention serves as an early prognostic predictor in patients with ST-segment elevation myocardial. 2014 , 10, 466-74	3
736	Safety and feasibility of a Paclitaxel-eluting balloon angioplasty in Primary Percutaneous coronary intervention in Amsterdam (PAPPA): one-year clinical outcome of a pilot study. 2014 , 10, 584-90	29
735	Coronary artery treatment with paclitaxel-coated balloon using a BTHC excipient: clinical results of the international real-world DELUX registry. 2014 , 10, 591-9	27
734	Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trial. 2014 , 10, 664-71	2
733	Impact of technological developments in drug-eluting stents on patient-focused outcomes: a pooled direct and indirect comparison of randomised trials comparing first- and second-generation drug-eluting stents. 2014 , 10, 942-52	17
732	Everolimus-eluting stent implantation versus repeat paclitaxel-coated balloon angioplasty for recurrent in-stent restenosis lesion caused by paclitaxel-coated balloon failure. 2015 , 10, e1-8	15
731	Significance of prior percutaneous revascularisation in patients with acute coronary syndromes: insights from the prospective PROSPECT registry. 2016 , 11, 1468-74	1
730	A novel approach to treat in-stent restenosis: 6- and 12-month results using the everolimus-eluting bioresorbable vascular scaffold. 2016 , 11, 1479-86	22
729	The use of a scoring balloon for optimal lesion preparation prior to bioresorbable scaffold implantation: a comparison with conventional balloon predilatation. 2016 , 11, e1580-8	23
728	Hybrid strategy with a bioresorbable scaffold and a drug-coated balloon for diffuse coronary artery disease: the "no more metallic cages" multicentre pilot experience. 2016 , 11, e1589-95	9
727	Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention. 2015 , 11, 171-9	9

726	Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trial. 2015 , 11, 180-7	12
725	Long-term outcomes of angiographically confirmed coronary stent thrombosis: results from a multicentre California registry. 2015 , 11, 188-95	7
724	Influence of arterial hypotension on fractional flow reserve measurements. 2015 , 11, 416-20	10
723	Impact of side branch stenting on five-year long-term clinical outcome with the bifurcation-dedicated Axxess Biolimus A9-eluting stent system. 2015 , 11, 860-7	4
722	Impact of J-CTO score on procedural outcome and target lesion revascularisation after percutaneous coronary intervention for chronic total occlusion: a substudy of the J-CTO Registry (Multicentre CTO Registry in Japan). 2016 , 11, 981-8	28
721	Long-term outcomes after Resolute zotarolimus-eluting stent implantation in patients with ST-segment elevation acute myocardial infarction: insights from the RESOLUTE All Comers Trial and the RESOLUTE Global Clinical Trial Program. 2016 , 12, 1207-1214	7
720	Outcomes of stenting extra-small (â2.25 mm) vessels using the Resolute zotarolimus-eluting stent (R-ZES). 2016 , 12, 1215-1221	6
719	One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials. 2016 , 12, 1255-1262	5
718	Biodegradable polymer-based, argatroban-eluting, cobalt-chromium stent (JF-04) for treatment of native coronary lesions: final results of the first-in-man study and lessons learned. 2016 , 12, 1271-1278	1
717	Clinical and multimodality imaging results at 6 months of a bioresorbable sirolimus-eluting scaffold for patients with single de novo coronary artery lesions: the NeoVas first-in-man trial. 2016 , 12, 1279-1287	11
716	Long-term follow-up after bioresorbable vascular scaffold implantation in STEMI patients: PRAGUE-19 study update. 2016 , 12, 23-9	16
715	Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study. 2016 , 12, 30-7	20
714	Percutaneous coronary intervention for chronic total occlusion of the coronary artery with the implantation of bioresorbable everolimus-eluting scaffolds. Poznan CTO-Absorb Pilot Registry. 2016 , 12, e144-51	11
713	One-year outcomes after Absorb bioresorbable vascular scaffold implantation in routine clinical practice. 2016 , 12, e152-9	6
712	Bioresorbable polymer sirolimus-eluting coronary stent compared with permanent polymer everolimus-eluting coronary stent implantation for treatment of small vessel coronary artery disease: CENTURY II trial. 2016 , 12, e167-74	19
711	Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. 2016 , 12, 312-8	22
710	Impact of non-compliant balloons on long-term clinical outcomes in coronary bifurcation lesions: results from the COBIS (COronary Bifurcation Stent) II registry. 2016 , 12, 456-64	11
709	Direct implantation of rapamycin-eluting stents with bioresorbable drug carrier technology utilising the Svelte coronary stent-on-a-wire: the DIRECT II study. 2016 , 12, e615-22	7

708	Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. 2016, 12, e623-31	12
707	Two-year clinical outcomes of Absorb bioresorbable vascular scaffold implantation in complex coronary artery disease patients stratified by SYNTAX score and ABSORB II study enrolment criteria. 2016, 12, e557-65	8
706	Periprocedural myocardial infarction in stent trials: how universal is the third universal definition?. 2016, 12, 813-7	3
705	Quantification by optical coherence tomography imaging of the ablation volume obtained with the Orbital Atherectomy System in calcified coronary lesions. 2016, 12, 1126-1134	17
704	External validity of a contemporaneous primary percutaneous coronary intervention trial in patients with acute ST-elevation myocardial infarction: insights from a single-centre investigation. 2016, 12, 1135-1143	3
703	Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: insights from the HORIZONS-AMI trial. 2016, 12, 1144-1153	1
702	Small coronary arteries treated with sirolimus-eluting stents: one-year results of the PORTO multicentre registry. 2007, 3, 197-205	2
701	Efficiency and safety of the sirolimus eluting stent in complex coronary artery lesions after cessation of dual antiplatelet therapy: fifteen months clinical outcome of the randomised Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. 2007, 3, 309-14	3
700	One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study. 2007, 3, 315-20	44
699	Making sense of the recent meta-analytical confusion concerning the safety of drug-eluting stents. 2007, 3, 381-5	12
698	Three-year follow-up of the ARTS-II# - sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease. 2008, 3, 450-9	35
697	Spelling out risk reduction strategies for intracoronary stenting. 2008, 3, 622-6	11
696	Have we been misled by the ESC DES firestorm?. 2008, 3, 535-7	14
695	Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic and 30-month clinical follow-up results from the series I prospective study. 2008, 4, 59-63	39
694	Two year follow-up after primary PCI with a paclitaxel-eluting stent versus a bare-metal stent for acute ST-elevation myocardial infarction (the PASSION trial): a follow-up study. 2008, 4, 64-70	39
693	Diabetic patients treated for unprotected left main coronary artery disease with drug eluting stents: a 3-year clinical outcome study. The diabetes and drug eluting stent for LeFT main registry (D-DELFT). 2008, 4, 77-83	7
692	One year results of a new in situ length-adjustable stent platform with a biodegradable biolimus A9 eluting polymer: results of the CUSTOM-II trial. 2008, 4, 200-7	11
691	Titanium-nitride-oxide coated stents versus paclitaxel-eluting stents in acute myocardial infarction: a 12-months follow-up report from the TITAX AMI trial. 2008, 4, 234-41	32

690	Four-year safety and efficacy of the unrestricted use of sirolimus- and paclitaxel-eluting stents in coronary artery bypass grafts. 2008 , 4, 311-7	26
689	Very late thrombosis in acute myocardial infarction: drug-eluting versus uncoated stents. 2008 , 4, 324-30	2
688	Long-term safety and efficacy are observed after implantation of Zotarolimus-Eluting stent in real-world clinical practice. 2008 , 4, 338-44	2
687	Meeting report ESC Forum on Drug Eluting Stents, European Heart House, Nice, 27-28 September 2007. 2009 , 4, 427-436	2
686	The relative safety and efficacy of bare-metal and drug-eluting stents in low and high-risk patient subsets. An epidemiological analysis of three sequential cohorts of consecutive all comers (n = 6129). 2009 , 4, 464-74	18
685	Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularisation in patients with multivessel coronary artery disease: insights from ARTS I and ARTS II. 2009 , 4, 492-501	17
684	Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy. 2009 , 4, 593-9	3
683	Patient selection to enhance the long-term benefit of first generation drug-eluting stents for coronary revascularisation procedures. Insights from a large multicentre registry. 2009 , 5, 57-66	9
682	Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programme. 2009 , 5, 67-77	26
681	Long-term clinical and angiographic outcomes of the sleeve technique on non-left-main coronary bifurcation lesions. 2009 , 5, 104-8	8
680	Clinical endpoints in transcatheter aortic valve implantation: a call to ARC for standardised definitions. 2009 , 5, 29-31	9
679	Three-year clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularisation Therapies Study, part II (ARTS II). 2009 , 5, 190-6	15
678	Long-term outcome after the V stenting technique in de novo bifurcation lesions using drug-eluting stents. 2009 , 5, 197-205	3
677	Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study. 2009 , 5, 255-64	19
676	Long-term follow-up after drug eluting stent implantation in left main trifurcations. 2009 , 5, 432-7	7
675	Comparison of the very long term (>1 year) outcomes of drug-eluting stents for the treatment of bare-metal and drug-eluting stent restenosis. 2009 , 5, 448-53	12
674	Transferability of data between different drug-eluting stents. 2009 , 5, 527-31	1
673	A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis. 2010 , 5, 788-94	24

672	Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. 2010 , 5, 871-4	224
671	Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. 2010 , 5, 898-905	39
670	Long-term follow-up (four years) of unprotected left main coronary artery disease treated with paclitaxel-eluting stents (from the TRUE Registry). 2010 , 5, 906-916	13
669	Everolimus-eluting bioabsorbable stent--Abbot Vascular programme. 2009 , 5 Suppl F, F98-F102	13
668	Vascular restoration therapy: what should the clinical and angiographic measures for success be?. 2009 , 5 Suppl F, F49-53	7
667	First human use of the TAXUs Petal paclitaxel-eluting bifurcation stent. 2010 , 6, 46-53	29
666	A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. 2010 , 6, 195-205	37
665	The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer. 2010 , 6, 233-239	39
664	A quantitative coronary angiography-matched comparison between a prospective randomised multicentre cutting balloon angioplasty and bare metal stent trial (REDUCE III) and the Rapamycin-Eluting Stent Evaluation At Rotterdam Cardiology Hospital (RESEARCH) study. 2010 , 6, 400-6	9
663	Safety and feasibility of frequency domain optical coherence tomography to guide decision making in percutaneous coronary intervention. 2010 , 6, 575-81	120
662	Late outcome after intracoronary beta radiation brachytherapy: a matched-propensity controlled ten-year follow-up study. 2011 , 6, 695-702	5
661	Triggering mechanisms of stent thrombosis. 2011 , 6, 722-8	3
660	Clinical usefulness of drug-eluting stents in the treatment of dialysis patients with coronary artery disease. 2011 , 6, 754-9	11
659	Clinical results after coronary stenting with the GenousâBio-engineered R stentâ12-month outcomes of the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) worldwide registry. 2011 , 6, 819-25	46
658	Percutaneous coronary interventions with an endothelial progenitor cell capture stent (EPC) for high risk patients with no option for drug eluting stents: long term clinical outcomes of a single centre registry. 2011 , 6, 826-30	5
657	A prospective evaluation of the safety and efficacy of TAXUS Element paclitaxel-eluting coronary stent implantation for the treatment of de novo coronary artery lesions in small vessels: the PERSEUS Small Vessel trial. 2011 , 6, 920-7, 1-2	26
656	The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer. 2011 , 6, 928-35	16
655	A clinical risk score for the prediction of very late stent thrombosis in drug eluting stent patients. 2011 , 6, 949-54	14

654	Periprocedural (30-day) risk of myocardial infarction after drug-eluting coronary stent implantation: a meta-analysis comparing cobalt-chromium and stainless steel drug-eluting coronary stents. 2011 , 6, 1003-10	10
653	Five-year outcomes of percutaneous coronary intervention compared to bypass surgery in patients with multivessel disease involving the proximal left anterior descending artery: an ARTS-II sub-study. 2011 , 6, 1060-7	8
652	Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. 2010 , 6 Suppl J, J44-52	19
651	Non-compliant balloons for final kissing inflation in coronary bifurcation lesions treated with provisional side branch stenting: a pilot study. 2012 , 7, 1162-9	22
650	One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International Registry. 2012 , 7, 1181-8	39
649	Five-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II study). 2012 , 7, 1189-96	33
648	A prospective multicentre registry, evaluating real-world usage of the Tryton side branch stent: results of the E-Tryton 150/Benelux registry. 2012 , 7, 1293-300	27
647	Procedural and early clinical outcomes of patients with de novo coronary bifurcation lesions treated with the novel Nile PAX dedicated bifurcation polymer-free paclitaxel coated stents: results from the prospective, multicentre, non-randomised BIPAX clinical trial. 2012 , 7, 1301-9	11
646	Comparison of biolimus eluted from an erodible stent coating with bare metal stents in acute ST-elevation myocardial infarction (COMFORTABLE AMI trial): rationale and design. 2012 , 7, 1435-43	25
645	Effect of paclitaxel elution from reservoirs with bioabsorbable polymer compared to a bare metal stent for the elective percutaneous treatment of de novo coronary stenosis: the EUROSTAR-II randomised clinical trial. 2011 , 7, 64-73	7
644	PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses. 2011 , 7, 84-90	33
643	Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry. 2011 , 7, 201-8	6
642	Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. 2011 , 7, 307-13	12
641	Two-year clinical outcomes of paclitaxel-eluting stents for in-stent restenosis in patients from the ARRIVE programme. 2011 , 7, 314-22	1
640	Late lumen loss and intima hyperplasia after sirolimus-eluting and zotarolimus-eluting stent implantation in diabetic patients: the diabetes and drug-eluting stent (DiabeDES III) angiography and intravascular ultrasound trial. 2011 , 7, 323-31	19
639	In-hospital outcomes of percutaneous coronary intervention in patients with chronic total occlusion: insights from the ERCTO (European Registry of Chronic Total Occlusion) registry. 2011 , 7, 472-9	244
638	Clinical performance of drug-eluting stents with biodegradable polymeric coating: a meta-analysis and systematic review. 2011 , 7, 505-16	28
637	Implantation of the biodegradable polymer biolimus-eluting stent in patients with high SYNTAX score is associated with decreased cardiac mortality compared to a permanent polymer sirolimus-eluting stent: two year follow-up results from the "all-comers" LEADERS trial. 2011 , 7, 605-13	20

636	Unprotected left main stenting with a second-generation drug-eluting stent: one-year outcomes of the LEMAX Pilot study. 2011 , 7, 689-96	31
635	The Valentines Trial: results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation DIOR paclitaxel drug-eluting balloon for in-stent restenosis treatment. 2011 , 7, 705-10	66
634	Comparison of target-lesion revascularisation between left main coronary artery bifurcations and left anterior descending coronary artery bifurcations using the one and two stent approach with sirolimus-eluting stents. 2011 , 7, 796-804	11
633	Outcomes in patients undergoing multivessel percutaneous coronary intervention using sirolimus-eluting stents: a report from the e-SELECT registry. 2011 , 7, 962-8	2
632	Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. 2011 , 7, 977-84	32
631	Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. 2011 , 7, 985-94	84
630	Clinical long-term outcome after implantation of titanium nitride-oxide coated stents compared with paclitaxel- or sirolimus-eluting stents: propensity-score matched analysis. 2012 , 7, 1043-50	3
629	Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. 2012 , 7, 1060-1	94
628	Safety and effectiveness of the Catania Polyzene-F coated stent in real world clinical practice: 12-month results from the ATLANTA 2 registry. 2012 , 7, 1062-8	7
627	Stent implantation in aorto-ostial lesions: long-term follow-up and predictors of outcome. 2012 , 7, 1069-76	15
626	Adverse event rates following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trial. 2013 , 8, 1134-42	37
625	Long-term outcome of second-generation everolimus-eluting stents and Endeavor zotarolimus-eluting stents in a prospective registry of ST-elevation myocardial infarction patients. 2013 , 8, 1199-206	10
624	Acute procedural and six-month clinical outcome in patients treated with a dedicated bifurcation stent for left main stem disease: the TRYTON LM multicentre registry. 2013 , 8, 1259-69	19
623	Impact of infarct-related artery patency before primary PCI on outcome in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. 2013 , 8, 1307-14	26
622	Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials. 2012 , 8, 87-93	5
621	Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study. 2012 , 8, 109-16	46
620	A prospective randomised comparison of titanium-nitride-oxide-coated bioactive stents with everolimus-eluting stents in acute coronary syndrome: the BASE-ACS trial. 2012 , 8, 306-15	36
619	SPIRIT Women, evaluation of the safety and efficacy of the XIENCE V everolimus-eluting stent system in female patients: referral time for coronary intervention and 2-year clinical outcomes. 2012 , 8, 325-35	20

618	Clinical event committees in coronary stent trials: insights and recommendations based on experience in an unselected study population. 2012 , 8, 368-74	5
617	Contemporary use and outcome of percutaneous coronary interventions in patients with acute coronary syndromes: insights from the 2010 ACSIS and ACSIS-PCI surveys. 2012 , 8, 465-9	17
616	The risk and prognostic impact of definite stent thrombosis or in-stent restenosis after coronary stent implantation. 2012 , 8, 591-8	17
615	Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. 2012 , 8, 599-606	46
614	Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and Xience V drug-eluting stents. 2012 , 8, 664-71	15
613	Simultaneous kissing drug-eluting stents to treat unprotected left main stem bifurcation disease: medium term outcome in 150 consecutive patients. 2012 , 8, 691-700	8
612	Angiographic and clinical outcome of percutaneous coronary intervention for in-stent restenosis of bifurcated lesions. 2012 , 8, 701-7	3
611	Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA I trial. 2012 , 8, 796-802	12
610	Five-year clinical follow-up of unprotected left main bifurcation lesion stenting: one-stent versus two-stent techniques versus double-kissing crush technique. 2012 , 8, 803-14	35
609	A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study. 2012 , 8, 815-22	21
608	Angiography alone versus angiography plus optical coherence tomography to guide decision-making during percutaneous coronary intervention: the Centro per la Lotta contro l'Infarto-Optimisation of Percutaneous Coronary Intervention (CLI-OPCI) study. 2012 , 8, 823-9	255
607	The utility of a 5-in-6 double catheter technique in treating complex coronary lesions via transradial approach: the DOCA-TRI study. 2012 , 8, 848-54	16
606	Comparison of intravascular ultrasound versus angiography-guided drug-eluting stent implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patients. 2012 , 8, 855-65	136
605	Real-world use of the second-generation cobalt-chromium sirolimus-eluting stents: 12-month results from the prospective multicentre FOCUS registry. 2012 , 8, 896-903	8
604	Plaque sealing and passivation with a mechanical self-expanding low outward force nitinol vShield device for the treatment of IVUS and OCT-derived thin cap fibroatheromas (TCFAs) in native coronary arteries: report of the pilot study vShield Evaluated at Cardiac hospital in Rotterdam for Investigation and Treatment of TCFA (SECRITT). 2012 , 8, 945-54	37
603	Very long-term outcomes after percutaneous coronary intervention with bare metal stents for unprotected left main coronary artery disease. 2012 , 8, 962-9	1
602	Unprotected left main stenting in the real world: five-year outcomes of the French Left Main Taxus registry. 2012 , 8, 970-81	12
601	Clinical and angiographic experience with a third-generation drug-eluting Orsiro stent in the treatment of single de novo coronary artery lesions (BIOFLOW-I): a prospective, first-in-man study. 2013 , 8, 1006-11	64

600	First-in-man evaluation of the MOMO cobalt-chromium carbon-coated stent. 2013 , 8, 1012-8	9
599	Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial. 2013 , 8, 1033-9	19
598	Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial. 2013 , 8, 1047-51	48
597	Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents. 2013 , 8, 1061-71	33
596	Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. 2014 , 9, 1271-84	184
595	Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting. 2013 , 9, 62-9	50
594	A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. 2013 , 9, 75-83	43
593	Impact of ad hoc percutaneous coronary intervention with drug-eluting stents in angina patients. 2013 , 9, 110-7	9
592	Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population. 2013 , 9, 118-24	12
591	First-in-human evaluation of a sirolimus-eluting coronary stent on an integrated delivery system: the DIRECT study. 2013 , 9, 46-53	14
590	Six-month and one-year clinical outcomes after placement of a dedicated coronary bifurcation stent: a patient-level pooled analysis of eight registry studies. 2013 , 9, 195-203	24
589	Outcomes of a preoperative "bridging" strategy with glycoprotein IIb/IIIa inhibitors to prevent perioperative stent thrombosis in patients with drug-eluting stents who undergo surgery necessitating interruption of thienopyridine administration. 2013 , 9, 204-11	36
588	The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. 2013 , 9, 316-27	27
587	Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial. 2013 , 9, 328-35	16
586	Long-term comparison of everolimus-eluting and biolimus-eluting stents. 2013 , 9, 336-44	7
585	One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial. 2013 , 9, 430-6	20
584	Outcome of patients after emergency conversion from transcatheter aortic valve implantation to surgery. 2013 , 9, 446-51	42
583	Two-year outcomes of everolimus vs. paclitaxel-eluting stent for the treatment of unprotected left main lesions: a propensity score matching comparison of patients included in the French Left Main Taxus (FLM Taxus) and the Left MAin Xience (LEMAX) registries. 2013 , 9, 452-62	25

582	First-in-human evaluation of the novel BioMime sirolimus-eluting coronary stent with bioabsorbable polymer for the treatment of single de novo lesions located in native coronary vessels - results from the meriT-1 trial. 2013 , 9, 493-500	23
581	Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study. 2013 , 9, 573-81	25
580	Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study: are lesions clinically stable from 12 to 36 months?. 2013 , 9, 620-8	68
579	Two-year follow-up of the NEVO ResElution-I (NEVO RES-I) trial: a randomised, multicentre comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Libert [®] paclitaxel-eluting stent in de novo native coronary artery lesions. 2013 , 9, 721-9	10
578	Optimal treatment of recurrent restenosis lesions after drug-eluting stent implantation for in-stent restenosis lesions. 2013 , 9, 788-96	17
577	Two-year outcomes following unprotected left main stenting with first vs. new-generation drug-eluting stents: the FINE registry. 2013 , 9, 809-16	19
576	Peri-stent contrast staining and very late stent thrombosis after sirolimus-eluting stent implantation: an observation from the RESTART (REgistry of Stent Thrombosis for review And Re-evaluaTion) angiographic substudy. 2013 , 9, 831-40	9
575	Single-vessel or multivessel PCI in patients with multivessel disease presenting with non-ST-elevation acute coronary syndromes. 2013 , 9, 916-22	12
574	Stent-related defects in patients presenting with stent thrombosis: differences at optical coherence tomography between subacute and late/very late thrombosis in the Mechanism Of Stent Thrombosis (MOST) study. 2013 , 9, 936-44	43
573	Optical coherence tomography-based evaluation of in-stent neoatherosclerosis in lesions with more than 50% neointimal cross-sectional area stenosis. 2013 , 9, 945-51	41
572	Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. 2014 , 9, 1036-41	78
571	Impact of stent overlap on long-term clinical outcomes in patients treated with newer-generation drug-eluting stents. 2014 , 9, 1076-84	25
570	Natural history of optical coherence tomography-detected non-flow-limiting edge dissections following drug-eluting stent implantation. 2014 , 9, 1085-94	53
569	Relation of genetic profile and novel circulating biomarkers with coronary plaque phenotype as determined by intravascular ultrasound: rationale and design of the ATHEROREMO-IVUS study. 2014 , 10, 953-60	18
568	Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial. 2015 , 10, 1383-90	26
567	Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial. 2015 , 11, 381-90	28
566	Efficacy of contrast medium induced Pd/Pa ratio in predicting functional significance of intermediate coronary artery stenosis assessed by fractional flow reserve: insights from the RINASCI study. 2015 , 11, 421-7	46
565	Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. 2015 , 10, 1144-53	34 ⁰

564	Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials. 2015 , 11, 391-8	9
563	Clinical results with the Resolute zotarolimus-eluting stent in total coronary occlusions. 2015 , 11, 650-7	4
562	Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. 2015 , 11, 196-203	27
561	Prognostic impact of multivessel versus culprit vessel only percutaneous intervention for patients with multivessel coronary artery disease presenting with acute coronary syndrome. 2015 , 11, 293-300	21
560	A first-in-man clinical evaluation of Ultimaster, a new drug-eluting coronary stent system: CENTURY study. 2015 , 11, 541-8	30
559	Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry. 2015 , 10, 1160-8	99
558	Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial. 2015 , 10, 1276-9	13
557	Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study. 2015 , 11, 926-34	46
556	Rationale and design of the RIBS IV randomised clinical trial (drug-eluting balloons versus everolimus-eluting stents for patients with drug-eluting stent restenosis). 2015 , 11, 336-42	7
555	Drug-eluting balloon versus second-generation drug-eluting stent for the treatment of restenotic lesions involving coronary bifurcations. 2016 , 11, 989-95	17
554	Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial. 2016 , 11, 1372-9	52
553	Five-year clinical outcome of the Nobori drug-eluting coronary stent system in the treatment of patients with coronary artery disease: final results of the NOBORI 1 trial. 2015 , 11, 549-54	16
552	One-year outcomes in unselected patients treated with a thin-strut, platinum-chromium, paclitaxel-eluting stent: primary endpoint results from the TAXUS Element European post-approval surveillance study (TE-PROVE). 2015 , 10, 1261-6	5
551	One-year clinical outcomes of the STENTYS Self-Apposing coronary stent in patients presenting with ST-segment elevation myocardial infarction: results from the APPOSITION III registry. 2015 , 11, 264-71	23
550	Procedural outcomes of patients with calcified lesions treated with bioresorbable vascular scaffolds. 2016 , 11, 1355-62	19
549	Safety and efficacy of lesion preparation with the AngioSculpt Scoring Balloon in left main interventions: the ALSTER Left Main registry. 2016 , 11, 1346-54	8
548	Impact of post-dilation on the acute and one-year clinical outcomes of a large cohort of patients treated solely with the Absorb Bioresorbable Vascular Scaffold. 2015 , 11, 141-8	15
547	First-in-man evaluation of the novel balloon delivery system STENTYS Xposition S for the self-apposing coronary artery stent: impact on longitudinal geographic miss during stenting. 2016 , 11, 1341-5	11

546	Value of the SYNTAX score for periprocedural myocardial infarction according to WHO and the third universal definition of myocardial infarction: insights from the TWENTE trial. 2016 , 12, 431-40	3
545	Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration. 2016 , 11, e1222-30	27
544	DESyne novolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial. 2016 , 12, e1336-e1342	12
543	Outcome after percutaneous coronary intervention for different indications: long-term results from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). 2016 , 12, 303-11	21
542	Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. 2016 , 12, 1239-1245	86
541	The SYNERGY II Everolimus elutiNg stent In patients Older than 75 years undergoing coronary Revascularisation associated with a short dual antiplatelet therapy (SENIOR) trial: rationale and design of a large-scale randomised multicentre study. 2017 , 12, 1614-1622	9
540	A double-blind randomised study to evaluate the efficacy and safety of bindarit in preventing coronary stent restenosis. 2016 , 12, e1385-e1394	6
539	The impact of in-stent neoatherosclerosis on long-term clinical outcomes: an observational study from the Kobe University Hospital optical coherence tomography registry. 2016 , 12, e1366-e1374	38
538	Clinical outcomes of "complete, partially complete, and incomplete" revascularisation at five-year follow-up after percutaneous intervention of unprotected left main coronary artery disease with drug-eluting stents. 2016 , 12, e957-e963	3
537	IVUS-guided treatment strategies for definite late and very late stent thrombosis. 2016 , 12, e1355-e1365	12
536	Impact of stent size on angiographic and clinical outcomes after implantation of everolimus-eluting bioresorbable scaffolds in daily practice: insights from the ISAR-ABSORB registry. 2016 , 12, e137-43	6
535	Rotational atherectomy followed by drug-eluting stent implantation in calcified coronary lesions. 2009 , 5, 370-4	68
534	Safety and efficacy of frequency-domain optical coherence tomography in evaluating and treating intermediate coronary lesions. 2018 , 10, 222-233	1
533	Does manual thrombus aspiration help optimize stent implantation in ST-segment elevation myocardial infarction?. 2014 , 6, 1030-7	5
532	Drug-eluting stents and acute myocardial infarction: A lethal combination or friends?. 2014 , 6, 929-38	2
531	Coronary stenting: A matter of revascularization. 2017 , 9, 207-211	2
530	High sensitive TROponin levels In Patients with Chest pain and kidney disease: A multicenter registry - The TROPIC study. 2017 , 24, 139-150	3
529	Comparison of short-term clinical outcomes between Resolute Onyx zotarolimus-eluting stents and everolimus-eluting stent in patients with acute myocardial infarction: Results from the Korea Acute Myocardial infarction Registry (KAMIR). 2019 , 26, 469-476	5

528	Long-term clinical results of biodegradable vascular scaffold ABSORB BVS using the PSP-technique in patients with acute coronary syndrome. 2020 , 27, 677-684	1
527	Stenosis level, plaque morphology and intima-media thickness of internal carotid artery in chronic stable angina and acute coronary syndrome; a comparative study. 2015 , 17, e10162	3
526	Bare-metal stent thrombosis two decades after stenting. 2015 , 26, e19-21	2
525	Miniaturized self-expanding drug-eluting stent in small coronary arteries: late effectiveness. 2013 , 101, 379-87	3
524	Diabetes mellitus and glucose as predictors of mortality in primary coronary percutaneous intervention. 2014 , 103, 323-30	7
523	First- Versus Second-Generation Drug-Eluting Stents in Acute Coronary Syndromes (Katowice-Zabrze Registry). 2016 , 106, 373-81	7
522	Impact of Paclitaxel-Eluting Balloons Compared to Second-Generation Drug-Eluting Stents for of In-Stent Restenosis in a Primarily Acute Coronary Syndrome Population. 2017 , 109, 277-283	1
521	Ischemic and Bleeding Events After First Major Bleeding Event in Patients Undergoing Coronary Stent Implantation. 2021 ,	
520	Long-term effects of the mean hemoglobin A1c levels after percutaneous coronary intervention in patients with diabetes. 2021 , 36, 1365-1376	0
519	Impact of Periprocedural Myocardial Injury and Infarction Definitions on Long-Term Mortality After Chronic Total Occlusion Percutaneous Coronary Intervention. 2021 , 14, e010923	0
518	Clinical outcomes of ultrathin biodegradable polymer-coated sirolimus-eluting stents in an all-comer population: One-year results from the T-FLEX registry including high-risk subgroups. 2021 , 25, 706-715	0
517	Integrated coronary disease burden and patterns to discriminate vessels benefiting from percutaneous coronary intervention. 2021 ,	0
516	Rationale and design of a multi-center, prospective randomized controlled trial on the effects of sacubitril-valsartan versus enalapril on left ventricular remodeling in ST-elevation myocardial infarction: The PERI-STEMI study. 2021 ,	2
515	[stent thrombosis: 'A won battle?' (data from the France PCI registry)]. 2021 , 70, 388-394	
514	Proximal optimisation technique versus final kissing balloon inflation in coronary bifurcation lesions: the randomised, multicentre PROPOT trial. 2021 , 17, 747-756	5
513	Polymer-free biolimus-A9-eluting stent performance according to renal impairment: insights from the RUDI-FREE registry. 2021 , 23,	
512	Effectiveness of hospital lipid-lowering protocol of intensive lipid-lowering therapy for patients with acute coronary syndrome. 2021 ,	
511	Utility of a pharmacogenetic-driven algorithm in guiding dual antiplatelet therapy for patients undergoing coronary drug-eluting stent implantation in China. 2021 ,	

- 510 Predictors of Adverse Events Among Chronic Total Occlusion Patients Undergoing Successful Percutaneous Coronary Intervention and Medical Therapy. **2021**, 16, 1847-1855 2
- 509 Clinical outcomes of an ultrathin-strut sirolimus-eluting stent in all-comers population: Thailand Orsiro registry. **2021**, 21, 501 1
- 508 Performance of the REACH, PARIS, BleeMACS, and PRECISE-DAPT scores for predicting 1-year bleeding events in patients undergoing coronary drug-eluting stent implantation. **2021**, 1-8
- 507 Outcomes of Different Reperfusion Strategies of Multivessel Disease Undergoing Newer-Generation Drug-Eluting Stent Implantation in Patients with Non-ST-Elevation Myocardial Infarction and Chronic Kidney Disease. **2021**, 10, 0
- 506 Percutaneous Treatment of Unprotected Left Main Disease With Thin-Strut Durable-Polymer or Early Generation Thicker-Strutted and Coated Bioabsorbable-Polymer Drug-Eluting Stents in a Large-Scale Registry. **2021**, 32, 43-49
- 505 Cardiac Surgery in Patients with Drug Eluting Stents: The Risk of Stopping Clopidogrel. **2007**, 1, CMC.S340
- 504 Percutaneous cardiovascular intervention. The time has come for a big change. **2008**, 4, 17, 19, 21 2
- 503 Predictors for very late stent thrombosis after drug-eluting stent implantation in diabetic patients. **2009**, 4, 485-91 3
- 502 Interventional Cardiology. **2010**, 847-866
- 501 A Case of Early Stent Restenosis Observed by Angioscopy after Implantation of Drug-eluting Stents. **2010**, 69, 90-94
- 500 Modern Coronary Stenting. 23-39
- 499 Clinical Trials in Interventional Cardiology: Focus on XIENCE V Drug-Eluting Stent. 1
- 498 A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions: study design and protocol. **2010**, 5, 976-980
- 497 Coronary Artery Stenting. **2011**, 243-261
- 496 A stent thrombosis 1465 days after implantation. **2011**, 23, 184-5
- 495 Comparison of Characteristics and Outcomes of Patients Undergoing Saphenous Vein Graft Stenting Who Were or Were Not Enrolled in the Stenting of Saphenous Vein Grafts Randomized Controlled Trial. **2011**, 59, 259-266
- 494 Everolimus Eluting Coronary Stents: Clinical Trials. 528-538
- 493 Zotarolimus Eluting Stent Clinical Studies. 519-527

492 Novel Drug Eluting Stent Systems. 539-555

491 Effect of tirofiban on short-term prognosis of elderly patients with acute coronary syndrome undergoing percutaneous coronary intervention. **2011**, 10, 329-332

490 Single-centre all-comers registry reveals promising long-term clinical results of the EndeavorTM-Stent. **2012**, 02, 82-89

0

489 Simultaneous Thrombosis of Two Drug-Eluting Stents After Discontinuation of Dual Antiplatelet Therapy for a Day. **2012**, 3, 281-283

488 Sirolimus-Versus Zotarolimus-Eluting Stents in Acute Coronary Syndromes With C Type Left Anterior Descending Artery Lesions: A Three-Year Clinical Follow-Up. **2012**, 3, 116-122

487 The evaluation for Clinical usefulness and Safety of Sirolimus-eluting stent and Paclitaxel-Eluting Stents In Patients With Acute Myocardial Infarction. **2012**, 6, 5-10

486 Interventional X-Ray Coronary Angiography. **2013**, 279-301

485 Intracoronary Stenting Strategies. **2013**, 497-529

484 Occurrence and Prognosis for the Thrombosis in the Drug-Eluting Stents and Bare-Metal Stents. **2012**, 12, 273-283

483 Platelet ADP P2Y12 Inhibitors: Thienopyridines. 26-46

482 Percutaneous coronary intervention using a full metal jacket with drug-eluting stents: major adverse cardiac events at one year. **2013**, 101, 117-26

1

481 Third universal definition of myocardial infarction. **2013**, 32, 29-46

480 Regulatory science for antiplatelet therapies. **2013**, 24, 269-281

479 Relationship between Antiphospholipid Antibodies and Major Adverse Cardiovascular Events after Drug-Eluting Stent Implantation in Patients with Acute Myocardial Infarction. **2013**, 84, 681

1

478 Designing Biomedical Stents for Vascular Therapy. **2013**, 216-239

477 Unprotected left main coronary artery stenting with everolimus (Xience V) drug-eluting stents: A single center retrospective experience. **2013**, 03, 183-190

476 Prozedurale Komplikationen. **2013**, 21-82

475 Percutaneous treatment of <i>de novo</i> unprotected left main stenosis in unselected consecutive patients: Experience of a high volume center. **2013**, 03, 419-427

474 PERIPROCEDURAL MYOCARDIAL DAMAGE. **2013**, 12, 95-101

473 Transcatheter Aortic Valve Replacement: Current Evidence from Large Multicenter Registries. **2014**, 19-37

472 Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: the D-DELTA registry. **2013**, 9, 803-8 2

471 Clinical Outcomes of Stent Thrombosis after Drug-Eluting Coronary Stent Implantation. **2013**, 13, 880-892 3

470 Seven Years Follow-Up of Biodegradable Polymer Coated Paclitaxel-Eluting Infinium Coronary Stent in Saudi Arabia. **2014**, 05, 216-224

469 Asymptomatic in-stent thrombus formation after Zotarolimus-eluting stent implantation in a patient on dialysis. **2014**, 21, 115-118

468 Incidence, Predictors, Treatment, and Long-Term Prognosis of Patients with Restenosis after Long Drug-Eluting Stent Implantation for Coronary Arteries. **2014**, 04, 631-641

467 Domestic versus imported drug-eluting stents for the treatment of patients with acute coronary syndrome. **2014**, 5, 175-81 3

466 [Value of the optical coherence tomography in the treatment guided of the stent failure. Case report]. **2014**, 84, 305-9

465 Stent Thrombosis. **2015**, 147-165

464 Nine-Months Clinical Outcome of Biodegradable Polymer Coated Sirolimus-eluting Stent System: A Multi-Centre "Real-World" Experience. **2015**, 9, OC23-6

463 Coronary Stent Thrombosis in 2015: A Comprehensive and Updated Review. **2015**, 2, 131-149

462 Very Late Stent Thrombosis 11 Years after Implantation of a Drug-Eluting Stent. **2015**, 42, 487-90 2

461 Clinical Outcome Comparison of Everolimus- and Biolimus-eluting Stents in Patients with Acute Myocardial Infarction. **2015**, 89, 418-427

460 Long-Term Follow-Up of Patients after Percutaneous Coronary Intervention with Everolimus-Eluting Bioresorbable Vascular Scaffold. **2017**, 108, 109-115

459 Twelve Months Clinical Outcomes after Percutaneous Coronary Intervention with Bare Metal Stents in Unselected Real-Life Patients with Coronary Artery Disease: Results from FLEXUS Study. **2016**, 06, 342-351

458 Efficacy and safety of short-term (3 months) duration of dual antiplatelet therapy after drug-eluting stents: a meta-analysis of randomized controlled trials. **2017**, 17, 168-175 1

457 Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention. **2016**, 11, e1275-82

- 456 Can Platforms Affect the Safety and Efficacy of Drug-Eluting Stents in the Era of Biodegradable Polymers?: A Meta-Analysis of 34,850 Randomized Individuals. **2016**, 11, e0151259
- 455 FFR guided PCI on long coronary lesions: 2-year clinical results with 2nd or newer generation DES. **2016**, 23, 5-10
- 454 Five-year clinical outcomes of drug-eluting stents according to on-label and off-label use. **2016**, 31, 678-84
- 453 Bioresorbable vascular scaffolds - Magic of the ephemeral?. **2016**, 15, 127-134 2
- 452 Late-acquired incomplete stent apposition after everolimus-eluting stent versus sirolimus-eluting stent implantation in patients with non-ST-segment elevation myocardial infarction and ST-segment elevation myocardial infarction. **2016**, 12, e979-e986 1
- 451 Atrial Fibrillation on Non-vitamin K Antagonist Oral Anticoagulant Undergoing Elective Percutaneous Coronary Intervention for Stable Effort Angina. **2017**, 19-38
- 450 New-Onset Atrial Fibrillation in a Stable Patient with Remote Percutaneous Coronary Intervention. **2017**, 141-152
- 449 Atrial Fibrillation on Vitamin K Antagonist Undergoing Elective Percutaneous Coronary Intervention for Stable Effort Angina. **2017**, 1-18
- 448 Atrial Fibrillation on Vitamin K Antagonist Undergoing Urgent Percutaneous Coronary Intervention for Non-ST-Elevation Acute Coronary Syndrome. **2017**, 39-58
- 447 Atrial Fibrillation Early Complicating Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention. **2017**, 121-140
- 446 Analysis of 12 Months Clinical Outcomes Associated with Implantation of Ultrathin (60 μ m) Bare Metal Stent in an Unselected Real-world Population with Coronary Artery Disease. **2017**, 11, OC12-OC16 3
- 445 First-in-man six-month results of a surface-modified coronary stent system in native coronary stenosis. **2017**, 12, 2118-2127 1
- 444 Stent thrombosis and restenosis. **2017**, 205-212
- 443 Clinical outcome of patients treated with Absorb BVS: a single centre experience. **2017**, 16, 98-102
- 442 The Impact of In-stent Restenosis Detected upon Routine Follow-up Angiography after Percutaneous Coronary Intervention with Metallic Stent. **2018**, 9, 53-62
- 441 Extremely late stent thrombosis after more than 7 years (2691 days) of sirolimus-eluting stent implantation. **2018**, 19, 287-288 1
- 440 GENDER DIFFERENCES IN OUTCOME FOLLOWING PRIMARY PERCUTANEOUS CORONARY INTERVENTION. **2018**, 7, 578-584
- 439 Everolimus-eluting bioresorbable vascular scaffolds for the left anterior descending coronary artery disease: 12-month follow up. **2018**, 13, 41

- 438 Safety and Efficacy of Ultra-Thin, Biodegradable Polymer Coated Sirolimus-Eluting Supralimus-Core Stents in Real-World Patients: Outcomes at 24-Month Follow-Up. **2018**, 08, 523-532
- 437 Post-reperfusion syndrome in patients with ischemic heart disease after coronary stenting.. **2018**, 96, 73-77 0
- 436 ONE-YEAR CLINICAL OUTCOMES IN INDIAN PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION WITHOUT ON-SITE SURGICAL BACKUP. **2018**, 7, 3674-3678
- 435 Merging the properties of a sirolimus coated balloon with those of a bioresorbable polymer sirolimus eluting stent to address the "diabetes issue". Results from the En-Abl multicenter registry. **2018**, 66, 536-542 4
- 434 [Comparative results of using coronary drug-eluting stents 'NanoMed' and Orsiro]. **2019**, 25, 57-63
- 433 Major risk factors of stent thrombosis in patients with acute coronary syndrome. **2019**, 12, 329
- 432 A Review of the Ultrathin Orsiro Biodegradable Polymer Drug-eluting Stent in the Treatment of Coronary Artery Disease. **2019**, 13, 17 2
- 431 Long-term results of stenting unprotected left main of the left coronary artery in patients with a stable ischemic heart disease using different types of stents with antiproliferative coating. **2019**, 14, 33
- 430 Time to Treatment and In-Hospital Major Adverse Cardiac Events Among Patients With ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention (PCI) According to the 24/7 Primary PCI Service Registry in Iran: Protocol for a Cross-Sectional Study. **2019**, 8, e13161 1
- 429 Drug Eluting Stents versus Bare Metal Stents in ST- Segment Elevation Myocardial Infarction. 62-68 1
- 428 Clinical outcomes of bioresorbable vascular scaffolds implanted with routine versus selective optical coherence tomography guidance: results from a single-centre experience. **2019**, 14, 1776-1783 1
- 427 (Tryton - an alternative to established bifurcation techniques?). **2019**, 61, e285-e289
- 426 One-year outcomes of a NeoHexa sirolimus-eluting coronary stent system with a biodegradable polymer in all-comers coronary artery disease patients: Results from NeoRegistry in India. **2019**, 11, 200-208 0
- 425 Derivation and external validation of a novel risk score for prediction of 30-day mortality after percutaneous coronary intervention. **2019**, 15, e551-e557 2
- 424 Angiographically Based Direct Implantation of the Bioresorbable Vascular Scaffold in Non-ST Segment Elevation Acute Coronary Syndrome: Feasibility and Outcome. **2019**, 7, 2419-2423
- 423 Comparison of patency between two different peripheral self-expandable stents, absolute Pro \square versus complete SE \square in femoropopliteal occlusive disease. **2019**, 38, 305-311 0
- 422 Retrospective Study of Clinical and Epidemiological Parameters of Patients Undergoing Percutaneous Coronary Intervention with Their Follow-Up. **2019**, 7, 3603-3607
- 421 [Relation of Functional Activity of Platelets to Prognosis of Unfavorable Cardiovascular Events in Patients with Acute Coronary Syndrome. Results of a Registry Study]. **2019**, 59, 5-13 1

- 420 Long-term clinical outcomes of direct absorb bioresorbable vascular scaffold implantation in acute coronary syndrome. **2019**, 67, 374-379
- 419 [Acute Coronary Syndrome Registry of High Risk Patients: 30-Day Outcome]. **2019**, 59, 14-20
- 418 [Multifactorial Prognostication of the Development of Stent Thrombosis in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention on the background of Dual Antiplatelet Therapy]. **2019**, 59, 5-13 1
- 417 Wissenschaftliche Grundlagen der herzchirurgischen Fachliteratur. **2020**, 327-345
- 416 Coronary bifurcations treated with thin-strut drug-eluting stents: a prespecified analysis of the randomized BIO-RESORT trial. **2021**, 32, 51-57
- 415 A case of very late stent thrombosis immediately after thoracoscopic lobectomy under antiplatelet therapy. **2020**, 34, 205-211
- 414 Polymer-free drug-coated vs. bare-metal coronary stents in patients undergoing non-cardiac surgery: a subgroup analysis of the LEADERS FREE trial. **2021**, 110, 162-171 0
- 413 From Stenosis to Restenosis - The New Coronary Artery Disease Continuum in the PCI Era. **2020**, 17, 61-68
- 412 Coronary stent thrombosis: the problem still persists. **2020**, 19, 117-121
- 411 Association between mild thyroid dysfunction and clinical outcome in acute coronary syndrome undergoing percutaneous coronary intervention. **2020**, 27, 262-271 1
- 410 Validation of the long-term prognostic capability of the SYNTAX score II in patients undergoing biodegradable polymer-based Sirolimus-eluting stents: 2-year outcomes from the PANDA III trial. **2020**, 309, 27-32 0
- 409 Scoring balloon predilation before bioresorbable vascular scaffold implantation in patients with in-stent restenosis: the RIBS VI 'scoring' study. **2021**, 32, 96-104 1
- 408 Clinical Outcomes after Percutaneous Coronary Intervention Over Time on the Basis of CYP2C19 Polymorphisms. **2021**, 0
- 407 Impact of prediabetes and diabetes on 3-year outcome of patients treated with new-generation drug-eluting stents in two large-scale randomized clinical trials. **2021**, 20, 217 1
- 406 Intravascular Imaging Guidance Reduce 1-Year MACE in Patients Undergoing Rotablator Atherectomy-Assisted Drug-Eluting Stent Implantation. **2021**, 8, 768313 1
- 405 Does Prior Stroke Predict Long-Term Recurrent Stroke After Percutaneous Coronary Intervention? Five-Year Results From a Large Cohort Study. **2021**, 12, 740136 0
- 404 Stent thrombosis in acute coronary syndromes: Patient-related factors and operator-related factors. **2020**, 24, 274-279 2
- 403 Ultrathin (60 μ m), ultralong (240 mm) sirolimus-eluting stent: study of clinical and safety profiles among real-world patients. **2021**, 25, 111-119

402	Determinants and Clinical Outcomes of Extended Dual Antiplatelet Therapy over 3 Years after Drug-Eluting Stent Implantation: A Retrospective Analysis. 2020 , 61, 597-605	1
401	Impact of ultra-long sirolimus-eluting stents on coronary artery lesions: one-year results of real-world FLEX-LONG Study. 2020 , 111, 529-535	0
400	Efficacy and safety of TiNO-coated stents versus drug-eluting coronary stents. Systematic literature review and meta-analysis.	
399	Short- versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes mellitus: A meta-analysis of randomized controlled trials. 2020 , 15, e0242845	0
398	Safety and performance of the EverPro everolimus-eluting coronary stent system with biodegradable polymer in a real-world scenario. 2020 , 12, 615-625	0
397	Four-year outcomes after percutaneous coronary intervention of unprotected left main coronary artery disease in patients with stable angina and acute coronary syndrome. 2021 , 59, 141-150	0
396	Long-Term Follow-Up of Percutaneous Coronary Intervention With Paclitaxel-Eluting Balloon Catheter. 2021 , 72, 364-370	1
395	Two-Year Outcomes of Asymptomatic vs. Symptomatic Patients After Deferral of Revascularization Based on Fractional Flow Reserve - Insights From the J-CONFIRM Registry. 2020 , 2, 744-752	1
394	Optimal Duration for Dual Antiplatelet Therapy After Left Main Coronary Artery Stenting. 2020 , 85, 59-68	2
393	Clinical impact of bifurcation angle change between diastole and systole in complex stenting for left main distal bifurcation: The Milan and New-Tokyo (MITO) Registry. 2021 , 98, E24-E34	0
392	Percutaneous coronary intervention of severely/moderately calcified coronary lesions using single-burr rotational atherectomy: A retrospective study. 2021 , 25, 395-401	
391	Multivessel percutaneous coronary intervention in patients with acute myocardial infarction and severe renal dysfunction. 2019 , 15, e1014-e1021	3
390	Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients. 2020 , 16, 391-398	
389	Perkutan koroner girişim yapımında heretik yaşımlı hastalarda ikili antitrombosit tedavi kullanımı PRECISE-DAPT, DAPT skorlarına göre değerlendirilmesi ve bu skorların akut stent trombozu, ciddi kanama ile ilişkisi.	
388	Twelve-month clinical outcomes of sirolimus-eluting stent in coronary artery disease: An experience in real-world Indian patients. 2020 , 24, 364-369	0
387	Prozedurale Komplikationen. 2020 , 25-98	
386	Intracoronary Imaging for Assessment of Vascular Healing and Stent Follow-up in Bioresorbable Vascular Scaffolds. 2020 , 16, 123-134	
385	Effect of Operator Volume on In-Hospital Outcomes Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: Based on the 2014 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry. 2020 , 50, 133-144	3

384	Malnutrition and Clopidogrel Non-Use Worsen Prognosis of Critical Limb Ischemia Patients After Revascularization. 2019 , 2, 121-127	1
383	İfarktla İlişkili Koroner Damarlar Olan ST-Yİselmeli Miyokard İfarkt Hastalarda Sigara İminin Klinik Sonuçlarına Etkisi.	
382	The angiography-guided spot versus entire stenting in patients with long coronary lesions trial: Study design and rationale for a randomized controlled trial protocol. 2020 , 17, 100523	0
381	Impact of stent edge dissection detected by optical coherence tomography after current-generation drug-eluting stent implantation. 2021 , 16, e0259693	2
380	Prognostic significance of intra-aortic balloon pumping support in patients with acute myocardial infarction and veno-arterial extracorporeal membrane oxygenation therapy. 2021 ,	1
379	Extremely Late In-Stent Thrombosis 12 Years After Implantation of a Drug-Eluting Stent. 2020 , 12, e9053	0
378	Designing Biomedical Stents for Vascular Therapy. 972-996	
377	Impact of peripheral artery disease on short-term outcomes after percutaneous coronary intervention: A report from Japanese nationwide registry. 2020 , 15, e0240095	0
376	Impact of high triglyceride/high-density lipoprotein cholesterol ratio (insulin resistance) in ST-segment elevation myocardial infarction. 2020 , 99, e22848	1
375	Safety and performance of everolimus-eluting stents comprising of biodegradable polymers with ultrathin stent platforms. 2020 , 111, 315-323	0
374	Differential efficacy between stenting and plain balloon angioplasty for femoropopliteal disease with or without total occlusion. 2020 , 35, 1114-1124	1
373	Clinical Outcomes and Angiographic Results of Bailout Stenting for Guide Catheter-Induced Iatrogenic Coronary Artery Dissection - Impact of Stent Type. 2020 , 84, 1746-1753	0
372	Neointima characteristics as a prognostic marker for drug-coated balloon angioplasty in patients with in-stent restenosis: an optical coherence tomography study. 2020 , 31, 694-702	1
371	Subanalysis of the AUGUSTUS trial. 25, 4104	0
370	Long-Term Safety and Efficacy of Extended Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Real-World Practice. 2020 , 84, 2175-2184	2
369	Optimal Strategy for Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation in High-Risk "TWILIGHT-like" Patients With Diabetes Mellitus. 2020 , 7, 586491	2
368	Estrategia ptima para el tratamiento de lesiones en bifurcaci3 del tronco coronario izquierdo. 2020 , 74, 691-691	0
367	One-year performance of thin-strut cobalt chromium sirolimus-eluting stent versus thicker strut stainless steel biolimus-eluting coronary stent: a propensity-matched analysis of two international all-comers registries. 2021 , 32, 391-396	1

366	REabsorbable vs. DUrable Polymer Drug-Eluting Stents in All-Comer PatiEnts: the REDUCE registry. 2021 , 32, 281-287	0
365	The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: results of the OPCES study. 2011 , 16, 640-50	14
364	Sirolimus-eluting stents versus bare-metal stents in routine clinical use: a nonrandomized comparison. 2011 , 38, 508-15	
363	Evaluation of the effect of elective percutaneous coronary intervention as a treatment method on the left ventricular diastolic dysfunction in patients with coronary artery disease. 2010 , 5, 194-8	5
362	Drug-eluting stents versus bare metal stents in ST elevation myocardial infarction at a follow-up of three years or longer: A meta-analysis of randomized trials. 2012 , 17, 169-74	8
361	Outcome and Predictors of Stent Thrombosis in the First Romanian Registry of Drug Eluting Stent (RODESINO EXTENSION). 2013 , 8, 153-63	1
360	Long-term clinical outcomes of drug-eluting stents vs. bare-metal stents in Chinese geriatric patients. 2013 , 10, 330-5	2
359	Comparative prognostic value of C-reactive protein & fibrinogen in patients with coronary artery disease. 2014 , 140, 392-400	4
358	Efficacy and safety of cangrelor for patients with coronary artery disease: a meta-analysis of four randomized trials. 2015 , 8, 800-8	2
357	Comparison of Bare-Metal Stent and Drug-Eluting Stent for the Treatment of Patients Undergoing Percutaneous Coronary Intervention for Unprotected Left Main Coronary Artery Disease - Long-Term Result from a Single Center Experience. 2015 , 31, 381-9	4
356	One-Year Outcome of Everolimus-Eluting Stents Versus Biolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention. 2016 , 11, 62-67	1
355	Staged versus "one-time" multivessel intervention in elderly patients with non-ST-elevation acute coronary syndrome. 2016 , 13, 760-767	2
354	Three-Year Clinical Outcomes of a Polymer-Free Paclitaxel-Eluting Microporous Stent in Real-World Practice: Final Results of the Safety and Efficacy Registry of the Yinyi Stent (SERY-I). 2017 , 33, 28-33	2
353	Nine-year clinical outcomes of drug-eluting stents . bare metal stents for large coronary vessel lesions. 2017 , 14, 35-41	2
352	Long-term clinical outcomes of patients with rheumatoid arthritis and concomitant coronary artery disease. 2017 , 7, 9-18	6
351	Everolimus-Eluting Bioresorbable Vascular Scaffold in Real World Practice - A Single Center Experience. 2017 , 33, 250-257	3
350	Long-term outcomes of PCI CABG for ostial/midshaft lesions in unprotected left main coronary artery. 2017 , 14, 254-260	1
349	Thirty-Day and One-Year Clinical Outcomes of Bioresorbable Vascular Scaffold Implantation: A Single-Center Experience. 2017 , 33, 614-623	3

348	Double-vessel very late stent thrombosis following Resolute Onyx zotarolimus eluting stents implantation in an octogenarian. 2018 , 15, 639-643	2
347	Clinical outcomes of rotational atherectomy in severely calcified in-stent restenosis: a single-center, retrospective study. 2019 , 81, 313-323	1
346	Optimal duration for dual antiplatelet therapy with COMBO dual therapy stent. 2019 , 16, 840-843	
345	Switching from Ticagrelor to Clopidogrel in Asian Patients with ST-Elevated Myocardial Infarction - A Time Dependent Analysis Study. 2020 , 36, 8-15	1
344	Long-term clinical outcomes of thrombus aspiration in STEMI patients undergoing primary percutaneous coronary intervention. 2020 , 10, 117-123	1
343	Modified subintimal plaque modification improving future recanalization of chronic total occlusion percutaneous coronary intervention. 2020 , 17, 393-399	0
342	Procedural safety and outcome of ultrathin strut stents (30 mm) - A retrospective real world study. 2020 , 10, 182-188	1
341	Clinical safety and efficacy of World's thinnest (50 μ m), very long (>40 mm) Everolimus Eluting Stent (SES) among real world patients. 2020 , 10, 317-328	
340	Gender differences in clinical outcomes of acute myocardial infarction undergoing percutaneous coronary intervention: insights from the KAMIR-NIH Registry. 2020 , 17, 680-693	1
339	Clinical outcomes of ultrathin strut biodegradable polymer-coated everolimus-eluting stent in patients with coronary artery disease. 2020 , 16, 130-135	
338	Long-Term Clinical Outcomes of New-Generation Drug-Eluting Stents in Coronary Artery Disease: A Real-World Observational Study. 2021 , 37, 484-495	
337	Clinical Characteristics and Prognosis of Young Middle Eastern Adults with ST-Elevation Myocardial Infarction: One-Year Follow-Up. 2021 , 22, 88-95	
336	Validation of the Academic Research Consortium for High Bleeding Risk criteria in Chinese patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention. 2021 , 209, 16-22	
335	Study of Safety and Efficacy of Novel Sirolimus-Eluting Stent Incorporating Properties of Drug Coating Balloon Among Real World Patients Focusing Younger Population (. 2021 , 33, 321-331	0
334	Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI. 2021 , 78, 2060-2072	2
333	Real-Life Outcomes of Coronary Bifurcation Stenting in Acute Myocardial Infarction (Zabrze-Opole Registry). 2021 , 8,	1
332	Clinical outcomes in 2481 unselected real-world patients treated with a polymer-free sirolimus-eluting stent: 3 years results from the NANO multicenter Registry. 2021 , 21, 537	
331	Relationship between the amount and location of macrophages and clinical outcome: subanalysis of the CLIMA-study. 2022 , 346, 8-12	0

- 330 A prospective trial of a novel low-dose paclitaxel-coated balloon therapy in patients with restenosis in drug-eluting coronary stents Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-stent REstenosis 3A (ISAR-DESIRE 3A). **2021**,
- 329 Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting Stents. **2021**, 1, 345-345 ○
- 328 Lesion impacts on long-term outcomes in patients implanted with bioresorbable vascular scaffold. **2021**,
- 327 Clinical Impact of Single and Dual Antiplatelet Therapy Beyond 12 Months on Ischemic Risk in Patients With Acute Myocardial Infarction.. **2021**, 8, 783344 1
- 326 Prevalence and Impact of High Bleeding Risk in Patients Undergoing Left Main Artery Disease PCI. **2021**, 14, 2447-2457 1
- 325 Effect of Timing of Staged Percutaneous Coronary Intervention on Clinical Outcomes in Patients With Acute Coronary Syndromes. **2021**, 10, e023129
- 324 Optical coherence tomographic insights of very late stent thrombosis of a second-generation drug-eluting stent: a case report.. **2021**, 5, ytab490
- 323 Clinical Outcomes following Large Vessel Coronary Artery Perforation Treated with Covered Stent Implantation: Comparison between Polytetrafluoroethylene- and Polyurethane-Covered Stents (CRACK-II Registry). **2021**, 10, ○
- 322 3-Year Clinical Outcomes After Implantation of Permanent-Polymer Versus Polymer-Free Stent: ReCre8 Landmark Analysis. **2021**, 14, 2477-2486 2
- 321 Association between nocturnal heart rate variability and incident cardiovascular disease events: The HypnoLaus population-based study. **2021**, ○
- 320 Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2.. **2022**, CIRCINTERVENTIONS121011325 1
- 319 Five year clinical outcomes of the COBRA Polyzene F NanoCoated Coronary Stent System.. **2022**, ○
- 318 A randomized comparison of a novel iopromide-based paclitaxel-coated balloon Shenqi versus SeQuent Please for the treatment of in-stent restenosis. **2021**, 32, 526-533
- 317 The Impact of Short-Term Outdoor Air Pollution on Clinical Status and Prognosis of Hospitalized Patients with Coronary Artery Disease Treated with Percutaneous Coronary Intervention.. **2022**, 11,
- 316 Impact of peripheral artery disease on prognosis after percutaneous coronary intervention: Outcomes from the multicenter prospective e-ULTIMASTER registry.. **2022**, ○
- 315 Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy. **2022**, 1, 100004 1
- 314 Thrombotic vs. Bleeding Events of Interruption of Dual Antiplatelet Therapy within 12 Months among Patients with Stent-Driven High Ischemic Risk Definition following PCI.. **2022**, 2022, 3895205
- 313 Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.. **2021**, CIRCINTERVENTIONS120010390 ○

312	JCS 2018 Guideline on Revascularization of Stable Coronary Artery Disease.. 2022 , 86,	3
311	Social deprivation index and ischemic events after percutaneous coronary intervention in patients with diabetes mellitus.. 2022 ,	0
310	Safety and efficacy of low-dose aspirin in patients with coronary artery spasm: long-term clinical follow-up. 2022 , 4, 26-33	
309	Ticagrelor vs. Clopidogrel in Acute Coronary Syndrome Patients With Chronic Kidney Disease After New-Generation Drug-Eluting Stent Implantation.. 2021 , 8, 707722	0
308	Gastrointestinal and Intracranial Bleeding Events After Second-Generation Drug-Eluting Stent Implantation - Their Association With High Bleeding Risk, Predictors, and Clinical Outcomes.. 2022 ,	0
307	Ticagrelor Monotherapy After 3-Month Dual Antiplatelet Therapy in Acute Coronary Syndrome by High Bleeding Risk: The Subanalysis From the TICO Trial.. 2021 ,	1
306	Procedural Results and One-Year Clinical Outcomes of Treatment of Bioresorbable Vascular Scaffolds Restenosis (from the RIBS VII Prospective Study).. 2022 , 162, 31-40	1
305	Access route and clinical outcomes after ticagrelor versus prasugrel in patients with acute coronary syndrome undergoing invasive treatment strategy.. 2022 ,	
304	Sex-Specific Outcomes After Coronary Intravascular Lithotripsy: A Patient-Level Analysis of the Disrupt CAD Studies. 2022 , 1, 100011	1
303	Coronary Stent Thrombosis in COVID-19 Patients: A Systematic Review of Cases Reported Worldwide.. 2022 , 14,	3
302	Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: a systematic review and Bayesian network meta-analysis of randomized trials comprising of 43,875 patients.. 2022 , 53, 671	1
301	Sustained safety and efficacy of magnesium reabsorbable scaffold. 2-year follow-up analysis from first Magmaris multicenter Italian registry.. 2022 ,	1
300	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy.. 2022 , 15, 282-282	0
299	Value of M2BP in predicting in-stent restenosis in patients after coronary drug-eluting stent implantation.. 2022 ,	1
298	Individualizing dual antiplatelet therapy (DAPT) duration based on bleeding risk, ischemic risk, or both: An analysis from the DAPT Study.. 2022 ,	0
297	Improved 3-Year Cardiac Survival After IVUS-Guided Long DES Implantation: A Patient-Level Analysis From 2 Randomized Trials.. 2022 , 15, 208-216	1
296	Predictive performance of different bleeding risk scores in patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention.. 2022 , 1-11	1
295	Association of Guideline-Directed Medical Therapy Adherence with Outcomes After Fractional Flow Reserve-Based Deferral of Revascularization.. 2022 ,	0

- 294 Effect of Procedural Volume on In-Hospital Outcomes After Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease (from the Japanese National Clinical Data [J-PCI Registry]). **2021,**
- 293 The LDL/HDL ratio predicts long-term risk of coronary revascularization in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: a cohort study.. **2022, 55, e11850** ○
- 292 One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients.. **2022, e023454** ○
- 291 Índice de masa corporal y eficacia y seguridad del ticagrelor frente al prasugrel en pacientes con síndrome coronario agudo. **2022,**
- 290 High-speed rotational atherectomy in coronary artery calcification: The randomized ROTAXUS and PREPARE-CALC trials.. **2022,** ○
- 289 Long-term clinical impact of low-density lipoprotein cholesterol target attainment according to lesion complexity after percutaneous coronary intervention.. **2022,**
- 288 Frequency and Outcomes of Periprocedural MI in Patients With Chronic Coronary Syndromes Undergoing PCI.. **2022, 79, 513-526** 1
- 287 Adverse 30-Day Clinical Outcomes and Long-Term Mortality Among Patients With Preprocedural Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.. **2022,** ○
- 286 Target and non-target vessel related events at 10 years post percutaneous coronary intervention.. **2022, 1** ○
- 285 Outcomes of supraflex sirolimus eluting coronary stents. **2022, 3, 25**
- 284 Association of Timing of Revascularization on Clinical Outcomes of Percutaneous Coronary Intervention Relative to Surgery in Non-ST-Elevation Acute Coronary Syndrome Patients With Multivessel Disease. **2022, 1, 72**
- 283 Evaluation of Only Heparin-Based Rota-Flush Solution against Alternative Rota-Flush Solution in Patients with Severe Coronary Artery Calcification Undergoing Rotational Atherectomy. **2021,** ○
- 282 Clinical End Result in Indian Patients Undergoing Primary Percutaneous Coronary Intervention in Institution without Onsite Surgical Facilities. **2022, 11, 157-162**
- 281 Incidence, Predictors, and Outcomes of Acute and Sub-acute Stent Thrombosis after Emergency Percutaneous Coronary Revascularization with Drug-Eluting Stents: A Prospective Observational Study.. **2022, 17, 24** ○
- 280 Long-Term Safety and Efficacy of Prolonged Dual Antiplatelet Therapy according to Baseline Anemia after Percutaneous Coronary Intervention.. **2022, 63, 211-219** ○
- 279 Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial.. **2022, 1** ○
- 278 Yearly Incidence of Stroke and Bleeding in Atrial Fibrillation with Concomitant Hyperthyroidism: A National Discharge Database Study.. **2022, 11,** ○
- 277 Self-reported non-adherence to P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: Application of the medication non-adherence academic research consortium classification.. **2022, 17, e0263180**

276	Complex vs. non-complex percutaneous coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials.. 2022 , 1	1
275	Thrombotic Risk and Cardiovascular Events in Patients With Revascularization Deferral After Fractional Flow Reserve Assessment.. 2022 , 15, 427-439	0
274	Clinical Outcomes and Cardiovascular-Related Events in Young Diabetic Patients with Acute Coronary Syndrome.. 2022 , 18, 55-60	
273	Blood direct PCR: impact of and variants for bleeding prediction in ST-elevation myocardial infarction patients with ticagrelor.. 2022 ,	0
272	Safety and Efficacy of Periprocedural Bridging With Cangrelor Versus Eptifibatide.. 2022 , 79, 383-389	0
271	Intravascular Lithotripsy for the Treatment of Stent Underexpansion: The Multicenter IVL-DRAGON Registry.. 2022 , 11,	0
270	Impacts of Lesion Characteristics on Procedures and Outcomes of Chronic Total Occlusion Recanalization With Antegrade Guidewire True Lumen Tracking Techniques: A Substudy of Taiwan True Lumen Tracking Registry.. 2022 , 9, 769073	1
269	Temporal trends in clinical outcomes after percutaneous coronary intervention: a systematic review of 66,327 patients from 25 all-comers trials. 2021 ,	2
268	Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION.. 2022 , CIRCINTERVENTIONS121011069	
267	Association of ectatic non-infarct-related artery with 1-month stent thrombosis in patients with ST elevation myocardial infarction.. 2022 ,	
266	Plasma Big Endothelin-1 Levels and Long-Term Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.. 2022 , 9, 756082	
265	A Propensity Score-Matched Comparison of Midterm Outcomes Between Drug-Coated Balloons and Drug-Eluting Stents for Patients with Acute Coronary Syndrome.. 2022 , 63,	4
264	Optimal low-density lipoprotein cholesterol target level in Korean acute myocardial infarction patients (. 2021 ,	1
263	Effects of Aggressive PSP Strategy for Coronary Bioresorbable Vascular Scaffolds Implantation.. 2022 ,	
262	Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD.. 2022 ,	0
261	Impact of lipoprotein (a) on long-term outcome after percutaneous coronary intervention in the era of new generation drug-eluting stents.. 2022 ,	
260	Indirect Transfer to Catheterization Laboratory for ST Elevation Myocardial Infarction Is Associated With Mortality Independent of System Delays: Insights From the France-PCI Registry.. 2022 , 9, 793067	
259	Impact of the COVID-19 Pandemic on ST-Elevation Myocardial Infarction Management in Hunan Province, China: A Multi-Center Observational Study.. 2022 , 9, 851214	

258	Comparison of original and modified Academic Research Consortium for High Bleeding Risk definitions in real-world practice.. 2022,	
257	Safety and Efficacy of Ticagrelor Monotherapy According to Drug-Eluting Stent Type: The TWILIGHT-STENT Study. 2021,	0
256	Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in Germany.. 2022, 1	0
255	Initial experience of a single referral centre using excimer laser coronary atherectomy-assisted expansion in undilatable stents: Excimer laser in undilatable stents.. 2022, 8, 32-41	0
254	Outcomes of patients undergoing PCI of ostial coronary lesions. A single center study.. 2022,	
253	Long-Term Clinical Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: Final 5-Year Results of the AIDA Randomized Clinical Trial. 2021,	2
252	Long-Term Outcomes in Elderly Patients After Deferral of Coronary Revascularization Guided by Fractional Flow Reserve.. 2022,	0
251	Comparison of 2 Different Paclitaxel-Coated Balloons in Coronary In-Stent Restenosis. 2022,	
250	Role of Intravascular Ultrasound-Guided Percutaneous Coronary Intervention in Optimizing Outcomes in Acute Myocardial Infarction.. 2022, e023481	1
249	Prognostic Value of Coronary Angiography-Derived Fractional Flow Reserve Immediately After Stenting.. 2022, 9, 834553	0
248	Impact of Hemodialysis Duration on Coronary Artery Calcification Among Hemodialysis Patients Who Underwent Percutaneous Coronary Intervention.. 2022, 33197211073407	1
247	Long-Term Outcomes and Clinical Predictors of Mortality Following Occurrence of Stent Thrombosis.. 2022, 11, e023276	1
246	Device and Procedure Relatedness: Viewpoint From Members of the ARC Steering Group.. 2022, 15, 783-788	
245	A Novel Strategy to Simplify the Procedures in Treating Complicated Coronary Bifurcation Lesions: From a Bench Test to Clinical Application.. 2022, 9, 854063	
244	Sirolimus vs Paclitaxel: Second Round.. 2022,	
243	Prognostic value of post-percutaneous coronary intervention diastolic pressure ratio.. 2022, 1	0
242	Prognostic Impact of Mildly Impaired Renal Function in Patients Undergoing Multivessel Coronary Revascularization.. 2022, 79, 1270-1284	0
241	Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI: An ADAPT-DES Substudy.. 2022,	3

240	Short-term dual antiplatelet therapy in diabetic patients admitted for acute coronary syndrome treated with a new-generation drug-eluting stent.. 2022 , e3530	
239	Treatment of Coronary De Novo Lesions by a Sirolimus- or Paclitaxel-Coated Balloon.. 2022 ,	1
238	Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent.. 2022 ,	0
237	Three-dimensional QCA-based vessel fractional flow reserve (vFFR) in Heart Team decision-making: a multicentre, retrospective, cohort study.. 2022 , 12, e054202	0
236	Platelet reactivity testing in peripheral artery disease.. 2022 ,	0
235	Sex-Based Difference in Clinical Presentation and Outcomes—A Single-Center Experience. 2021 , 06, 241-247	1
234	Simultaneous Multi-Vessel Very Late Stent Thrombosis in Acute ST-Segment Elevation Myocardial Infarction.. 2021 , 2021, 2658094	0
233	Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations.. 2021 , 8, 807925	0
232	Optimal Dual Antiplatelet Therapy Duration for Bioresorbable Scaffolds: an Individual Patient Data Pooled Analysis of the ABSORB Trials. 2021 ,	2
231	ST-segment elevation versus non-ST-segment elevation myocardial infarction in current smokers after newer-generation drug-eluting stent implantation. 2021 , 100, e28214	
230	Association between DBP and major adverse cardiovascular events in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. 2021 , 40,	0
229	Renal Function Effect on the Association Between Body Mass Index and Mortality Risk After Acute Myocardial Infarction.. 2021 , 8, 765153	0
228	Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes.. 2021 ,	
227	Clopidogrel monotherapy in patients with and without on-treatment high platelet reactivity: a SMART-CHOICE substudy. 2021 , 17, e888-e897	1
226	Novel Use of Dual Guiding Catheters Technique to Prevent Distal Embolization and Slow Flow during PCI of Coronary Stent Thrombosis.	
225	Randomised controlled trial to investigate optimal antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: a study protocol of the OPTIMA-AF trial.. 2021 , 11, e048354	1
224	Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention.. 2022 ,	0
223	The Role of the Association Between Serum C-Reactive Protein Levels and Coronary Plaque Macrophage Accumulation in Predicting Clinical Events - Results from the CLIMA Registry.. 2022 , 1	0

222	Which pre-dilatation balloons provide the best lesion preparation prior to use of drug coated balloons in De Novo lesions? Results from the PREPARE study.. 2022 ,	
221	Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy.. 2022 , CIRCINTERVENTIONS120009495	0
220	Long-Term Outcomes After Implantation of Magnesium-Based Bioresorbable Scaffolds-Insights From an All-Comer Registry.. 2022 , 9, 856930	1
219	Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial.. 2022 , 101161CIRCINTERVENTIONS121011569	0
218	Cutting balloons versus conventional balloons for treating patients with coronary artery disease presenting with moderate-to-severely calcified lesions: impact on post-interventional minimum stent area.. 2022 , 1	0
217	Angiographic complete revascularization versus incomplete revascularization in patients with diabetes mellitus.. 2022 , 21, 56	0
216	Prediction of residual ischemic risk in ticagrelor-treated patients with acute coronary syndrome.. 2022 , 20, 21	0
215	Table_1.DOCX. 2020 ,	
214	First Experience Using the Sheathless Hyperion Guiding Catheter System Designed for Direct Insertion.. 2022 , 2022, 5668728	
213	Stent Optimization Using Optical Coherence Tomography and Its Prognostic Implications After Percutaneous Coronary Intervention.. 2022 , e023493	0
212	3-Year outcomes in patients with heavily calcified lesions undergoing percutaneous coronary intervention using cutting balloons.. 2022 , 22, 187	1
211	A prospective, multicentre first-in-man study of the polymer-free ultrathin-strut BIOrapid stent (BIOVITESSE). 2021 ,	
210	Coronary lithotripsy for the treatment of underexpanded stents; the international multicentre CRUNCH registry.. 2022 ,	0
209	Clinical outcomes of suboptimal stent deployment as assessed by optical coherence tomography: long-term results of the CLI-OPCI registry. 2021 ,	1
208	Coronary vasomotion after treatment with drug-coated balloons or drug-eluting stents: a prospective, open-label, single-centre randomised trial. 2021 ,	0
207	Magnesium-based resorbable scaffold vs permanent metallic sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction: 3-year results of the MAGSTEMI randomised controlled trial.. 2022 ,	0
206	Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial.. 2022 ,	0
205	Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial.. 2022 ,	2

204	Polymer-free biolimus-coated stents versus ultrathin-strut biodegradable polymer sirolimus-eluting stents: two-year outcomes of the randomised SORT OUT IX trial.. 2022,	1
203	Prevalence and outcomes of stent thrombosis with in-stent calcified nodules: substudy from the REAL-ST registry.. 2022,	1
202	Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial.. 2022,	1
201	Feasibility and Safety of Drug-Coated Balloon-Only Angioplasty for De Novo Ostial Lesions of the Left Anterior Descending Artery: Two-Center Retrospective Study.. 2022, 9, 874394	
200	Efficacy and Safety of the Reduced Bivalirudin in Patients Undergoing Coronary Angiography or Percutaneous Coronary Intervention Stratified by Renal Function (REDUCE BOLUS): A Single-Blind, Stratified Randomized, Non-inferiority Trial.. 2022, 9, 864048	0
199	Early vascular healing of ultra-thin strut polymer-free sirolimus-eluting stents in acute coronary syndrome: USUI-ACS study.. 2022, 1	0
198	In-Stent Restenosis in the New Generation DES Era. 2022, 237-247	
197	How Do Lipoprotein(a) Concentrations Affect Clinical Outcomes for Patients With Stable Coronary Artery Disease Who Underwent Different Dual Antiplatelet Therapy After Percutaneous Coronary Intervention?. 2022, e023578	0
196	Impact of dual antiplatelet therapy duration on clinical outcome after coronary bifurcation stenting: results from the Euro Bifurcation Club registry.. 2022,	0
195	Balance of Ischemia and Bleeding in Selecting Intensity and Duration of Antithrombotic Regimens. 2022, 465-474	
194	Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial.. 2022,	0
193	The Association Between Serum Uric Acid and Mortality in Patients with Acute Coronary Syndrome After Percutaneous Coronary Intervention.. 2022, 63,	1
192	Prediabetes versus type 2 diabetes in patients with acute myocardial infarction and current smoking. 2022,	
191	Use of intravascular ultrasound and long-term cardiac death or myocardial infarction in patients receiving current generation drug-eluting stents.. 2022, 12, 8237	0
190	Non-inferiority of 1 month versus longer dual antiplatelet therapy in patients undergoing PCI with drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. 2022, 13, 204062232210937	
189	A Rare Case of Coronary Stent Thrombosis in the Modern Era. 2022,	
188	Magmaris resorbable magnesium scaffold versus conventional drug-eluting stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison. 2022,	1
187	Risk stratification for hospital-acquired venous thromboembolism in medical patients (RISE): Protocol for a prospective cohort study. 2022, 17, e0268833	2

- 186 Outcome after percutaneous coronary intervention with contemporary stents in patients with concomitant peripheral arterial disease: A patient-level pooled analysis of four randomized trials. **2022,** ○
- 185 Comparative Safety and Effectiveness of Ticagrelor versus Clopidogrel in Patients With Acute Coronary Syndrome: An On-Treatment Analysis From a Multicenter Registry. **2022, 9,**
- 184 Newer P2Y12 Inhibitors vs Clopidogrel in Acute Myocardial Infarction With Cardiac Arrest or Cardiogenic Shock: A Systematic Review and Meta-analysis. **2022, 97, 1074-1085** 1
- 183 A Randomized Comparison of the Healing Response Between the Firehawk Stent and the Xience Stent in Patients With ST-Segment Elevation Myocardial Infarction at 6 Months of Follow-Up (TARGET STEMI OCT China Trial): An Optical Coherence Tomography Study. **2022, 9,** 1
- 182 Grade 3 coronary artery perforations in chronic total occlusion-percutaneous coronary intervention: Mechanisms, locations, and outcomes from the G3CAP Registry.
- 181 Safety and feasibility of transradial access for percutaneous coronary intervention in chronic total occlusions. **2022,**
- 180 Safety and Feasibility of Rotational Atherectomy for Retrograde Recanalization of Chronically Occluded Coronary Arteries. 9, ○
- 179 Mortality and Major Cardiovascular Events among Patients with Multiple Myeloma: Analysis from a Nationwide French Medical Information Database. **2022, 14, 3049**
- 178 Five-Year Impacts of Antithrombotic Therapy Based on 10-Year Clinical Outcomes of Cypher[®] Stent Implantation.
- 177 Optical coherence tomography-derived lipid core burden index and clinical outcomes: results from the CLIMA registry. ○
- 176 Alkaline phosphatase and prognosis in patients with diabetes mellitus and ischemic heart disease. **2022, 533, 1-7**
- 175 A novel “nano-crush” technique for the management of coronary bifurcation lesions: in vitro bench test analysis and preliminary report on real-world clinical evaluation in patients with one-year angiographic follow-up. **2019, 5, 41-51** ○
- 174 Recurrent Coronary Artery Thrombosis on Triple Anti-Thrombotic Therapy, Is There a Possible Association with ChAdOx1 nCoV-19 Vaccination?. **2022, 11, 234-243**
- 173 Coronary Heart Disease and Coronavirus Disease 2019: Pathogenesis, Epidemiology, Association with Myocardial Revascularization. **2022, 10, 319-325**
- 172 Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients. **2022, 15, 1153-1163** ○
- 171 Mechanical circulatory support devices for elective percutaneous coronary interventions: Novel insights from the Japanese nationwide J-PCI registry. ○
- 170 Correlation Between the Japanese Version of the High Bleeding Risk (J-HBR) Criteria and the PRECISE-DAPT Score, and Optimal J-HBR Cut-Off Score to Predict Major Bleeding. **2022,**
- 169 Long-Term Performance of the Magmaris Drug-Eluting Bioresorbable Metallic Scaffold in All-Comers Patients's Population. **2022, 11, 3726**

168	Ultrathin, Biodegradable-Polymer Sirolimus-Eluting Stent vs Thin, Durable-Polymer Everolimus-Eluting Stent. 2022 , 15, 1324-1334	1
167	Procedural Characteristics of Intravascular Ultrasound-Guided Percutaneous Coronary Intervention and Their Clinical Implications.	
166	Outcomes of early versus delayed invasive strategy in older adults with non-ST-segment elevation myocardial infarction. 2022 , 12,	0
165	Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench to bedside.	2
164	Nanomaterials-Mediated Therapeutics and Diagnosis Strategies for Myocardial Infarction. 10,	
163	The impact of chronic kidney disease severity on clinical outcomes after current generation drug-eluting stent implantation for left main distal bifurcation lesions: the Milan and New-Tokyo registry. 2022 , 56, 236-242	
162	Coronary In-Stent Restenosis. 2022 , 80, 348-372	3
161	Clinical Outcomes and Unique Restenosis of Calcified Nodule in Heavily Calcified Coronary Artery. 2022 ,	0
160	Safety and Efficacy of Contemporary Drug-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction and a High Ischemic Risk. 9,	
159	Infarct Size and Long-Term Clinical Outcomes of Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Coronary Artery Stenting: A Prospective Randomized Study.	
158	Impact of hemoglobin levels at admission on outcomes among elderly patients with acute coronary syndrome treated with low-dose Prasugrel or clopidogrel: A sub-study of the ELDERLY ACS 2 trial. 2022 ,	1
157	Triglyceride-glucose index in the prediction of adverse cardiovascular events in patients with premature coronary artery disease: a retrospective cohort study. 2022 , 21,	0
156	Impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention: an analysis from the e-Ultimaster registry.	0
155	Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort. 2022 , 15,	1
154	Value of serum albumin, age, serum creatinine, and left ventricular ejection fraction for the assessment of 4-year mortality risk in patients with acute myocardial infarction: parsimonious and better performed.	
153	Gender Differences in 10-Year Outcomes Following STEMI. 2022 ,	1
152	Prognostic significance of thrombus burden on short- and long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Publish Ahead of Print,	
151	Comparison between Optical Coherence Tomography and Intravascular Ultrasound in Primary Percutaneous Coronary Intervention for ST-segment Elevation Myocardial Infarction.	

- 150 Intravascular imaging in coronary stent restenosis: Prevention, characterization, and management. 9,
- 149 Coronary Stenting in Patients With Small Coronary Arteries at High Risk of Bleeding: Onyx ONE Clear. **2022**, 100432
- 148 The predictive value of the triglyceride-glucose index for cardiovascular events in patients with coronary chronic total occlusion. **2022**, 21, 0
- 147 Stroke Risk Stratification With the CHADS2 Score in Patients Without Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention. **2022**,
- 146 Prognostic value of myocardial salvage index assessed by cardiovascular magnetic resonance in reperfused ST-segment elevation myocardial infarction. 9, 0
- 145 Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy. **2022**, 80, 766-778 0
- 144 Comparison of 3-Year Outcomes between Early and Delayed Invasive Strategies in Older and Younger Adults with Non-ST-Segment Elevation Myocardial Infarction Undergoing New-Generation Drug-Eluting Stent Implantation. **2022**, 11, 4780 1
- 143 Mechanical Sensors for Cardiovascular Monitoring: From Battery-Powered to Self-Powered. **2022**, 12, 651 3
- 142 Treatment of in-stent restenosis using a dedicated super high-pressure balloon. **2022**, 0
- 141 Seguridad y viabilidad del acceso radial para intervenciones coronarias percutáneas de oclusiones totales crónicas. **2022**,
- 140 Patients With Diabetes at High Bleeding Risk With 1-Month Dual Antiplatelet Therapy: Onyx ONE Clear Results. **2022**, 100441
- 139 Prognostic value of De Ritis ratio in patients with acute myocardial infarction. **2022**, 535, 75-81 0
- 138 Comparison of Two Different Rota-Flush Solutions in Patients Undergoing Rotational Atherectomy: A Randomized, Controlled, Triple-Blind Trial. 0
- 137 Device-based therapy for decompensated heart failure: An updated review of devices in development based on the DRI2P2S classification. 9, 0
- 136 Impact of Diabetes Mellitus on One-Year Clinical Outcomes in Patients Anticoagulated with Bivalirudin Undergoing Elective Percutaneous Coronary Intervention. **2022**, 28, 107602962211133 0
- 135 Safety and Efficacy of Short-Term vs. Standard Periods Dual Antiplatelet Therapy After New-Generation Drug-Eluting Stent Implantation: A Meta-analysis. **2022**, 701-725 0
- 134 Sex Differences in Pharmacotherapy and Long-Term Outcomes in Patients with Ischaemic Heart Disease and Comorbid Left Ventricular Dysfunction. 0
- 133 Clinical Impact of Platelet Reactivity and Gene Polymorphisms in Patients With Ischemic Heart Disease After Percutaneous Coronary Intervention. **2022**, 1, 168 0

132	Durable Polymer Versus Biodegradable Polymer Drug-Eluting Stents in Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock: Results from the RESCUE Registry.	0
131	Does the use of polymer-free drug eluting stents improve clinical outcomes of patients undergoing percutaneous coronary interventions?. 2022 , 33, 354-361	0
130	Design of the PERSEO Registry on the management of patients treated with oral anticoagulants and coronary stent. Publish Ahead of Print,	0
129	Impact of Coronary Chronic Total Occlusion on Long-term Clinical Outcome in Patients with Unprotected Left Main Disease Undergoing Percutaneous Coronary Intervention. 2022 , 2, 145-151	0
128	Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention.	0
127	Frequency and outcomes of periprocedural myocardial infarction in patients with chronic coronary syndromes undergoing percutaneous coronary intervention. 2022 , 37, 488-494	0
126	Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. 2022 , 15, 1852-1860	0
125	Definition of Optimal Optical Coherence Tomography-Based Stent Expansion Criteria: In-Stent Minimum Lumen Area Versus Residual Stent Underexpansion. 2022 , 15,	2
124	Prevalence and Impact of Neoatherosclerosis on Clinical Outcomes After Percutaneous Treatment of Second-Generation Drug-Eluting Stent Restenosis. 2022 , 15,	1
123	Sex Difference in Coronary Artery Spasm Tested by Intracoronary Acetylcholine Provocation Test in Patients with Nonobstructive Coronary Artery Disease. 2022 , 2022, 1-10	0
122	24-month clinical follow-up and mechanistic insights from intravascular imaging following coronary implantation of the novel DynamX Bioadaptor platform. 2022 ,	0
121	Five-year clinical outcomes using the bioresorbable vascular scaffold: Insights from the FRANCE ABSORB registry. 2022 ,	0
120	In-Stent Restenosis. 2022 ,	0
119	Five-year clinical outcomes of a 2.25 mm sirolimus-eluting stent in Japanese patients with very small coronary artery disease: final results of the CENTURY JSV study.	0
118	Bioresorbable scaffolds vs. drug-eluting stents on short- and mid-term target lesion outcomes in patients after PCI: A systematic review and meta-analysis. 9,	0
117	Effect of Stenting Strategy on the Outcome in Patients with Non-Left Main Bifurcation Lesions. 2022 , 11, 5658	0
116	Long-term outcomes of drug-coated balloons in patients with diffuse coronary lesions. 9,	1
115	Fractional Flow Reserve or Intravascular Ultrasonography to Guide PCI. 2022 , 387, 779-789	3

114	Combined Analysis of Two Parallel Randomized Trials of Sirolimus-Coated and Paclitaxel-Coated Balloons in Coronary In-Stent Restenosis Lesions. 2022 , 15,	○
113	Effect of direct stenting on microvascular dysfunction during percutaneous coronary intervention in acute myocardial infarction: a randomized pilot study. 2022 , 50, 030006052211278	○
112	Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry. 2022 , 18, e656-e665	○
111	Performance of stent thrombosis and bleeding risk scores in out-of-hospital cardiac arrest due to acute coronary syndromes. 2022 ,	○
110	Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index. 2022 , 15, 1948-1960	○
109	Clinical Outcomes of Rotational Atherectomy in Heavily Calcified Lesions: Evidence From the Largest Cardiac Center in Thailand. 2022 , 17,	1
108	The mega COMBO collaboration: An individual patient data pooled analysis of patients undergoing PCI with COMBO stent. 2022 ,	○
107	Impact of intravascular ultrasound-incomplete stent apposition on stent failure.	○
106	Impact of intravascular ultrasound in acute myocardial infarction patients at high ischemic risk. 2022 ,	○
105	Design and Rationale of Targeted Therapy With a Sirolimus-Eluting, Biodegradable Polymer Coronary Stent in Chronic Total Occlusions (TARGET CTO): A Multicenter, Open-Label, Randomized Noninferiority Trial. 2022 , 100511	○
104	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome and High Bleeding Risk. 2022 , 15,	○
103	Non-Culprit Left Main Coronary Artery Disease in Acute Myocardial Infarction Complicated by Cardiogenic Shock.	○
102	Bivalirudin vs. heparin on a background of ticagrelor and aspirin in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A multicenter prospective cohort study. 9,	○
101	Combined rotational atherectomy and cutting balloon angioplasty prior to drug-eluting stent implantation in severely calcified coronary lesions: The PREPARE-CALC-COMBO study.	○
100	Intra- and Postprocedural Management of Coronary Artery Perforation During Percutaneous Coronary Intervention. 2022 ,	○
99	Outcomes of paclitaxel-coated balloon angioplasty for in-stent calcified nodule: An optical coherence tomography study.	○
98	Efficacy and safety of drug-coated balloon combined with cutting balloon for side branch of true coronary bifurcation lesions: Study protocol for a multicenter, prospective, randomized controlled trial. 9,	○
97	Three versus 12-month dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.	1

- 96 Inhibition of mitochondrial complex I leading to NAD⁺/NADH imbalance in type 2 diabetic patients who developed late stent thrombosis: Evidence from an integrative analysis of platelet bioenergetics and metabolomics. **2022**, 57, 102507 ○
- 95 Incidence and impact on prognosis of impaired kidney function in Middle Eastern patients undergoing percutaneous coronary intervention: results from the first Jordanian PCI Registry. **2019**, 5, 18-26 ○
- 94 Outcomes of supraflex Sirolimus-eluting coronary stents. **2022**, 20, 130 ○
- 93 Impact of Sex on Clinical Outcomes in Patients undergoing Complex Percutaneous Coronary Angioplasty (from the e-ULTIMASTER Study). **2023**, 186, 71-79 ○
- 92 Structural and temporal dynamics analysis on drug-eluting stents: History, research hotspots and emerging trends. **2023**, 23, 170-186 1
- 91 Long-term clinical outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer sirolimus-eluting stents. **2018**, 4, 77-86 ○
- 90 Three-Year Outcomes of Biodegradable Polymer-Coated Ultra-Thin (60 µm) Sirolimus-Eluting Stents in Real-World Clinical Practice. **2019**, 48, 150-155 ○
- 89 Angiographic and clinical outcomes in patients with versus without diabetes mellitus after revascularization with BioMime sirolimus-eluting stent. **2022**, 33, 643-647 ○
- 88 Impact of Smoking Status on Mortality in STEMI Patients Undergoing Mechanical Reperfusion for STEMI: Insights from the ISACSâSTEMI COVID-19 Registry. **2022**, 11, 6722 ○
- 87 Final 5-Year Report of the Randomized BIO-RESORT Trial Comparing 3 Contemporary Drug-Eluting Stents in All-Comers. **2022**, 11, ○
- 86 Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. **2022**, 1 ○
- 85 Periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention. **2022**, ○
- 84 Comparison of outcomes in patients with or without ARC-HBR criteria undergoing PCI with polymer-free biolimus coated stents: The BioFreedom France study. ○
- 83 Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent. ○
- 82 Impact of ultrasound reverberation in calcified coronary arteries: Intravascular ultrasound study. **2022**, ○
- 81 The outcome of primary percutaneous coronary intervention in patients with stent thrombosis. **2022**, ○
- 80 High bleeding risk in patients undergoing percutaneous coronary intervention with drug-eluting stent implantation: ReCre8 subanalysis. **2022**, 24, 100227 ○
- 79 Three-Year Clinical Outcomes of a Thin-Strut Biodegradable-Polymer Everolimus-Eluting Stent in Patients With Acute Coronary Syndrome. 2, ○

78	Rivaroxaban in Patients With Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention in Clinical Practice. 2023 , 189, 31-37	○
77	Impact of Age at the Time of the First ST-Elevation Myocardial Infarction on 10-Year Outcomes (from the EXAMINATION-EXTEND Trial). 2023 , 190, 32-40	○
76	International randomized trial on the effect of revascularization or optimal medical therapy of chronic total coronary occlusions with myocardial ischemia - ISCHEMIA-CTO trial rationale and design. 2023 , 257, 41-50	○
75	Stent or Scaffold Thrombosis: Past, Current, and Future Perspectives. 55-61	○
74	Association of Glycosylated Hemoglobin with Long-Term Adverse Cardiac Events after Percutaneous Coronary Intervention in Non Diabetes and Controlled Diabetes Patients: An Observational Study from the Korean COACT Registry. 2022 , 12, 1945	○
73	Safety and Efficacy of Bivalirudin versus Unfractionated Heparin Monotherapy in Patients with CAD and DM Undergoing PCI: A Retrospective Observational Study. 2022 , 2022, 1-10	1
72	Midterm Safety and Efficacy of Elective Drug-coated Balloon Angioplasty in Comparison to Drug-Eluting Stents for Unrestrictive De Novo Coronary Lesions: A Single Center Retrospective Study. 2022 ,	1
71	A Randomized Controlled Trial of a Biodegradable Polymer, Microcrystalline Sirolimus-Eluting Stent (MiStent) versus Another Biodegradable Polymer Sirolimus-Eluting Stent (TIVOLI): The DESSOLVE-C Trial. Publish Ahead of Print,	○
70	Risk of bleeding after percutaneous coronary intervention and its impact on further adverse events in clinical trial participants with comorbid peripheral arterial disease. 2022 ,	○
69	Triglyceride-glucose index level and variability and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an observational cohort study. 2022 , 21,	○
68	Late outcomes of ST-elevation myocardial infarction treated by pharmaco-invasive or primary percutaneous coronary intervention.	○
67	Prevalence and Effects of High-Intensity Statins for Japanese Patients Presenting With Acute Coronary Syndrome – A Post Hoc Secondary Analysis of STOPDAPT-2 ACS – 2022 ,	○
66	Long-term outcomes following intravascular lithotripsy (IVL) for calcified coronary lesions: A Real-World Multicenter European Study.	○
65	Relationship Between Optical Coherence Tomography-Derived In-Stent Neointima and the Extent of Lipid-Rich Neointima by Near-Infrared Spectroscopy and Intravascular Ultrasound: A Multimodal Imaging Study. 2022 , 11,	○
64	BioMatrix Versus Orsiro Stents for Coronary Artery Disease: A Multicenter, Randomized, Open-Label Study.	○
63	Drug-Coated Balloon for the Treatment of Small Vessel Coronary Artery Disease – A Randomized Non-Inferiority Trial – 2022 ,	○
62	Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. 2022 , 18, e897-e909	○
61	Drug-coated balloon for the treatment of small vessel disease: 9 months of angiographic results and 12 months of clinical outcomes of the PEPCAD China SVD study.	○

60	Utility of the ACC/AHA Lesion Classification to Predict Outcomes After Contemporary DES Treatment: Individual Patient Data Pooled Analysis From 7 Randomized Trials. 2022 , 11,	0
59	On-Treatment Platelet Reactivity and Ischemic Outcomes in Patients With Diabetes Mellitus: Two-Year Results From ADAPT-DES.	0
58	Construction and evaluation of nomogram model for individualized prediction of risk of major adverse cardiovascular events during hospitalization after percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. 9,	0
57	Prior Myocardial Infarction and Treatment Effect of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndromes - A Post-hoc Analysis of the ISAR-REACT 5 Trial. 2022 , 11,	0
56	Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention. 2022 ,	0
55	De Ritis ratio and long-term major cardiovascular adverse events in patients undergoing elective percutaneous coronary intervention.	0
54	A Novel Reperfusion Strategy for Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction: A Prospective Case Series. 2023 , 12, 433	0
53	Efficacy and safety outcomes of long-term anti-thrombotic treatment of chronic coronary artery disease: A systematic review and network meta-analysis. 9,	0
52	Third-Generation Sirolimus-Eluting Bioresorbable Tyrocore Scaffold Implantation in Patients with ST-Segment Elevation Myocardial Infarction: Baseline and 6-Month OCT and Clinical Outcomesâ FANTOM STEMI Pilot Study.	0
51	Long-term follow-up of contemporary drug-eluting stent implantation in diabetic patients: Subanalysis of a randomized controlled trial.	0
50	Short and Long-Term Prognostic Significance of Galectin-3 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. 000331972211498	4
49	Clinical Impact of Drug-Coated BalloonâBased Percutaneous Coronary Intervention in Patients With Multivessel Coronary Artery Disease. 2023 ,	1
48	Clopidogrel Monotherapy After 1-Month DAPT in Patients With High Bleeding Risk or Complex PCI. 2023 ,	0
47	Genetic Backgrounds Associated With Stent Thrombosis. 2023 , 2, 100172	0
46	Impacto del uso de ultrasonido intravascular en pacientes con infarto agudo de miocardio y alto riesgo isqu�mico. 2023 ,	0
45	The contemporary use of intracoronary brachytherapy for instent restenosis: A review. 2023 ,	0
44	The standard versus prolonged dual antiplatelet therapy after the XINSORB bioresorbable scaffold implantation (SPARTA) trial: study protocol for a randomized controlled trial. 2023 , 24,	0
43	Impact of Comorbid Disease Burden on Clinical Outcomes of Female Acute Myocardial Infarction Patients. 2023 , 59, 61	0

- 42 Incidence of Major Adverse Cardiovascular and Cerebrovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention with Iodixanol: An Observational Postauthorization Study. Publish Ahead of Print, ○
- 41 Outcomes of optical coherence tomography guided percutaneous coronary intervention against angiography guided in patients with coronary artery disease: A systematic reviews and meta-analyses. **2023**, 75, 108-114 ○
- 40 Effects of Metabolic Syndrome on Cardiovascular Outcomes of Psoriatic Patients with Coronary Artery Disease: A Single Center Retrospective Cohort Study. Volume 16, 1003-1012 ○
- 39 Self-Expanding Versus Balloon Expanding Coronary Stents in Intervention of the Degenerated Saphenous Vein Graft: Memmingen Coronary Artery Bypass Stenosis Trial (MECAST). **2023**, 2023, 1-10 ○
- 38 Complementary evidence on the performance of coronary stents generated by a randomized controlled trial and a worldwide registry. **2023**, 261, 35-44 ○
- 37 Stent Thrombosis and Restenosis with Contemporary Drug-Eluting Stents: Predictors and Current Evidence. **2023**, 12, 1238 ○
- 36 Late and Very Late Stent Thrombosis in the Era of Second-Generation Drug-Eluting Stents. 85-93 ○
- 35 Revolution of Drug-Eluting Coronary Stents: An Analysis of Market Leaders. 114-125 ○
- 34 Clopidogrel Use in <i>CYP2C19</i> Loss-of-Function Carriers With High Bleeding Risk After Percutaneous Coronary Intervention. **2023**, ○
- 33 High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry. ○
- 32 Assessment of In-Hospital Mortality and Its Risk Factors in Patients with Myocardial Infarction Considering the Logistical Aspects of the Treatment ProcessâA Single-Center, Retrospective, Observational Study. **2023**, 20, 3603 ○
- 31 Impact of the ultra-long 48 mm drug-eluting stent on procedural and clinical outcomes in patients with diffuse long coronary artery disease. **2023**, 46, 416-424 ○
- 30 Percutaneous Coronary Intervention Offers Clinical Benefits to Diabetic Patients With Stable Chronic Total Occlusion. 000331972311532 ○
- 29 Early vascular healing after neXt-generation drug-eluting stent implantation in Patients with non-ST Elevation acute Coronary syndrome based on optical coherence Tomography guidance and evaluation (EXPECT): study protocol for a randomized controlled trial. 10, ○
- 28 Impact of calcified nodule on target lesion failure after stent implantation in hemodialysis patients. **2023**, 101, 701-712 ○
- 27 Peri-coronary adipose tissue is a predictor of stent failure in patients undergoing percutaneous coronary intervention. **2023**, ○
- 26 Sex Differences in Delayed Hospitalization in Patients with Non-ST-Segment Elevation Myocardial Infarction Undergoing New-Generation Drug-Eluting Stent Implantation. **2023**, 12, 1982 ○
- 25 Long-term outcomes of less drug-eluting stents by the use of drug-coated balloons in de novo coronary chronic total occlusion intervention: A multicenter observational study. 10, ○

- 24 Stent expansion evaluated by optical coherence tomography and subsequent outcomes. **2023**, 13, ○
- 23 Comparison of the OPTIVUS-Complex PCI Multivessel Cohort With the Historical CREDO-Kyoto Registry Cohort-3. **2023**, ○
- 22 Prasugrel Monotherapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Platinum-Chromium Everolimus Eluting Stent for Japanese Patients With Chronic Coronary Syndrome (ASET-JAPAN). **2023**, ○
- 21 Optimal Intravascular Ultrasound-Guided Percutaneous Coronary Intervention in Patients With Multivessel Disease. **2023**, 3, 211-225 ○
- 20 Reduced-dose prasugrel monotherapy without aspirin after PCI with the SYNERGY stent in East Asian patients presenting with chronic coronary syndromes or non-ST-elevation acute coronary syndromes: rationale and design of the ASET Japan pilot study. **2023**, 9, 39-48 ○
- 19 Impact of Insulin-Treated Compared to Non-Insulin-Treated Diabetes Mellitus on Outcome of Percutaneous Coronary Intervention with Drug-Coated Balloons versus Drug-Eluting Stents in De Novo Coronary Artery Disease: The Randomized BASKET-SMALL 2 Trial. **2023**, 10, 119 ○
- 18 Effects of delayed hospitalization on the 3-year clinical outcomes of patients with or without diabetes who had non-ST-segment-elevation myocardial infarction and underwent new-generation drug-eluting stent implantation. ○
- 17 Association of serum platelet-to-lymphocyte ratio levels with the risk of stent thrombosis and long-term prognosis in patients undergoing percutaneous coronary intervention with and without type 2 diabetes mellitus: a large-scale prospective cohort study. ○
- 16 Real-world five-year outcomes of FlexyRap[®] cobalt-chromium rapamycin-eluting stents with biodegradable polymer in patients with de-novo coronary artery disease. 15, 84-94 ○
- 15 Drug-coated balloons for the treatment of stent edge restenosis. Publish Ahead of Print, ○
- 14 Ultra-thin everolimus-eluting stents in atherosclerotic lesions: Three years follow-up with subgroup analysis of ultra-long stents. **2023**, ○
- 13 The Supreme Biodegradable Polymer DES in Acute and Chronic Coronary Syndromes: A PIONEER III Substudy. **2023**, 100629 ○
- 12 Impact of Selection Preference on Longer-Term Outcomes between Bioresorbable Vascular Scaffold versus Everolimus-Eluting Stent for True Lumen Tracking-Recanalized Chronic Total Occlusion. **2023**, 64, 154-163 ○
- 11 Non-culprit left main coronary artery disease in acute myocardial infarction complicated by cardiogenic shock. **2023**, 18, e0276711 ○
- 10 Management of failed stenting of the unprotected left main coronary artery. ○
- 9 Derivation and validation of the ISAR score to predict the risk of repeat percutaneous coronary intervention for recurrent drug-eluting stent restenosis. **2023**, 18, e1328-e1338 ○
- 8 Procedural Complications. **2023**, 25-95 ○
- 7 Patients with higher-atherothrombotic risk vs. lower-atherothrombotic risk undergoing coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials. ○

- 6 Long-term clinical outcomes of percutaneous coronary intervention for ostial left main coronary artery disease. **2023**, 18, 1446-1455 ○
- 5 Predictive value of high sensitivity C-reactive protein in three-vessel disease patients with and without type 2 diabetes. **2023**, 22, ○
- 4 Long-term outcomes of patients treated with sirolimus-eluting resorbable magnesium scaffolds: Insights from the SHERPA-MAGIC study. **2023**, ○
- 3 Five-Year Clinical Outcomes After XIENCE PRIME Everolimus Elution Coronary Stent System (EECSS) Implantation. **2023**, 8, ○
- 2 The Efficacy of Drug-Coated Balloon for Acute Coronary Syndrome. **2023**, 2023, 1-9 ○
- 1 Target Lesion Revascularization After Intravascular Ultrasound-Guided Percutaneous Coronary Intervention. **2023**, 16, ○